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1 Study overview 
1.1 Study motivation 
Risk tolerance, or the willingness to take risks to obtain rewards, is a fundamental parameter in 
economics, finance, and behavioral decision theory. Different measures of risk preferences have 
previously been linked to real-world behaviors such as portfolio allocation and occupational 
choice, as well as health behaviors such as smoking, exercising, and alcohol and drug use1–5. 
Further, recent work has demonstrated the existence of a reliable general factor of risk preference 
that is generalizable both to specific and real-world risky behaviors6. 
Elucidating the determinants of individual differences in general risk tolerance is an active field 
of research3,4. General risk tolerance has been found to be moderately heritable in twin studies 
(ℎ"~30%), although heritability estimates in the literature vary, ranging from 20% to 60%2,7–9; 
an earlier study based on molecular genetic data had confirmed the heritability of the trait10. 
Some previous studies have attempted to identify specific genetic variants that are associated 
with general risk tolerance. However, most of these attempts have been conducted in relatively 
small samples with a few hundred to at most a few thousand individuals11–14; see 
Supplementary Table 11.1. Given that the effect of any specific single nucleotide 
polymorphism (SNP) on a genetically complex trait like general risk tolerance is likely to be 
extremely small10,15–18, these earlier studies were most likely underpowered. Low statistical 
power not only implies a low probability to detect true effects, but also a high chance of finding 
false positives, a strong tendency to overestimate the effects of statistically significant variables, 
and a high likelihood that significant findings will have the wrong sign19. Accordingly, the 
replication record of these underpowered studies has been disappointing20,21. 
The purpose of this study is to investigate the molecular genetic architecture of general risk 
tolerance, adventurousness, and of a number of risky behaviors and to identify specific genetic 
variants associated with the phenotypes in well-powered genome-wide association studies 
(GWAS). Our findings could help elucidate the genetic and biological mechanisms that underlie 
individual variation in the willingness to avoid or engage in risky behavior. 
1.2 Phenotype definitions  
1.2.1 General risk tolerance 
Our main phenotype is self-reported “general risk tolerance,” defined as one’s tendency or 
willingness to take risks in general. For our discovery stage, we combine data from the UK 
Biobank and from the 23andMe cohort.  
We use the following survey question from the UK Biobank (n = 431,126): 
“Would you describe yourself as someone who takes risks? Yes / No.” 
Throughout the study all risk-related phenotypes are coded so that a higher risk tolerance is 
associated with a higher phenotype value.  For example, in the UKB “yes” is coded as 1 and 
“no” as 0. The majority of the 431,126 respondents in the UKB were only assessed once, while a 
subset of 18,102 individuals answered the survey question a second time. 15,618 of these re-
assessed individuals gave consistent answers in both waves, while 2,484 changed their 
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responses. When the answer between the two assessments changed, we took the average 
response (i.e., 0.5) as the individual’s measure of risk tolerance. Consistent with prior 
research22,23, a much higher fraction of males (33%) than females (18%) in the UKB cohort 
described themselves as risk tolerant on the general-risk-tolerance measure (P < 1 × 10)*++, t-
test; Extended Data Fig. 1.1). 
In the 23andMe cohort, our main phenotype is again self-reported “general risk tolerance.” We 
use the survey question (n = 508,782): 
“In general, people often face risks when making financial, career, or other life decisions. 
Overall, do you feel comfortable or uncomfortable taking risks? [1] Very comfortable / [2] 
Somewhat comfortable / [3] Neither comfortable nor uncomfortable / [4] Somewhat 
uncomfortable / [5] Very uncomfortable.”  
We reverse this coding for our GWAS, so that “1” is coded as the least risk-related response 
category and “5” as the most risk-related response category.  
In total, then, our full general risk tolerance discovery meta-analysis includes 939,908 people 
from the UK Biobank and from the 23andMe cohort. 
For our replication stage (n = 35,445), we combined 10 independent cohorts from seven studies 
with survey questions on general risk tolerance, all of which included a question similar to the 
one asked in the UKB or in Dohmen et al.4: 
“How do you see yourself: are you generally a person who is fully prepared to take risks or do 
you try to avoid taking risks? Please tick a box on the scale, where the value 0 means: ‘not at all 
willing to take risks’ and the value 10 means: ‘very willing to take risks’.” 
In Supplementary Table 1.1 we report an overview of the cohorts included in our study. 
Supplementary Table 1.2 lists the detailed general-risk-tolerance survey questions available in 
each cohort. The UKB is the only cohort that asks the general-risk-tolerance question in a binary 
fashion; the 23andMe cohort asked this question on a 5-point Likert scale, and all seven 
replication cohorts asked their participants this question on a 10- or 11-point Likert scale. All of 
the replication cohorts are cross-sectional, and only the UKB includes more than one 
measurement over time for some individuals. 
As we further describe in Supplementary Information sections 3.3 and 7.4, we used bivariate 
LD Score Regression24 to estimate the genetic correlation between: (1) the UK Biobank risk-
tolerance GWAS and the 23andMe risk-tolerance GWAS; (2) the UK Biobank risk-tolerance 
GWAS and the replication GWAS; (3) the 23andMe risk-tolerance GWAS and the replication 
GWAS; and (4) the full discovery GWAS of general risk tolerance (UK Biobank + 23andMe) 
and the replication GWAS. For the last three correlations, we see significant, moderately high, 
and positive genetic correlations between 0.75 and 0.83 that are indistinguishable from unity. 
However, for (1), we find a genetic correlation that is distinguishable from unity (?̂?.= 0.767, SE 
= 0.021). Though this genetic correlation is lower than expected, it is high enough to justify the 
meta-analysis of the UK Biobank and 23andMe summary statistics for general risk tolerance that 
we perform as our discovery GWAS18. However, the imperfect correlation points to some degree 
of heterogeneity across the cohorts, which may attenuate the genetic signals we can observe in 
our study. 
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We note that there are various alternative ways to measure risk tolerance, including behavioral 
experiments with real stakes25, hypothetical choices1, and survey questions25. The phenotypic 
correlation between these measures is typically moderate2,4,26, although correcting for 
measurement error substantially increases these correlations2,26. 
Our approach of using survey measures of general risk tolerance has several advantages. First, 
these measures have been shown to correlate with a wide range of risky behaviors such as 
investments in stocks, active sports, self-employment, and smoking, even after controlling for 
age, sex, education, wealth, and income1,2,4,26. Thus, these survey measures capture an important 
dimension of individual differences. There is evidence that measures of general risk tolerance are 
good all-around predictors of risky behavior and perform better in this respect than more specific 
survey measures of risk tolerance4. Second, survey questions of general risk tolerance are cheap 
and easy to collect and have been added to numerous questionnaires, including the UKB, thus 
allowing us to reach a large enough sample size to conduct a well-powered GWAS.  
Although general risk tolerance may be closely related to some psychological measures of 
personality such as extraversion, novelty seeking, or sensation seeking, these constructs are not 
identical. For this reason, personality measures were not included in our main GWAS of general 
risk tolerance, but below we study the predictive power of a polygenic score of general risk 
tolerance for several of these psychological measures of personality, as well as the genetic 
correlation between general risk tolerance and some of these measures.  
We also performed supplementary GWAS for adventurousness, four risky behaviors in the UK 
Biobank (automobile speeding propensity, drinks per week, ever smoker, and number of sexual 
partners), and the first principal component of these four risky behaviors. Moving forward, we 
refer to the main GWAS of general risk tolerance as our “primary GWAS” and the GWAS of 
these additional six phenotypes as our “supplementary GWAS.”  
1.2.2 Adventurousness  
We also performed a GWAS of adventurousness, since this phenotype is known to be related to 
risk-taking behavior27. For this GWAS, we use only summary statistics from the 23andMe 
cohort, and we use the following survey question (n = 557,923): 
“If forced to choose, would you consider yourself to be more cautious or more adventurous? [1] 
Very cautious / [2] Somewhat cautious / [3] Neither / [4] Somewhat adventurous / [5] Very 
adventurous.” 
We maintain this coding, where “1” is coded as the least risk-related response category and “5” 
as the most risk-related response category.  
1.2.3 Other supplementary UKB Risky Behaviors 
We also conducted GWAS studies for other risky behaviors in the UKB.  Our selection strategy 
for these phenotypes was twofold. First, we chose a set of potential GWAS phenotypes by 
searching the UKB database for risky behaviors. The risky behaviors we originally considered 
included automobile speeding propensity, use of sun protection, age of first sexual intercourse, 
number of lifetime sexual partners, teenage conception (females only), as well as whether an 
individual was ever a tobacco smoker, whether an individual is a former tobacco smoker, age of 
tobacco smoking onset, number of cigarettes per day. The inclusion of these risky behaviors as 
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additional GWAS phenotypes builds on previous economics studies that demonstrate the 
predictive power of risk tolerance for various behaviors such as smoking, drinking, portfolio 
allocation, and occupational choice1–5,28. 
Finally, we considered whether an individual was ever an alcohol drinker, whether an individual 
is a current alcohol drinker, whether an individual is an excessive alcohol drinker, and number of 
drinks per day. Ultimately, we decided not to retain the use of sun protection in our main 
analyses, because there was no significant genetic correlation between this phenotype and the 
preliminary results from our GWAS of general risk tolerance using the first release of UKB data 
(?̂?. 	= 	0.025, P value = 0.701, as estimated using bivariate LD Score regression).  
Second, from the remaining phenotypes, we selected just one phenotype in each domain of risky 
behavior (i.e., driving behavior, drinking behavior, smoking behavior, and sexual behavior). To 
do so, we prioritized: 1) phenotypes available in the entire UKB sample, since our general-risk-
tolerance phenotype is defined for everyone in the UKB sample; 2) phenotypes that had been 
previously explored in other published GWAS; and 3) phenotypes which showed a high 
phenotypic correlation with our main general-risk-tolerance phenotype in the first release of the 
UKB data (this is the data we had access to when deciding which phenotypes to select). If not 
reported in the text below, these correlations from the first release of the UKB are available upon 
request, although the differences in the correlations between the first and full release are small. 
For a list of the phenotypic correlations between the selected phenotypes in the full release of the 
UKB, see Supplementary Table 1.3. Below we highlight how the phenotypes in each domain of 
risky behavior were selected and are defined. 
Automobile speeding propensity: Automobile speeding propensity is the only phenotype 
available that measures risky driving behavior in the UKB; its phenotypic correlation with 
general risk tolerance in the first release of the UKB is 0.164. Respondents were asked, “How 
often do you drive faster than the speed limit on the motorway?” Response options include: 1) 
Never/rarely; 2) Sometimes; 3) Often; 4) Most of the time; and 5) Do not drive on the motorway. 
We first dropped all participants who reported not driving on the motorway, and then we 
normalizeda our categorical variable for males and females separately. In total, this GWAS 
includes 404,291 individuals in the UK Biobank. 
Drinks per week: There are several phenotype options that measure drinking behavior in the 
UKB. After considering only phenotypes that cover the entire UKB sample, we were left with 
two: drinks per week and excessive alcohol drinking. Our drinks per week measure is 
constructed from responses to a sequence of questions. First, respondents were asked how often 
they drink alcohol, and response options include 1) daily or almost daily; 2) three or four times 
per week; 3) once or twice per week; 4) one to three times per month; 5) special occasions only; 
and 6) never. Respondents who reported drinking once per week or more were asked how many 
glasses of various types of alcoholic beverages they consume per week. We used the sum of all 
alcoholic drinks per week as our drinks per week phenotype for these respondents. Respondents 
who reported drinking less than once per week (one to three times per month or on special 
occasions only) were asked how many glasses of various types of alcoholic beverages they 
consume per month.  For these respondents, we added the total number of drinks per month and 
                                                        
a The normalized variable is the inverse normal cumulative distribution function (CDF) of the observations’ 
percentile ranks. 
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divided by 4 to arrive at an approximated number of drinks per week. Respondents who reported 
never drinking were coded as 0.  
For the excessive alcohol drinking phenotype, we use current UK Chief Medical Officer drinking 
guidelinesb to code respondents who drink 14 or fewer drinks per week as 0 and more than 14 
drinks per week as 1. Our drinks per week phenotype had a higher phenotypic correlation with 
general risk tolerance in the first release of the UKB (0.139) than did our excessive alcohol 
drinking phenotype (0.074); further, drinks per week is a consistent phenotype studied in the 
alcohol GWAS literature. We therefore use this drinks per week phenotype as our final drinking 
behavior GWAS phenotype. In total, this GWAS includes 414,343 individuals in the UK 
Biobank. 
Ever smoker: There are several potential measures of smoking behavior in the UKB.  These 
include: 1) ever-tobacco smoker status; 2) former tobacco smoker status (among ever-tobacco 
smokers); 3) age of tobacco smoking onset (among ever-tobacco smokers); and 4) number of 
cigarettes per day. Because former tobacco smoker status and age of tobacco smoking onset were 
measured only for individuals who had ever been tobacco smokers, they are not defined for the 
entire UKB sample, and we thus did not select these phenotypes.   
For our remaining possibilities, we coded ever-tobacco smoker status as 1 if a respondent 
reported that they were a current or previous smoker and 0 if they reported never smoking or 
only smoking once or twice. We coded cigarettes per day as 0 if ever-smoking status was also 0; 
otherwise, we used the maximum number of reported past or current cigarettes (or pipes/cigars) 
consumed per day, normalized separately for males and females. Our cigarettes per day 
phenotype had a slightly higher phenotypic correlation with general risk tolerance in the first 
release of the UKB (0.098) than ever-smoker status (0.092). However, we concluded that the 
consistency of the ever smoker phenotype with previous GWAS literature overrides this slightly 
higher phenotypic correlation, and we therefore use this ever smoker phenotype as our final 
smoking behavior GWAS phenotype.   
For our GWAS of ever smoker, we meta-analyzed the summary statistics from the UKB GWAS 
with those from the Tobacco, Alcohol and Genetics (TAG) Consortium29  (the TAG consortium 
refers to the ever smoker phenotype as “smoking initiation”). In total, this meta-analysis includes 
518,633 people from the meta-analyzed UK Biobank (444,598) and TAG (74,035) summary 
statistics. 
Number of sexual partners: The potential phenotypes for assessing risky sexual behavior in the 
UKB include teenage conception (which we coded ourselves from available phenotypes related 
to age and pregnancy), age of first sexual intercourse, and lifetime number of sexual partners. 
Because we only defined teenage conception for females, we did not pursue this phenotype. 
Lifetime number of sexual partners has a much higher phenotypic correlation with general risk 
tolerance in the first release of the UKB (0.207) than does age of first sexual intercourse.  We 
therefore use lifetime number of sexual partners (hereafter referred to as simply “number of 
sexual partners”) as our final risky sexual behavior GWAS phenotype. For this phenotype, 
respondents were asked, “About how many sexual partners have you had in your lifetime?” If 
respondents reported more than 99 lifetime sexual partners, they were asked to confirm their 
responses. We assigned a value of 0 to participants who reported having never had sex, and we 
                                                        
b https://www.drinkaware.co.uk/alcohol-facts/alcoholic-drinks-units/latest-uk-alcohol-unit-guidance/. 
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again normalized this measure separately for males and females. In total, this GWAS includes 
370,711 individuals in the UK Biobank. 
First PC of risky behaviors: We performed a principal component analysis (PCA) with our four 
selected risky behaviors above and obtained the first principal component (PC) (see 
Supplementary Table 1.4). The first PC is the linear combination of the four risky behaviors 
that has the largest possible variance (among all possible linear combinations where the squares 
of the weights on the four risky behaviors sum to one). It can be interpreted as a general factor of 
risky behavior. As we describe below, we performed a GWAS of this first PC of risky behaviors, 
and we also examined the genetic correlation between this PC and general risk tolerance (see 
Supplementary Table 7.1). In total, this GWAS includes 315, 894 people in the UK Biobank. 
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2 GWAS, quality control and meta-analysis 
2.1 Overview of primary GWAS 
All analyses were performed at the cohort level according to a pre-specified and publicly 
archived analysis plan30. The original analysis plan was archived on February 4, 2016. For self-
reported general risk tolerance, the analysis plan specified that the discovery GWAS would be 
conducted in the UKB and that the replication would be carried out in a meta-analysis of all 
other cohorts.  
We updated the analysis plan on November 9, 2016 to include the analysis of the four risky 
behaviors and their first PC. For these phenotypes, the analysis plan specified that the GWAS 
would be conducted in the UKB. We did not attempt replication for these phenotypes. We 
updated the analysis plan a second time on July 10, 2017 to add the 23andMe cohort to the 
discovery GWAS of self-reported general risk tolerance. Two minor updates were made on 
August 7 and September 14, 2017 to specify that follow-up analyses (such as polygenic 
prediction) would be performed, whenever possible, on a meta-analysis combining the discovery 
and replication GWAS of general risk tolerance, and that we would add a GWAS of 
adventurousness alongside the primary GWAS of general risk tolerance and the other 
supplementary GWAS. 
Cohorts other than the UKB could join this study by first supplying descriptive statistics and 
thereafter GWAS summary statistics from GWAS of self-reported general risk tolerance in 
November 2015 and December 2015, respectively. Two additional cohorts, Army STARRS and 
VHSS, joined the study later and provided descriptive and GWAS summary statistics in late 
2016. Summary statistics were uploaded to a central, secure server and subsequently meta-
analyzed. The lead PI of each cohort affirmed that the results contributed to the study were based 
on analyses approved by the local Research Ethics Committee and/or Institutional Review Board 
responsible for overseeing research. All participants provided written informed consent. We also 
obtained the descriptive and GWAS summary statistics from GWAS of self-reported general risk 
tolerance and adventurousness from 23andMe in late July 2017. An overview of the participating 
cohorts is reported in Supplementary Table 1.1. 
The analysis plan instructed all cohorts to limit the analysis to individuals of European ancestry, 
to exclude individuals with missing covariates, to remove samples that displayed a SNP call rate 
of less than 95%, and to apply cohort-specific standard quality control filters before imputation. 
The cohort-specific standard quality control filters are reported in Supplementary Table 2.1. 
GWAS were limited to the 22 autosomes. The cohorts were required to provide unfiltered 
GWAS summary statistics including the following information for each SNP: chromosome and 
base-pair position, rsID, effect-coded allele, other allele, sample size per SNP, coefficient 
estimate (beta), standard error of the coefficient estimate, P value of the association uncorrected 
for genomic control, effect-coded allele frequency (EAF), imputation status, imputation quality, 
and Hardy-Weinberg equilibrium exact test P value for directly genotyped markers.  
The analysis plan included power calculations assuming that 100,000 individuals in the UKB 
answered “Yes” (“cases”) to the general-risk-tolerance question, and 270,000 individuals 
answered “No” (“controls”). Under this assumption, our study would have 73% power to detect 
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single nucleotide polymorphisms (SNPs) with a minor allele frequency (MAF) of 0.3 and an 
odds ratio of 1.05 with a genome-wide significance threshold of P = 5×10–8.  
For general risk tolerance, the final sample size for the “discovery GWAS” meta-analysis of the 
UKB and 23andMe cohorts was 939,908 individuals. Replication was performed in a meta-
analysis of 10 independent cohorts from seven studies totaling 35,445 individuals. We will 
henceforth refer to this meta-analysis of the 10 replication cohorts as the “replication GWAS.” 
The follow-up analyses we describe in the following Supplementary Information sections 
were performed with GWAS summary statistics from a meta-analysis combining the discovery 
and replication GWAS (n = 975,353), except where otherwise noted. 
For adventurousness, GWAS summary statistics from 23andMe were analyzed (n = 557,923). 
For three of the four risky behaviors, namely automobile speeding propensity (n = 404,291), 
drinks per week (n = 414,343), and number of sexual partners (n = 370,711), and for the first PC 
of the four risky behaviors (n = 315,894), GWAS were conducted in the UKB only, as specified 
in the updated analysis plan. For the remaining risky behavior, ever smoker, we meta-analyzed 
the summary statistics from the UKB GWAS (n = 444,598) with those from the Tobacco, 
Alcohol and Genetics (TAG) Consortium29 (n = 74,035), leading to a total sample size of 
518,633 (the TAG consortium refers to the ever smoker phenotype as "smoking initiation"). 
2.2 Genotyping and imputation 
Genotypinga was performed using a range of common, commercially available genotyping 
arrays. An overview of the genotyping and imputation procedure is provided in Supplementary 
Table 2.1. The participating cohorts were encouraged to use their standard quality control 
protocols before imputation, as long as the applied filters satisfied the minimum requirements 
specified in the analysis plan (SNP call rate > 95%, HWE exact test P value > 10–6, MAF > 1%). 
For the UKB, different filters were used, following ref.31.  
The cohorts, except for 23andMe, Army STARRS, BASE-II, UKB, and VHSS imputed markers 
using the 1000 Genomes phase 1 reference panel (March 2012 release version 3). 23andMe used 
the 1000 Genomes phase 1 (September 2013 haplotype release). Army STARSS used the 1000 
Genomes phase 1 (August 2012 haplotype release). BASE-II used the more recent reference 
panel 1000 Genomes phase 3 (October 2014 haplotype release version 5). UKB used a 
customized reference panel based on the Haplotype Reference Consortium release 1.1 combined 
with the UK10K haplotype reference panel32. VHSS used the Haplotype Reference Consortium 
release 1.133. 
All genetic positions reported in this study are denoted with those of the Genome Reference 
Consortium’s human assembly 37 (GRCh37, sometimes referred to as the National Center for 
Biotechnology Information hg19). 
2.3 Association analyses 
Cohorts were encouraged to exclude individuals with SNP call rates less than 95%, with 
excessive autosomal heterozygosity, and with sex mismatch. Family-based cohorts were 
informed to control for family structure either with mixed linear modeling or with a procedure 
                                                        
a The UKB genotype data was handled with QCtool, available at http://www.well.ox.ac.uk/~gav/qctool/#overview 
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selecting only one individual in each pair that displayed relatedness greater than 5% in a genetic 
relatedness matrix. 
The genome-wide association analysis performed in each cohort estimated the following 
regression for each SNP, as in Okbay et al. 201616: 
(1) 𝑌5 = 𝛽+ + 𝛽*𝑆𝑁𝑃5 + 𝑷𝑪𝒊𝜸 + 𝑿𝒊𝜶 + 𝑪𝒊𝜽 + 𝜖5, 
where 𝑌5 is the phenotype for individual 𝑖, 𝑆𝑁𝑃5 is the number of effect-coded alleles of the 
SNPb, 𝑷𝑪𝒊 is a vector of principal components of the genetic relatedness matrix after application 
of the pre-imputation filters described above, and 𝑿𝒊 is a vector of control variables. The control 
variables include sex, birth year, birth year squared, birth year cubed, and the interactions 
between sex and the three birth-year variables. 𝑪𝒊 is a vector containing cohort-specific controls 
and technical covariates (such as dummy variables for genotyping array and genotyping batches) 
that were recommended in the analysis plan. All associations were performed with males and 
females pooled. A summary of the GWAS association models and control variables for each 
cohort is reported in Supplementary Table 2.2. 
In practice, the phenotype was often residualized by first regressing the phenotype on the control 
variables, and the residualized phenotype was then regressed on the genotypes. This approach 
leads to almost identical results as estimating the full regression model directly while drastically 
reducing the computation time needed for the GWAS.  
2.3.1 Linear mixed models in the UKB 
The association analyses in the UKB were performed with linear mixed models (LMM) with the 
BOLT-LMM v2.2 software34. The benefit of LMM is that the method accounts for cryptic 
relatedness and population structure, which allows the inclusion of related individuals in the 
sample, thereby yielding a larger sample size and greater statistical power. Using LMM is 
computationally intensive, and the BOLT algorithm is a new method that makes LMM analysis 
of hundreds of thousands of individuals computationally feasible. The method requires a set of 
SNPs to be included in the genetic variance component, and we included 483,680 directly 
genotyped bi-allelic autosomal SNPs with MAF > 0.005 and HWE P value > 10–6. We included 
individuals based on self-reported ancestry, specifically those who self-reported to be of “white” 
ancestry (i.e., self-reported white, British, Irish, or any other white background). In addition, we 
limited the GWAS to individuals for whom the value of the first principal component of the 
genetic relatedness matrix was less than “0,” which identifies the cluster of individuals of 
European ancestry. We dropped individuals whose reported sex did not match their genetic sex, 
individuals with putative sex chromosome aneuploidy, individuals that did not pass the UKB 
internal genotype quality control, and individuals with missing values. 
2.4 Main reference panel 
The full release of the UK Biobank genetic data was imputed with haplotypes from the 
Haplotype Reference Consortium v1.1 (HRC) and the UK10K haplotype reference panel32. A 
recommendation was communicated soon after the release of the genotype data in July 2017. It 
                                                        
b For imputed SNPs we used best-guess data for samples that were imputed with IMPUTE242, and dosage data for 
samples that were imputed with MaCH/Minimac243. 
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was recommended that only SNPs available in the HRC be used for analysis, because a subset of 
variants imputed from the UK10K reference panel have wrongfully imputed genomic positions, 
while none of the HRC SNPs are affected. We therefore used the HRC v.1.1 as the reference 
panel for quality control of the GWAS summary statistics, and to determine the independence of 
significant loci. The following section describes our quality control of the HRC whole-genome 
sequence data (WGS) when constructing the reference panel. We will hereafter refer to the 
resulting reference panel as the “main reference panel.” 
2.4.1 Quality-control of the main reference panel 
The HRC haplotypes were downloaded from the European Genome-phenome Archive (EGA) on 
August 1, 2017. Strict internal quality control had already been applied to the WGS data, as 
described in-depth elsewhere33, and we restricted the main reference panel to variants that passed 
all pre-applied genotype call filters (i.e., variants whose VCF FILTER status is “PASS”; these 
pre-applied filters included, among other filters, a filter to remove variants with minor allele 
count (MAC) ≤ 5.) Before our internal QC the WGS data contained 40,405,506 autosomal and 
X-chromosome SNPs. The following protocol was restricted to the 39,131,579 autosomal SNPs 
because the pre-registered analysis plan restricts our analyses to the autosomes. The HRC 
reference panel does not include any structural variants, such as INDELs33. 
We performed a series of best-practice alignments of the WGS data for consistent and unique 
identification of variants35 with the open-source software BCFtoolsc created by the Wellcome 
Trust Sanger Institute. Because PLINK cannot properly handle truly multi-allelic variants, we 
split multi-allelic variants into multiple bi-allelic variants. We then confirmed that all reference 
alleles and genomic positions matched the Genome Reference Consortium Human genome build 
37 (GRCh37)36. To avoid issues with chromosomal positions mapping to multiple NCBI marker 
IDs (rsIDs), all rsIDs were removed, and all variants were given a unique identifier (henceforth 
referred to the as the “unique ID”) in the form of chromosome, base-pair position, reference 
allele, and alternative allele, separated by colons (e.g., 1:123456:C:T). Using this format for 
variant IDs, together with the alignment to the reference genome GRCh37, ensures a unique 
representation of all SNPs and a lack of duplicate variants with switched reference alleles (e.g., 
1:123456:C:T and 1:123456:T:C). 
To avoid possible issues with inconsistencies with the UK10K haplotype reference in future 
work that may use that reference, we investigated possible strand and allele issues across the 
reference panels. By comparing the reference alleles and allele frequencies we found 24,394 loci 
with inconsistent alleles, and we decided to drop these from the main reference panel so that they 
would be removed during QC of the GWAS summary statistics. 
We converted the VCF data to PLINK binary format with PLINK v.1.9b3.4637, and we removed 
all multi-allelic loci (without retaining any of the multi-allelic variants coded as bi-allelic SNPs). 
Monomorphic SNPs (i.e., SNPs with MAF = 0) were kept in the reference panel as 
recommended33. We thereafter excluded one member of each pair of individuals with genomic 
relatedness greater than 0.025 from the sample, which removed 4,917 individuals of the 22,691 
individuals for whom data were available for all autosomes in the VCF data. 
                                                        
c BCFtools can be downloaded here: http://samtools.github.io/bcftools/bcftools.html. 
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In summary, the main reference panel consists of 17,774 individuals and includes 38,889,224 bi-
allelic autosomal SNPs that passed QC.  
2.4.2 rsID mapping 
Since rsIDs were removed from the SNPs to ensure unique identification, we created a map file 
so that each SNP could be assigned an rsID after meta-analysis, which is performed on the 
unique ID format described above (e.g., 1:123456:C:T). The map file contains the rsIDs from the 
HRC v1.1 sites list, and because we removed all multi-allelic variants there are no duplicate 
rsIDs. 
2.5 Quality control of allele-frequency differences between the UK Biobank 
genotyping arrays 
The participants of the UKB were genotyped with two different but similar genotyping arrays: 
the UK BiLEVE Axiom array (n ~ 50,000) and the UK Biobank Axiom array (n ~ 450,000)32. It 
was communicated that the first release of UKB data contained a small set of 65 autosomal SNPs 
that appeared to have flipped reference alleles contingent on the array. A subset of these had 
unfortunately been used during the imputation procedure. We already control for genotype array 
and batch during GWAS analyses, but as an additional QC step beyond excluding the 65 
previously reported flipped SNPs, we investigated the allele frequencies across the arrays to be 
sure that our results were unaffected by artifacts from the genotyping procedure. It should be 
noted that the participants genotyped with the UK BiLEVE array were chosen based on lung 
function and smoking behavior38, but the sample is in all other respects comparable to the rest of 
the UK Biobank39. 
We restricted the imputed genotype data to unrelated individuals of British ancestry to ensure 
that allele-frequency differences across the genotyping arrays would not be caused by differences 
in the proportion of ancestries or be affected by dependent observations. With PLINK37, we 
calculated the allele frequencies contingent on the genotyping array for both the directly 
genotyped and imputed SNPs. Because our quality-control protocol, described in the next 
section, restricts the GWAS to SNPs with MAF ≥ 0.001, we chose not to investigate SNPs with 
MAF < 0.001 (in the imputed genotype data) for allele-frequency differences between the UKB 
genotyping arrays. SNPs available on only one of the genotyping arrays and SNPs that were not 
available in our main reference panel were not considered in this investigation of allele-
frequency differences. 
For each SNP included in the investigation, three quantities measuring differences in allele 
frequencies were examined: the absolute value of the difference between the two arrays and the 
absolute value of the difference between the main reference panel and each of the arrays. We 
flagged a SNP as problematic if it fulfilled the following two conditions: (i) if the absolute value 
of the difference between the two arrays was greater than 0.25; and (ii) if the absolute value of 
the difference between the main reference panel and at least one of the genotyping arrays was 
greater than 0.25. The comparison resulted in 600 flagged autosomal SNPs (including the 65 
SNPs that were already reported as problematic) that were removed from the UKB summary 
statistics during QC in Supplementary Information section 2.6.2. 
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2.6 Description of major steps in quality-control (QC) analyses 
For each cohort, we applied a stringent quality-control protocol based on the EasyQC software 
(version 9.2) developed by the GIANT consortium40, as well as additional steps developed by the 
Social Science Genetic Association Consortium16,18. All issues raised during implementation of 
the protocol described below were resolved through iterations between the meta-analyst and the 
cohort analysts before any GWAS summary statistics were forwarded for meta-analysis. 
2.6.1 Pre-QC verification and harmonization of GWAS summary statistics 
All cohorts were asked to supply descriptive statistics and phenotype definitions according to the 
pre-specified analysis plan30. The completeness of these documents was assessed as the first step 
of the quality control, together with examination of the uploaded GWAS summary statistics. All 
GWAS summary statistics were harmonized to ensure that the SNP identifier was in an 
admissible format (i.e. either an rsID, or in a format containing the chromosome, base pair (bp), 
and the two alleles of the SNP), that the missing string operator was set to “NA,” and that all 
files had the same column delimiter.  
2.6.2 Filters applied before EasyQC protocol 
Following recommendations provided by the UK Biobank, we removed the 65 autosomal SNPs 
from the UKB that had been flagged as having incorrect annotation, together with the additional 
535 SNPs that we flagged in section 1.5, before applying the EasyQC protocol described below.  
Also, for cohorts imputed with the September or December 2013 haplotype release of the 1000 
Genomes imputation reference panel, we removed 737 SNPs with incorrect strand alignmentd. 
2.6.3 EasyQC protocol 
The filters applied in the EasyQC software are explained below in chronological order of 
implementation. Note that the order of the filters does not influence the outcome of the cleaned 
GWAS summary statistics (although it affects at which specific filter a SNP is removed). The 
number of SNPs filtered at each step of the EasyQC protocol is reported in Supplementary 
Table 2.3. 
Step 1 in the EasyQC protocol filtered out SNPs for which either the effect-coded allele or the 
other allele has values different from “A,” “C,” “G,” or “T.” This step removed all structural 
variants such as INDELs.  
Step 2 filtered out SNPs with missing values for one or more of the following variables: P value, 
an estimated effect size (beta) or its standard error, frequency of the reference allele, imputation 
status, and imputation accuracy (conditional on the SNP being imputed). This filter also removed 
SNPs with nonsense values outside of permissible ranges such as negative or infinite standard 
errors, nonsensical P values, allele frequencies greater than 1 or below 0, as well as imputation 
status not equal to 1 or 0.  
                                                        
d The announcements are available on the webpage of IMPUTE2 
https://mathgen.stats.ox.ac.uk/impute/data_download_1000G_1_integrated_SHAPEIT2_16-06-14.html and 
https://mathgen.stats.ox.ac.uk/impute/data_download_1000G_phase1_integrated_SHAPEIT2_9-12-13.html.  
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The thresholds chosen for the filters applied in steps 3 to 5 are summarized in Supplementary 
Table 2.4. Step 3 filtered out SNPs with a MAF below 0.1% for the UKB and 23andMe cohorts 
and below 1% for all other cohorts; this effectively removed any SNPs that were monomorphic 
in the summary statistics. Step 4 excluded SNPs based on imputation accuracy with a threshold 
contingent on the cohort-specific imputation software (0.6 for MACH, 0.7 for IMPUTE, and 0.8 
for PLINK). Step 5 filtered out directly genotyped SNPs with a Hardy-Weinberg equilibrium 
exact test P value below a threshold contingent on the cohort sample size. The applied thresholds 
were 10–3 if 𝑛 < 1,000, 10–4 if 1,000 ≤ 𝑛 < 2,000, and 10–5 if 2,000 ≤ 𝑛 < 10,000. 
Two additional filters were applied to ensure that only high-quality SNPs were being forwarded 
to the meta-analysis; step 6 removed SNP j if 
 
(2) 𝑆𝐸JK > 1.4 𝜎OPQ2 ∙ 𝑛K ∙ 𝑀𝐴𝐹K ∙ V1 − 𝑀𝐴𝐹KX, 
where 𝜎OP is the standard deviation of the phenotype, 𝑛K is the sample size,	𝑆𝐸K is the standard 
error of the coefficient estimate for SNP j, and 𝑀𝐴𝐹K is the minor allele frequency of SNP j.  
This filter eliminates SNPs whose coefficient estimates have standard errors that are more than 
~40% larger than what would be expected given the sample size, the MAF of the SNP, and the 
standard deviation of the phenotype. The second additional filter, step 7, removes SNPs with 
coefficient estimates larger than what would correspond to an R2 greater than 5%. We adapted 
the filter from Okbay et al.16 using an approximation to the R2: SNP j is dropped if 
 
(3) Y𝛽ZKY > √0.05 ∙ 𝜎OPQ2 ∙ 𝑀𝐴𝐹K ∙ V1 − 𝑀𝐴𝐹KX. 
Step 8 filtered out duplicate SNPs (SNPs with identical NCBI build 37 (UCSC hg19) 
chromosome and base-pair positions). This was implemented after the chromosome and base-
pair positions of the SNPs had been harmonized with the main reference panel described above. 
Step 9 aligned the SNPs to the main reference panel to ensure that the effect-coded allele was the 
same for all SNPs across the cohorts. This step removed SNPs that were not available in the 
main reference panel as well as SNPs that displayed an allele mismatch when compared to the 
reference (e.g., a SNP with the alleles A and T in the GWAS summary statistics would be 
removed if the alleles according to the reference panel were A and G). 
Step 10 removed SNPs that deviated from the main reference panel in terms of allele frequency. 
A SNP was removed if the absolute difference between its allele frequencies in the cohort’s data 
and in the main reference panel was greater than 0.2. Step 10 was applied to all cohorts including 
the UKB (for the UKB, this filter was thus applied in addition to the filter described in 
Supplementary Information section 2.5 and Supplementary Information section 2.6.2, the 
purpose of which was to avoid potential strand issues caused by the two different UKB 
genotyping arrays).  
The output from the quality control was examined to see if any filters removed an unusual or 
unexpected number of SNPs. Some cohorts required iterations with the analysts to ensure that all 
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possible errors were resolved. The number of SNPs filtered at each step of the final quality 
control iteration is reported in Supplementary Table 2.3 together with the estimated genomic 
inflation factor (𝜆]^).  
2.6.4 Visual inspection of diagnostic plots 
Once low-quality SNPs were filtered out, the remaining SNPs were used to produce several 
diagnostic plots for each cohort, most of which are the standard output of the EasyQC software. 
Visual inspection of these plots enabled the identification of possible issues or errors in the 
GWAS summary statistics of each cohort; for a more thorough discussion we refer the interested 
reader to Winkler et al.40. For any potential issues observed in these plots, we contacted the 
cohort-specific analyst and ensured that the observed issues were completely resolved. The 
following plots were examined: 
Allele Frequency Plots (AF Plots): The AF plot contrasts the observed allele frequencies with the 
expected allele frequencies calculated according to the main reference panel, and the plot was 
created before step 10 of the EasyQC protocol. If the sample closely resembles the reference 
panel in terms of allele frequencies, then the SNPs should align in a diagonal with positive slope. 
This plot enables the analyst to detect deviations in ancestry from the reference as well as issues 
related to the alignment of the effect-coded allele. If the wrong effect-coded allele has been 
specified, then the AF plot shows a diagonal with negative slope. 
P-Z Plots: Inspection of this plot shows if the reported P values are consistent with the reported 
coefficient estimates and their standard errors. One common problem observable with the P-Z 
plot is an erroneous column header in the GWAS summary statistics, such that the wrong column 
is used for either the beta estimates, standard errors or P values in the analysis. 
Q-Q Plots: Inspection of Q-Q plots enables visualization of unaccounted-for stratification in the 
cohorts. No cohort displayed premature lift-off in the Q-Q plot associated with unaccounted-for 
stratification. The genomic inflation factors 𝜆]^  are displayed in Supplementary Table 2.3.  
SE Plots: We plotted the observed standard errors (𝑆𝐸K) of the coefficient estimates versus the 
standard errors expected given the 𝑀𝐴𝐹K and the sample size 𝑛K of a given SNP j, and the 
standard deviation of the phenotype 𝜎OP (which is equal to 1 if the phenotype has been 
standardized). This enables visual inspection to identify groups of outlier SNPs with regard to 
the observed standard error. The expected standard error was calculated according to the 
following formula: 
 
(4) 𝑆𝐸JK ≈ 𝜎OPQ2 ∙ 𝑛K ∙ 𝑀𝐴𝐹K ∙ V1 − 𝑀𝐴𝐹KX	 
All cohorts had to pass visual inspection as well as inspection of the number of excluded SNPs at 
each of the exclusion filters described in the previous subsection before being passed on for the 
meta-analysis. 
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2.7 Meta-analysis and adjustment of the standard errors 
Sample-size weighted meta-analysis of the cleaned cohort-level GWAS summary statistics were 
carried out using the METAL software41. We conducted four main meta-analyses: (1) we meta-
analyzed the discovery GWAS combining the UKB and 23andMe cohorts; (2) we meta-analyzed 
the results of the 10 replication cohorts without the UKB and 23andMe discovery cohorts, to 
obtain our replication GWAS; (3) we meta-analyzed the results of the 10 replication cohorts 
together with those of the UKB and 23andMe discovery cohorts for the follow-up analyses that 
use GWAS summary statistics; and (4) we meta-analyzed the results from our UKB GWAS of 
ever smoker with those from the TAG Consortium29. No meta-analyses were conducted for the 
five other supplementary GWAS, because data for these GWAS each came from only one cohort 
(either the UKB or the 23andMe cohort). 
All meta-analyses were restricted to SNPs with a sample size greater than half of the maximum 
SNP sample size and were performed with the “ChrPosID” as the identifier of each SNP (e.g. 
1:123456)18 .  
Instead of applying genomic control with the over-conservative 𝜆]^ , we inflated the standard 
errors by the square root of the estimated intercept from an LD Score regression. This procedure 
allows us to correct only for inflation of test statistics caused by population stratification and 
other confounding factors rather than polygenicity42.  
For the discovery and replication GWAS of general risk tolerance and for the GWAS of ever 
smoker—all of which involved meta-analyses of cohort-level data—we only inflated the meta-
level standard errors (i.e., we did not inflate the cohort-level standard errors before the meta-
analysis). Likewise, for the meta-analysis of the discovery and replication GWAS for the follow-
up analyses, we only inflated the meta-level standard errors. We also inflated the standard errors 
of the other supplementary GWAS. 
In practice, for a given meta-analysis, the METAL software41 outputs the SNPs’ meta-analyzed 
z-statistics, deflated by the square root of the estimated intercept from an LD Score regression. 
We use SNP j’s GWAS sample size 𝑛K and minor allele frequency 𝑀𝐴𝐹K, as well as the 
phenotype’s standard deviation 𝜎O`, to approximate the inflated standard error of our estimate of 
SNP j’s effect size: 𝑆𝐸JK ≈ a𝐼𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡 ∙ 𝜎O`Q2 ∙ 𝑛K ∙ 𝑀𝐴𝐹KV1 − 𝑀𝐴𝐹KX	, 
where a𝐼𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡 is the square-root of the LD Score intercept used to deflate the z-statistic in 
the meta-analysis.  
We then used SNP j’s deflated z-statistics ?̂?K to approximate SNP j’s effect size as 𝛽ZK ≈ ?̂?K ∙ 𝑆𝐸hJ  e. 
Since the general-risk-tolerance phenotype is not measured in natural units, and since its standard 
deviation differs across cohorts, we normalize it to have a standard deviation of one when we 
estimate the SNPs’ effect sizes and standard errors. For consistency, we make the same 
assumption when approximating the SNPs’ effect sizes and standard errors for the risky 
                                                        
e Since ?̂?K is deflated and 𝑆𝐸J  is inflated by the square root of the intercept from the LD score regression, 𝛽ZK is neither 
deflated nor inflated. 
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behaviors and their first PC. Hence, our estimated effect sizes (the 𝛽ZK’s) are expressed in 
standard-deviation units of the phenotype per effect-coded allele; we hereafter refer to this as a 
“standardized beta,” although it is only standardized in terms of standard deviation units of the 
phenotype (and not with respect to the genotype). The standard deviations of the phenotypes, as 
originally measured, are reported in Supplementary Table 1.2. 
The coefficient of determination of SNP j is approximated as43: 
(5) 𝑅K" ≈ 2 ∙ 𝑀𝐴𝐹KV1 − 𝑀𝐴𝐹KX ∙ 𝛽ZK"𝜎O"` . 
2.8 Independence of significant loci and definition of locus 
To identify approximately independent genome-wide significant loci, we used PLINK37 to apply 
a “clumping algorithm” to the GWAS results. Our clumping algorithm identifies lead SNPs and 
defines independent loci that include SNPs with an r2 greater than 0.1 with each lead SNP. (A 
lead SNP is the most significant of the genome-wide significant SNPs in an independent locus.) 
Specifically, the clumping algorithm uses four parameters: a primary P value threshold (5×10–8), 
a secondary P value threshold (1×10–4), an r2 threshold (0.1), and a SNP window defined in 
kilobases (1,000,000 kb). First, the SNP with the lowest P value (less than the primary P value 
threshold) is taken as the lead SNP in the first clump, and the first clump is formed by all SNPs 
with a P value smaller than the secondary P value thresholdf, with an r2 greater than 0.1 with the 
clump’s lead SNP, and within a distance less than the SNP window from the lead SNPg. Next, 
the SNP with the second lowest P value (less than the primary P value threshold) outside the first 
clump becomes the lead SNP of the second clump, and the second clump is created analogously 
but using only the SNPs outside of the first clump. This process continues until all SNPs with a P 
value less than the primary P value threshold are either defined as the lead SNP of a clump or 
clumped with another lead SNP. The r2 was calculated with the main reference panel. 
Thus, our definition of a locus is the set of all SNPs that are in weak or stronger LD (pairwise r2 
> 0.1) with a lead SNP (and that have not been clumped to another, more significant, lead SNP). 
We note that, because we consider approximately independent (pairwise r2 < 0.1) lead SNPs 
(rather than fully independent lead SNPs), some of our lead SNPs could in principle be 
secondary associations that are driven by their LD with extremely strong primary associations. 
However, based on the results we present in Supplementary Information section 3.3 and report 
in Supplementary Tables 3.1-3.2, we believe this is unlikely to be the case for the vast majority 
of our lead SNPs, because they are not located near other associations that could be strong 
enough to be driving secondary associations. One exception is a very strong association in the 
gene ADH1B with drinks per week (rs1229984, P = 7.80×10–202), which could potentially be 
responsible for the genome-wide significance of some nearby lead SNPs in our GWAS of drinks 
per week. 
                                                        
f The secondary P value threshold lowers the computational effort by allowing the algorithm to ignore SNPs with 
large P values. 
g We used a very wide SNP window of 1,000,000 kb, which effectively makes the r2 and P value thresholds the only 
binding parameters for the PLINK clumping algorithm. 
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To see how sensitive the number of lead SNPs we report is to the r2 threshold used in the 
clumping algorithm, for our discovery GWAS of general risk tolerance we also applied the 
clumping algorithm with the more stringent r2 threshold of 0.01 (instead of 0.1) (Supplementary 
Information section 3.3). 
2.9 Check for long-range LD regions, candidate inversions, and 1000 
Genomes structural variants 
2.9.1 Check for long-range LD regions 
We investigated if the lead SNPs were located in larger structural variation in the form of long-
range LD regions, by using a set of long-range LD regions from Price et al.44. Price et al. 
identified 24 long-range LD regions from 327 European-ancestry individuals, which replicated in 
two independent samples comprising 1593 European-ancestry Americans and 3004 British 
individuals. We lifted the genomic positions of the long-range LD regions to build 37 (GRCh37) 
with the UCSC genome-annotation lift-over toolh, and there were nine long-range LD regions 
that could not be lifted due to non-overlapping genome sequences or ambiguous mapping across 
the builds. Hence, the combined map contains 15 long-range LD regions that have non-
ambiguous genomic positions available in build 37. These range from ~2.5 to ~8 Mb in genomic 
size.  
We checked if each lead SNP from the GWAS was within a long-range LD region, or within 250 
bp from the breakpoints of such a region. The results are reported in Supplementary Table 3.1 
and Supplementary Table 3.2.  
2.9.2 Check for candidate inversions 
We also investigated if the lead SNPs were located in larger structural variation in the form of 
candidate inversions, by using a list of genomic segments highly prone to inversion 
polymorphisms from an unpublished resource by Gonzalez, J.R. & Esko, T., (2017, 
unpublished). The genomic segments highly prone to inversion polymorphisms were identified 
based on the knowledge that submicroscopic human inversions are typically flanked by highly 
homologous flanking repeats45, which predisposes their occurrence by non-allelic homologous 
recombination. Therefore, a set of segments was selected that may be prone to submicroscopic 
inversions, consisting of all single copy segments in the Genome Reference Consortium’s human 
reference sequence build 36 (GRCh36) between 0.1 and 8 Mb in length, and flanked by 
segmental duplications with 90% identity (across the flanking duplications). In total, there were 
173 segments that met these criteria and that were thus considered as genomic segments highly 
prone to inversions. As detectable traces of inversions in SNPs depend on many factors—such as 
being frequent, ancient and nonrecurring—we tested whether the segments showed inversion 
patterns in any of two different SNP datasets. First, 69 (40%) of the segments overlapped with 
the inversions that Caceres et al.46 obtained in the phased genotypes of CEU individuals from the 
HapMap III project. Second, inversion-like haplotypes47 were inferred in a subsample of 882 
Estonians for which gene expression data was available in peripheral blood. In this case 65 
(38%) of the 173 segments were significantly associated with the expression of single copy 
                                                        
h The lift-over tool is available here: https://genome.ucsc.edu/cgi-bin/hgLiftOver 
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genes within the segment. In total 104 (60%) of the 173 segments showed an inversion signal, 
indicating their predisposition for inversion occurrence.  
We lifted the genomic positions of the genomic segments highly prone to inversion 
polymorphisms to build 37 (GRCh37) with the UCSC genome-annotation lift-over tooli, and 
there were 19 genomic segments that could not be lifted due to non-overlapping genome 
sequences or ambiguous mapping across the builds. Hence, the combined map contains 154 
segments prone to inversion polymorphisms (hereafter referred to as “the 154 candidate 
inversions”), that have non-ambiguous genomic positions available in build 37. These range 
from ~500 kb to ~8 Mb in genomic size.  
We checked if each lead SNP from the GWAS was within such a candidate inversion, or within 
250 bp from the breakpoints of such a candidate inversion. The results are reported in 
Supplementary Table 3.1 and Supplementary Table 3.2.  
2.9.3 Check for 1000 Genomes structural variants 
Sudmant et al. (2015)48 called and classified a large number of structural variants (SVs) with the 
final version of the 1000 Genomes Project phase 3 reference panel. They have released an 
integrated map of 37,250 smaller structural variants, together with enhanced resolution of the 
size and breakpoint compared to previous publications, and we hereafter refer to these as the 
“1000G structural variants.” The structural variants range from 1 bp to ~445 kb in genomic size. 
The smallest variants are generally insertions of 1 bp (~6,900 variants), and the larger variants 
are generally deletions larger than 50 bp. The majority of these structural variants are in LD with 
proximate SNPs, and we therefore checked if any of the lead SNPs from our main GWAS, and 
SNPs in strong LD with those lead SNPs, were located within the start and end positions of any 
of the 37,250 structural variants. We defined strong LD as an r2 greater than 0.8, which is the 
definition used by the 1000 Genomes Project Consortium48. The SNPs in LD were extracted 
using PLINK37 and the main reference panel. We report the results in Supplementary Table 3.1 
and Supplementary Table 3.2. 
2.10 Investigation of the novelty of our GWAS associations 
To investigate the novelty of our GWAS associations, we performed lookups of our lead SNPs 
(and the SNPs in LD with the lead SNPs, r2 > 0.1) in the NHGRI-EBI GWAS Catalog database 
(revision 2017-08-15)49 of genome-wide significant associations from previous GWAS. We also 
looked up our lead SNPs (and the SNPs in LD, r2 > 0.1) in some recent GWAS articles that have 
not been catalogued in the NHGRI-EBI GWAS Catalog database. The NHGRI-EBI GWAS 
Catalog is a resource that aims to catalogue all associations reported in published GWAS. 
For general risk tolerance, we performed a search with the term “risk” in the index of 
phenotypes, and we did not find any previous studies on general risk tolerance in the Catalog. 
We know of one previous study that identified one independent genome-wide significant 
association with general risk tolerance, and of one concurrent study that identified a second 
genome-wide significant association, both using the first UKB data release50,51; the authors of 
ref.50 referred to the phenotype as “risk-taking propensity,” and the authors of ref.51 referred to it 
as “risk-taking behavior.” The first genome-wide significant association is replicated in an online 
                                                        
i The lift-over tool is available here: https://genome.ucsc.edu/cgi-bin/hgLiftOver 
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publication published in advance52. We added the first of these two studies (i.e., Day et al.50) to 
our investigation of the novelty of our general-risk-tolerance lead loci, and the second we 
consider concurrent.  We also note that, in Supplementary Information section 11.1, we report 
the results of a literature search of association studies of risk tolerance; that literature search 
identified no previously reported genome-wide significant associations.  
The phenotypes drinks per week, ever smoker, and number of sexual partners (or related 
phenotypes such as alcoholism and age at first sex), were available in the NHGRI-EBI GWAS 
Catalog database (revision 2017-08-15). Since the GWAS Catalog is not always up-to-date, we 
additionally performed a literature search for genome-wide significant findings that might not yet 
have been included in the Catalog. We searched the Pubmed literature database on March 6 2017 
and September 13 2017, for the term “genome-wide association study” together with each of the 
terms “alcohol,” “sexual,” and “smoking” individually. We screened the abstracts and compared 
the resulting articles with the article list of the GWAS catalog. In addition to what was already 
reported in the GWAS Catalog (revision 2017-08-15), we found three additional studies with 
genome-wide significant findings on alcohol consumption, two additional studies on smoking, 
and no additional studies on sexual behaviors.  
To our knowledge, this is the first GWAS of adventurousness, automobile speeding propensity, 
and of the first PC of the four risky behaviors; unsurprisingly, we could not find previous GWAS 
on any of these phenotypes in the NHGRI-EBI GWAS Catalog database (revision 2017-08-15). 
2.11 GWAS catalog lookup  
We investigated whether the lead SNPs from our discovery GWAS of general risk tolerance and 
from our supplementary GWAS have previously been associated at genome-wide significance 
with any phenotypes in the NHGRI-EBI GWAS Catalog database49 (revision 2017-08-15). We 
query the GWAS Catalog with our list of lead SNPs, and the SNPs in LD with a lead SNP (r2 > 
0.6). 
Since the NGRI-EBI GWAS Catalog is not always up-to-date with results from the most recent 
publications (especially in non-peer reviewed outlets such as BioRxiv), we also queried the 
summary statistics of the most recently published GWAS on attention deficit hyperactivity 
disorder53, autism spectrum disorder54, and anorexia nervosaj. We also queried the genome-wide 
significant findings from the additional GWAS on alcohol intake and smoking, which we found 
in addition to the GWAS Catalog, as detailed in the previous section. We queried the additional 
GWAS on alcohol intake and smoking because they contained at least one genome-wide 
significant result; because their results were publicly available; and because the meta-analysis 
that produced them did not include the UK Biobank (that comprise our discovery sample 
together with 23andMe).  
We perform these lookups because the existence of SNPs and genes associated with both one of 
our studied phenotypes and another phenotype can point to a common genetic etiology. 
However, it is important to note that two phenotypes that share a genetic locus do not necessarily 
have to share the same causal variant at that locus due to the widespread LD that characterizes 
                                                        
j The Psychiatric Genomics Consortium’s GWAS summary statistics for attention deficit hyperactivity disorder, 
autism spectrum disorder, and anorexia nervosa (referred to as “ED,” i.e. eating disorder) are publicly available and 
can be downloaded here: https://www.med.unc.edu/pgc/results-and-downloads. 
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the human genome. Moreover, even if two phenotypes do share a single causal variant, they do 
not have to share general underlying genetic etiologies. For instance, recent work24 has shown 
that two types of autoimmune diseases (rheumatoid arthritis and ulcerative colitis/Crohn’s 
disease) that are known to share risk loci are not genetically correlated at a genome-wide level. 
Here, the reason was the lack of an overall directional trend: some risk alleles for one disease 
were also risk alleles for the other disease, but some alleles that were protective for the one 
disease were risk alleles for the other. This resulted in a near-zero correlation at the genome-wide 
level. Thus, we emphasize that the current lookup does not make it possible to determine 
etiological overlap, but only hints at overlapping loci, between general risk tolerance or the 
supplementary GWAS phenotypes, and the phenotypes reported in the GWAS Catalog.  
2.12 Cross-lookup of GWAS results 
We performed cross-lookups of the lead SNPs across our discovery GWAS of our primary and 
supplementary phenotypes. Specifically, for each lead SNP in each of the GWAS, we checked if 
the SNP is in LD (with an r2 greater than 0.1) with lead SNPs in the other GWAS. LD was 
calculated using PLINK37 and the main reference panel. The results of the cross-lookups are 
reported in Supplementary Table 3.1 and Supplementary Table 3.2. As we describe above, we 
also investigated if there were any long-range LD regions or candidate inversions that contained 
lead SNPs for multiple GWAS. 
2.13 Gene annotation 
We annotated the lead SNPs with gene information using the National Institute of Health (NIH) 
National Center for Biotechnology Information (NCBI) gene ontology database (version 2016-
05-25)k. As the general rule, a SNP was annotated to its most proximate gene. If a SNP was 
located between two genes, then we compared the distance to the end coordinate of the gene 
upstream with the distance to the start coordinate of the gene downstream to find the most 
proximate gene. If a SNP was located within multiple overlapping genes, then the SNP was 
annotated to the gene with the most proximate start coordinate. This means that all lead SNPs 
were annotated to a single gene. The approach roughly partitions the SNPs throughout the 
genome into separate genomic segments. The annotations are displayed in Supplementary 
Table 3.1 and Supplementary Table 3.2, where we also indicate if a lead SNP is located within 
or outside the gene’s start and end coordinates. We also checked if there were genes to which 
lead SNPs from multiple GWAS were annotated (the results are reported in Supplementary 
Information section 3.2). 
  
                                                        
k The NCBI gene ontology database is available here: 
ftp://ftp.ncbi.nlm.nih.gov/gene/DATA/GENE_INFO/Mammalia/. 
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3 GWAS results 
In this section, we report, compare, and discuss the results of our seven main GWAS (of our 
primary phenotype—self-reported general risk tolerance—and of our six supplementary 
phenotypes—adventurousness, the four risky behaviors, and their first PC). In Supplementary 
Information sections 3.1 and 3.2, we present a summary of our results, and we also describe 
several notable genomic regions that contain lead SNPs for all or most of our main GWAS. 
Supplementary Information sections 3.3 and 3.4 contain a more detailed description of the 
results of our discovery GWAS of general risk tolerance and the results of our six other main 
GWAS, respectively. Throughout, we place particular emphasis on long-range LD regions and 
candidate inversions (defined in Supplementary Information section 2.9) that contain lead 
SNPs for all or most of our GWAS. (We focus on these because, as we explain below, very few 
genomic blocks outside of these regions or candidate inversions contain lead SNPs shared across 
most of our GWAS.)  
3.1 Summary of the GWAS results 
We identified 124 lead SNPs associated with general risk tolerance, 167 with adventurousness, 
42 with automobile speeding propensity, 85 with drinks per week, 223 with ever smoker, 118 
with number of sexual partners, and 106 with the first PC of the four risky behaviorsl. To the best 
of our knowledge, 853 of these 865 associations are novel. We were able to replicate the only 
previously published50 genome-wide significant association with general risk tolerance, located 
within CADM2 on chromosome 3, that was also replicated in ref.52 and in a concurrent study51. 
We replicated another genome-wide significant association with general risk tolerance from the 
concurrent study51, located in proximity to the HLA-complex on chromosome 6. We also 
replicated the TAG Consortium’s previous association with ever smoker in the gene NCAM129. 
The NHGRI-EBI GWAS Catalog database49 lookup of general-risk-tolerance lead SNPs resulted 
in 61 overlapping associations distributed across 27 lead SNPs, and the lookup of our six other 
main GWAS resulted in 939 overlaps distributed across 130 lead SNPs. Notably, for all our main 
phenotypes we find overlaps with schizophrenia, cognitive performance, and information 
processing speed.  
The detailed results of the cross-lookup of our GWAS results (the investigation of whether the 
lead SNPs of each of our GWAS are in LD, defined as a r2 greater than 0.1, with the lead SNPs 
of our other GWAS (Supplementary Information section 2.12)) are reported in 
Supplementary Tables 3.1 and 3.2. In total, we identified 865 lead SNPs across the GWAS of 
our primary and supplementary phenotypes. Of these 865, 34 exact lead SNPs are counted twice 
by being shared by two phenotypes (there are no exact lead SNPs shared across more than two 
phenotypes; thus, in total there are 831 unique lead SNPs identified across the phenotypes). 441 
of the 865 lead SNPs are in loci that also contain a lead SNP for at least one of the other GWAS. 
                                                        
l It should be noted that for each of our seven main GWAS phenotypes, there are sets of lead SNPs located within 
the same long-range LD region44 or candidate inversion. Taking this into account in our clumping algorithm might 
result in lower estimates of the total number of loci we identified. However, estimating the independence of GWAS 
associations in these regions requires conditional GWAS analyses, and we therefore chose to keep our definition of 
independent loci in these regions and to indicate which SNPs are located in these regions (Supplementary Table 
3.1 and 3.2). 
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To find the number of independent loci across all our phenotypes, we used the clumping 
algorithm described in Supplementary Information section 2.8 on the 865 lead SNPs. We first 
removed the duplicate lead SNPs by keeping the strongest associated SNP as one record, and the 
clumping algorithm was thereafter applied to the 831 unique lead SNPs that had the strongest 
associations across the phenotypes. The clumping algorithm resulted in 611 independent loci 
across the phenotypes.  
To find how many loci from the six supplementary GWAS are independent from the 124 loci 
identified in our GWAS of general risk tolerance (our primary GWAS), we removed the 124 
general-risk-tolerance lead SNPs, as well as the SNPs in LD (r2 > 0.1) with them, from the 865 
lead SNPs. After removing duplicate lead SNPs by keeping the strongest associated SNP as one 
record, there were 599 remaining unique lead SNPs that are approximately independent from the 
124 general-risk-tolerance lead SNPs (but not necessarily independent from one another). 
Finally, we re-ran the clumping algorithm and we identified 483 approximately independent lead 
SNPs across our six supplementary GWAS.  
In sum, our seven GWAS identified 865 lead SNPs located across 611 approximately 
independent loci. Of the 865 lead SNPs, 68 involve 34 exact lead SNPs that were each identified 
in two separate GWAS, and 441 are in loci that also contain a lead SNP for at least one of the 
other GWAS. Removing the loci around our 124 general-risk-tolerance lead SNPs left us with 
483 approximately independent loci that contain a lead SNP for at least one of our other six 
GWAS phenotypes.  
3.2 Summary of genetic overlap across our main GWAS 
3.2.1 Summary and discussion of notable genomic regions  
Five genomic regions stand out because they contain lead SNPs for all or most of our seven 
phenotypes. Two of these regions are among the 15 long-range LD regions identified by Price et 
al.44, and the other three are among the 154 genomic segments deemed highly prone to inversion 
polymorphisms (i.e., the 154 “candidate inversions”; both the 15 long-range LD regions and the 
154 candidate inversions are described in Supplementary Information section 2.9). One long-
range LD region (chromosome 3, ~83.4 to 86.9 Mb, Extended Data Fig. 3.4) and one candidate 
inversion (chromosome 18, ~49.1 to 55.5 Mb, Extended Data Fig. 3.4) each contain lead SNPs 
for all of our seven GWAS phenotypes; the other three regions each contain lead SNPs for 
general risk tolerance and for four or five of our six supplementary GWAS.  
The first notable region is the long-range LD region on chromosome 3 (~83.4 to 86.9 Mb, 
Extended Data Fig. 3.4), which contains lead SNPs for all our GWAS. The only gene within the 
long-range LD region is CADM2, and there are few other genes in proximity (only VGLL3 is 
within 250 kb of the breakpoints, ~69.8 kb downstream). The relatively large CADM2 gene 
(~85.0 to 86.2 Mb) covers ~1.2 Mb of the ~3.5 Mb long-range LD region and contains our 
strongest association with general risk tolerance (rs993137, P = 2.14×10–40). The Bonferroni-
corrected P-value of CADM2 in the MAGMA gene analysis is P = 1.09×10–50 (Supplementary 
Table 12.3), consistent with the GWAS results. A recent study52 reports that CADM2 contains a 
replicated association with general risk tolerance, and that study also reports suggestive 
associations between SNPs in CADM2 and different measures of personality. As we discuss in 
Supplementary Information section 12, CADM2 “encodes a member of the synaptic cell 
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adhesion molecule 1 (SynCAM) family which belongs to the immunoglobulin (Ig) 
superfamily”55, and it is related to synapse formation56 and brain plasticity57. CADM2 is 
overexpressed in the brain, and in particular in the frontal cortex, according to GTEx58. The 
GWAS Catalog database49 reports genome-wide significant associations in the long-range LD 
region with many phenotypes, including age at menarche, BMI, educational attainment, and 
information processing speed. Most of the GWAS Catalog database49 associations within the 
long-range LD region (~83.4 to 86.9 Mb on chromosome 3) are annotated to the gene CADM2.  
The second notable region is a candidate inversion located on chromosome 18 (~49.1 to 55.5 
Mb, Extended Data Fig. 3.4). Within the candidate inversion there are previous genome-wide 
associations in the GWAS Catalog database49 with traits such as autism spectrum disorder, 
ADHD, depression, educational attainment, schizophrenia, and subcortical brain region volumes. 
The candidate inversion contains ~20 genes, and the MAGMA gene analysis resulted in one 
significant gene after Bonferroni correction—TCF4 (Bonferroni-corrected P = 5.51×10–9, 
Supplementary Table 12.3). TCF4 is interesting because it is known to play an important role 
in nervous system development55. De novo mutations in TCF459 are known to cause the rare Pitt-
Hopkins syndrome60, with few described cases in the medical literature61. The syndrome is 
characterized by distinct facial features, intellectual disability, delayed motor skills, and epilepsy, 
among many other symptoms59–61. The GWAS Catalog database49 reports genome-wide 
significant associations mapped to TCF4 with schizophrenia, and TCF4 has been hypothesized to 
be involved in more neuropsychiatric phenotypes62. This observation is consistent with the non-
zero genetic correlations that we estimated with bivariate LD Score regression between general 
risk tolerance and many neuropsychiatric disorders (Fig. 2, Supplementary Information 
section 7). As we describe below, all phenotypes have lead SNPs annotated to TCF4 except ever 
smoker, for which there are three lead SNPs within the candidate inversion annotated to the 
proximate genes DCC and TXNL1. We annotated two lead SNPs for general risk tolerance, two 
for adventurousness, two for automobile speeding propensity, one for drinks per week, six for 
number of sexual partners, and three for the first PC of the risky behaviors, to TCF4. 
The third notable genomic region is the long-range LD region located on chromosome 6 (~25.3 
to 33.4 Mb, Extended Data Fig. 3.4). The region covers the HLA-complex55 (~29.6 to 33.1 Mb 
on chromosome 663), and contains lead SNPs for all phenotypes except drinks per week (for 
which we identified a suggestive association, with a P = 3.83×10–7). There are at least 250 genes 
in the region, and the MAGMA gene analysis resulted in ~30 significant genes after Bonferroni-
correction (however, none of the actual HLA genes were significant; Supplementary Table 
12.3). The GWAS Catalog database49 reports more than a thousand genome-wide significant 
associations in the region. The associations relate to hundreds of traits, including alcohol 
consumption, Alzheimer’s disease, autism spectrum disorder, educational attainment, and 
schizophrenia. The HLA-complex contains thousands of SNP associations in the GWAS Catalog 
database49, and those relate to hundreds of traits, including alcohol consumption, Alzheimer’s 
disease, autism spectrum disorder, and educational attainment. The HLA genes encode the major 
histocompatibility complex (MHC) proteins, whose main function is to alert cells of the immune 
system about infection from pathogens64. The region is known to be highly polygenic, and its 
high rates of recombination lead to a large number of possible haplotypes in the population. For 
certain classes of MHC proteins there are more than 1,000 alleles in the human population, and 
most individuals are therefore heterozygous. However, there is also a small subset of proteins 
encoded for which the coding alleles are practically monomorphic, and this is probably caused 
by certain constraints on the viability of the variability for these specific protein chains. The 
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HLA genes have been found to be under strong selectionm. The constant struggle to counter 
pathogens results in selection pressures that favor polymorphisms that are able to provide 
protection. 
The fourth notable genomic region is the candidate inversion on chromosome 7 (~124.6 to 132.7 
Mb; Extended Data Fig. 3.4), which was identified in all our GWAS except automobile 
speeding propensity (for which it contains a suggestive association: rs141450, P = 7.88×10–8). 
The candidate inversion contains ~50 genes, and 5 of those were significant after Bonferroni 
correction in the MAGMA gene analysis (Supplementary Table 12.3). Among them are SND1 
(Bonferroni-corrected P = 5.08×10–10) and PAX4 (Bonferroni-corrected P = 1.43×10–5). SND1 is 
implicated as an important factor for normal cell growth55, and PAX4 is critical to normal fetal 
development55. The candidate inversion contains genome-wide significant associations in the 
GWAS Catalog database49 with alcohol dependence, educational attainment, and schizophrenia, 
among other phenotypes. 
The fifth notable genomic region is the candidate inversion on chromosome 8 (~7.89 to 11.8 
Mb), which contains lead SNPs for all of our GWAS except those of drinks per week and of the 
first PC of the risky behaviors (Extended Data Fig. 3.4). (The strongest associations with drinks 
per week and the first PC of the risky behaviors have P values of 5.64×10–4 and 1.27×10–7, 
respectively.) There are ~20 genes within the candidate inversion, and interestingly, practically 
all are significant in the MAGMA gene analysis after Bonferroni-correction (Supplementary 
Table 12.3). Two notable examples are MSRA and CTSB (with Bonferroni-corrected P values of 
2.94×10–24 and 4.37×10–5, respectively). MSRA is known to be highly expressed in human 
nervous tissue55, and CTSB has a known effect on the processing of an amyloid precursor protein 
(APP)55. Incomplete processing of APP has been suggested as one of the causes of Alzheimer’s 
disease65. However, the GWAS Catalog database49 does not report any previous associations 
with Alzheimer’s disease within the candidate inversion, or within 500kb of its breakpoints. The 
GWAS Catalog database49 reports genome-wide associations within the breakpoints of the 
candidate inversion with many other phenotypes, including extraversion, schizophrenia, and 
chronotype, and the candidate inversion has been analyzed in-depth in a study of neuroticism and 
depressive symptoms18. 
3.2.2 Overlap within approximately independent LD blocks  
The observation that several genomic regions contain at least one lead SNP from all or most of 
our GWAS prompted further investigation. To begin with, we divided the genome into 1703 
approximately independent LD blocks identified by Pickrell et al.66. We then counted the 
number of blocks that contain lead SNPs from exactly one, two, three, four, five, six, and seven 
of our main GWAS. Of the 1703 LD blocks, 234 contain at least one lead SNP from exactly one 
of our seven main GWAS; 93 contain at least one lead SNP from exactly two GWAS; 40 contain 
at least one lead SNP from exactly three GWAS; 20 contain at least one lead SNP from exactly 
four GWAS; 7 contain at least one lead SNP from exactly five GWAS; one block (~84.4 Mb to 
85.6 Mb on chromosome 3) contains at least one lead SNP from exactly six GWAS; and one 
block (~51.6 Mb to 55.2 Mb on chromosome 18) contains at least one lead SNP from all seven 
of our main GWAS. These last two blocks on chromosomes 3 and 18 are respectively located 
                                                        
m A good example of the strong selection is the differences in allele frequencies across populations for alleles that 
affect resistance to a lethal form of malaria (see, e.g., ref.244). The protective alleles are very common in areas where 
the disease is endemic compared to areas where the risk of infection is low or absent. 
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within the first and the second notable genomic region highlighted above and displayed in 
Extended Data Fig. 3.4.  
The nine blocks that contain at least one lead SNP from exactly five, six, or seven GWAS each 
contain at least one general-risk-tolerance lead SNP. Five of these nine blocks are located within 
the five notable regions described above, with one block in each of the five regionsn. The striped 
areas in Fig. 3.4 show these five blocks. The five blocks include the two blocks that contain lead 
SNPs from six and from all seven of our GWAS. The other four blocks are located on 
chromosome 2 (~44.3 to 46.5 Mb), chromosome 3 (~70.5 to 72.5 Mb), chromosome 6 (~97.8 to 
100.6 Mb), and chromosome 7 (113.7 ~ 116.8 Mb). Thus, nine genomic regions contain lead 
SNPs for at least five of our seven GWAS: the five notable regions described in the previous 
subsection and the four LD blocks located on chromosomes 2, 3, 6, and 7.  
We ran a simulation to benchmark those results and to assess the likelihood of observing such a 
high level of within-block overlap across the GWAS results, under the null hypothesis that the 
LD blocks containing the lead SNPs of each GWAS are distributed randomly across the genome 
and independently from those of the other GWAS. (This null hypothesis is not perfectly realistic: 
in practice, the phenotypes are phenotypically correlated and their GWAS samples overlap 
substantially, and some LD blocks are located within regions of the genome that are more likely 
to contain causal variants. Thus, although informative, this simulation exercise has limitations.) 
We conducted this analysis with only the general risk tolerance, automobile speeding propensity, 
drinks per week, ever smoker, and number of sexual partners phenotypes. We excluded 
adventurousness and the first PC of risky behaviors, because adventurousness is strongly 
genetically correlated with general risk tolerance, and because the first PC of risky behaviors is 
constructed from the four risky behaviors. The simulation proceeded in the following way: Since 
larger LD blocks are more likely to contain lead SNPs for any of our phenotypes, we classified 
each LD block by length and randomly permuted the LD blocks within each length class 
independently for each phenotypeo. We then counted the number of LD blocks that contain hits 
from exactly one, two, three, four, and five GWAS, and we averaged these numbers over 10,000 
simulations.  
Our results indicate that, under the null hypothesis, we would expect 357.064 LD blocks to 
contain at least one lead SNP from exactly one GWAS; 43.212 to contain at least one lead SNP 
from exactly two GWAS; 2.734 to contain at least one lead SNP from exactly three GWAS; 
0.077 to contain at least one SNP from exactly four GWAS; and 0.001 to contain at least one 
lead SNP from all five GWAS. By contrast, the actual number of blocks that contain at least one 
lead SNP from exactly one, two, three, four, and five of these GWAS are 253, 61, 20, 3, and 1. 
The expected overlap from our simulation thus differs markedly from the overlap that we 
actually observe. To investigate this more formally, we conducted a non-parametric Mann-
                                                        
n There are 27 LD blocks that overlap with the five notable genomic regions, and these are shown, separated by the 
dotted vertical gray lines, in Extended Data Fig. 3.4. Of these 27 blocks, four blocks contain at least one lead SNP 
from exactly one GWAS; two contain at least one lead SNP from exactly two GWAS; four contain at least one lead 
SNP from exactly three GWAS; three contain at least one lead SNP from exactly four GWAS; three contain at least 
one lead SNP from exactly five GWAS; one contains at least one lead SNP from exactly six GWAS; and one 
contains at least one lead SNP from all seven GWAS (these last two blocks are the ones on chromosomes 3 and 18, 
located within the first and the second notable genomic regions). 
o We sorted the LD blocks into 9 classes based on the following lengths: 0 to 0.5 Mb (36 blocks), 0.5 to 1 Mb (263 
blocks), 1 to 1.5 Mb (526 blocks), 1.5 to 2 Mb (478 blocks), 2 to 2.5 Mb (256 blocks), 2.5 to 3 Mb (82 blocks), 3 to 
3.5 Mb (29 blocks), 3.5 to 7.5 Mb (25 blocks), and greater than 7.5 Mb (8 blocks).  
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Whitney test67 to compare the actual and simulated distributions of within-block overlaps across 
GWAS. Our results strongly suggest that the distribution of overlap in the simulation is different 
from the distribution of overlap that we actually observe (P = 0.0023).  
The simulation exercise thus clearly suggests that the high level of within-block overlap across 
the results of our seven GWAS are highly unlikely to be due to chance. However, we emphasize 
again that our null hypothesis is not perfectly realistic and that the simulation exercise has 
limitations, and that these results should therefore be interpreted with caution. 
3.2.3 Concordance of SNP effects across the nine regions associated with five or 
more of our phenotypes 
Above, we identified nine genomic regions that contain lead SNPs for at least five of our seven 
GWAS: the five notable regions on chromosomes 3, 6, 7, 8, and 18, and the four LD blocks 
located on chromosomes 2, 3, 6, and 7. We investigated whether the signs of the lead SNPs 
located in these regions tend to be concordant across our primary and supplementary GWAS (in 
the sense that general-risk-tolerance-increasing alleles are also associated with higher risk taking 
in the supplementary GWAS, and vice-versa).  
These nine regions harbor a total of 37 general-risk-tolerance lead SNPs and 111 lead SNPs from 
our six supplementary GWASp. 217 coefficients of the 37 general risk tolerance lead SNPs are 
available in the results of the six supplementary GWAS (one of the 37 SNPs is only available in 
the adventurousness GWAS). 205 of these coefficients are have concordant signs, 147 are 
significant at the 5% level in the supplementary GWAS, and 26 are genome-wide significant. 
Under the null hypothesis that the coefficients have an equal probability of being concordant or 
discordant across the general risk tolerance and supplementary GWAS, the probability of 
observing 205 or greater concordant coefficients is very small (𝑃	 ≤ 	9 × 10)kl). We only found 
12 discordant coefficients (9 of which are for drinks per week), and the total number of 
discordant coefficients is reduced to 4 if for each of the nine regions we exclude coefficients of 
GWAS that do not contain any lead SNP in the region. None of the discordant coefficients are 
genome-wide significant, and only 1 is significant at the 5% level (for drinks per week).  
As for the 111 lead SNPs from our six supplementary GWAS, 109 of these 111 SNPs have 
concordant coefficients in our GWAS of general risk tolerance. Under the null hypothesis that 
the coefficients have an equal probability of being concordant or discordant across the general 
risk tolerance and supplementary GWAS, the probability of observing 109 or greater concordant 
SNPs is very small (𝑃	 ≤ 	3 × 10)m+). 98 of the concordant coefficients are significant at the 5% 
level for general risk tolerance, and 31 of these are genome-wide significant; the two discordant 
coefficients are not significant at the 5% level for risk tolerance.  
Thus, the signs of the lead SNPs located in these regions tend to be highly concordant across our 
primary and supplementary GWAS, which suggests that these regions represent shared genetic 
influences on our seven phenotypes (rather than colocalization of causal SNPs). 
                                                        
p There are 141 unique lead SNPs across our seven main GWAS in these nine regions. Note that these lead SNPs 
were obtained using a clumping algorithm with an r2 threshold of 0.1. If we instead used a threshold of 0.01, there 
would likely be fewer lead SNPs. See Supplementary Information sections 2.8 and 3.3 for more details. 
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3.2.4 Gene overlap across our seven GWAS 
We annotated each lead SNP from our seven GWAS with its most proximate gene, as described 
in Supplementary Information section 2.13. This approach roughly partitions the SNPs 
throughout the genome into different genomic segments—each associated with a single gene—
that can be compared across our main GWAS. When we compared the gene-associated segments 
identified across our seven GWAS, we found that the only gene segment that is identified in all 
of them is the one associated with CADM2 on chromosome 3 (that is located within the long-
range LD region on chromosome 3, ~83.4 to 86.9 Mb, that is shared across all our GWAS; 
Extended Data Fig. 3.4).  
The second most shared gene segment is the one associated with TCF4 (discussed in more detail 
above). TCF4 is located within the candidate inversion on chromosome 18 (~49.1 to 55.5 Mb) 
that is shared across all our GWAS (Extended Data Fig. 3.4). Lead SNPs from six of our 
GWAS, but not ever smoker, are annotated to TCF4. Three lead SNPs for ever smoker are 
located within the candidate inversion but are instead annotated to the genes DCC and TXNL1. 
DCC ends ~1.5 Mb before TCF4, and TXNL1 starts ~967 kb after TCF4. Four segments, which 
were associated with the genes FOXP1, MDFIC, SIX3, and VGLL3 (which is located ~69.8 kb 
downstream of the notable long-range LD region spanning ~83.4 to 86.9 Mb on chromosome 3), 
were each identified in five GWAS. 
We searched the GWAS Catalog database49 for previous associations with the genes associated 
with these shared segments, and we found some notable associations: FOXP1 has been 
associated with ADHD, autism spectrum disorder, chronotype, and schizophrenia; MDFIC with 
BMI and obesity; SIX3 with fasting plasma glucose, metabolite levels, and myopia; and VGLL3 
with age at menarche and pubertal anthropometrics.  
3.3 Results of the discovery GWAS of general risk tolerance 
The discovery GWAS of general risk tolerance identified 124 independent genome-wide 
significant SNPs (i.e., lead SNPs), distributed across chromosomes 1 to 19. The strongest 
associations were found in the gene CADM2 on chromosome 3 (rs993137, P = 2.14×10–40), on 
chromosome 7 in the gene FOXP2 (rs7783012, P = 7.57×10–25) and in proximity to the gene 
MDFIC (rs9641536, P = 5.01×10–23), and in the gene MFHAS1 (rs2409095, P = 1.01×10–20) on 
chromosome 8. We report the association results for the 124 lead SNPs in Supplementary 
Table 3.1, together with estimated effect sizes (the 𝛽ZK’s) expressed in phenotype standard-
deviation units per effect-coded allele. Supplementary Information section 5 reports the results 
of our successful attempt to replicate these results in our replication GWAS.  
As mentioned in Supplementary Information section 2.8, to see how sensitive the number of 
lead SNPs is to our definition of an approximately independent locus (i.e., the set of all SNPs in 
weak LD (pairwise r2 > 0.1) with a lead SNP), we counted how many lead SNPs our clumping 
algorithm yields when the more stringent r2 threshold of 0.01 (instead of 0.1) is used. 94 lead 
SNPs remained when we applied the clumping algorithm with the more stringent threshold. The 
column “Lead SNP with stringent locus definition (r2 > 0.01)?” in Supplementary Table 3.1 
reports whether each lead SNP remains a lead SNP with the more stringent threshold. 
We display the Manhattan plot of the discovery GWAS in Fig. 1a and the quantile-quantile (Q-
Q) plot in Extended Data Fig 3.2a. The genomic inflation factor (𝜆]^) was 1.405 before, and 
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1.378 after inflation of the standard errors with the square root of the estimated intercept from an 
LD Score regression (𝐼𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡n = 1.040, 𝑆𝐸 = 0.011). As we discuss in Supplementary 
Information section 4, an observed genomic inflation factor larger than 1 is consistent with the 
expectation that complex traits are polygenic68, and an estimated LD Score regression intercept 
close to unity suggests that the inflation is mainly due to polygenicity rather than to confounding 
factors42.  
All 124 general-risk-tolerance lead SNPs have MAF larger than 1%; only two of the lead SNPs 
have MAF lower than 5%; four have MAF between 5% and 10%; 33 have MAF between 10% 
and 25%; and 85 have MAF between 25% and 50%. Thus the vast majority of our lead SNPs are 
very common SNPs. 
To evaluate the magnitude of the effect-size estimates of the 124 lead SNPs, we compared them 
with the 124 top associations reported in recent GWAS of height and body mass index (BMI), 
with the 74 top associations reported in a recent GWAS of educational attainment, and with the 
48 top associations reported in a recent GWAS of waist-to-hip ratio adjusted for BMI (WHR)q. 
We display the comparison in Extended Data Fig. 3.3. The effect-size estimates of the 124 lead 
SNPs are consistently smaller than the top effect-size estimates of height, BMI, educational 
attainment, and WHR, both in terms of standard deviation units of the phenotype per effect-
increasing allele, as well as in terms of variance explained (𝑅"). The general-risk-tolerance effect 
sizes range from 0.008 to 0.026 in phenotype standard-deviation units per effect-increasing 
allele, compared to a range of 0.038 to 0.191 for height, 0.019 to 0.082 for BMI, 0.014 to 0.048 
for educational attainment, and 0.012 to 0.043 for WHR. The variance explained (𝑅") by the 
general-risk-tolerance lead SNPs ranges from 0.003% to 0.019%, compared to 0.036% to 
0.283% for height, 0.013% to 0.325% for BMI, 0.010% to 0.036% for educational attainment, 
and 0.004% to 0.072% for WHR.  
We then paired the top SNPs of general risk tolerance with the top SNPs of height, BMI, 
educational attainment, and WHR (after ranking the SNPs by 𝑅" for each phenotype), and we 
calculated the median of the ratio of the 𝑅" across the paired SNPs. The median ratio was 13.64 
between general risk tolerance and height (i.e., for the median ratio, the variance explained was 
13.64 times larger for height compared to general risk tolerance), 4.58 between general risk 
tolerance and BMI, 3.85 between general risk tolerance and WHR, and 2.73 between general risk 
tolerance and educational attainment. Thus, effect sizes and 𝑅" of the general-risk-tolerance lead 
SNPs are substantially lower than those for the comparison phenotypes. 
3.3.1 Genetic correlation between females and males 
We used bivariate LD Score regression42 to calculate the genetic correlation between GWAS 
performed separately in the sample of females and in the sample of males in the first release of 
UKB data. Our estimate of the genetic correlation (?̂?. = 0.949, SE = 0.135) is not significantly 
different from 1, thus validating our strategy of pooling females and males in our GWAS. (For 
further details, see Supplementary Information section 7.4)  
                                                        
q The data for height, BMI, and WHR are from the publicly available GWAS results of the GIANT consortium, with 
males and females pooled and restricted to European-ancestry individuals, and the data for educational attainment 
are from the largest previously published GWAS of educational attainment by Okbay et al.16. 
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3.3.2 Genetic correlations between the UKB, 23andMe, and the replication GWAS 
Using bivariate LD Score regression42 we estimated the genetic correlation between the cohort-
level GWAS summary statistics from the general-risk-tolerance GWAS in the 23andMe and 
UKB cohorts, as well as between these GWAS and our replication GWAS (which includes 10 
cohorts). Our estimates of the genetic correlations between the 23andMe and UKB GWAS (?̂?. =	0.767, SE = 0.021), between the 23andMe and the replication GWAS (?̂?. =	0.759, SE = 0.126), 
and between the UKB and the replication GWAS (?̂?. = 0.828, SE = 0.135) are all smaller than 
unity (though only the first of these estimates is significantly different from unity at the 5% 
level), pointing to substantial cross-cohort heterogeneity. (For further details, see 
Supplementary Information section 7.4.) 
We also used bivariate LD Score regression42 to estimate the genetic correlation between the 
summary statistics from the discovery GWAS and those from the replication GWAS. As in the 
case of the genetic correlation between males and females, we could not reject the null 
hypothesis of a genetic correlation equal to 1 (?̂?.= 0.834, SE = 0.129). (For further details, see 
Supplementary Information section 7.4) 
3.3.3 Results of the cross-lookup of the general-risk-tolerance lead SNPs in the 
supplementary GWAS 
The results of the cross-lookup (described in Supplementary Information section 2.12) suggest 
substantial genetic overlap between the lead SNPs of our primary GWAS and those of our 
supplementary GWAS. 72 of the 124 general-risk-tolerance lead SNPs are also lead SNPs, or in 
LD (r2 > 0.1) with a lead SNP, for at least one of the other main phenotypes. The overlap is 
particularly large between general risk tolerance and adventurousness: 45 of the 124 general-
risk-tolerance lead SNPs are also lead SNPs, or in LD with a lead SNP (r2 > 0.1), for 
adventurousness. We also found that 49 of the 124 general-risk-tolerance lead SNPs are also lead 
SNPs, or in LD with a lead SNP (r2 > 0.1), of one of the four risky behaviors or their first PC. 
To benchmark the likelihood of observing such substantial genetic overlap between the lead 
SNPs of our primary and supplementary GWAS, we conducted a resampling exercise under the 
null hypothesis that the lead SNPs of our supplementary GWAS are distributed randomly across 
the genome and independently from those of the other GWAS. The resampling exercise involved 
10,000 runs. In each run, for each lead SNP of the supplementary GWAS we randomly selected 
an autosomal SNP matched on MAF (with five-percentage-point MAF windows). We then 
counted how many of the 124 general risk tolerance lead loci contain at least one of the 
resampled lead SNP, and took the average count across the 10,000 runs. Our results imply that, 
under the null hypothesis, we would expect 10.3 of the 124 general-risk-tolerance loci to also 
contain a lead SNP for at least one of the supplementary phenotypes; 2.2 to also contain a lead 
SNP for adventurousness; and 8.1 to also contain a lead SNP for at least one of the four risky 
behaviors or their first PC. In all three cases, we strongly reject the null hypothesis (P < 0.0001 
in all three cases). The overlap we observe between the 124 general risk tolerance loci and the 
lead SNPs from the other GWAS is thus much greater than what could be expected by chance. 
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3.3.4 Novelty of the lead SNPs of the discovery GWAS of general risk tolerance 
We assessed the novelty of the lead SNPs by performing a lookup in the NHGRI-EBI GWAS 
Catalog database49 for each of the 124 general-risk-tolerance lead SNPs (and the SNPs in LD, r2 
> 0.1), searching specifically for previous associations with general risk tolerance (and similar 
phenotypes) (see Supplementary Information section 2.10 for details). We found that the 
GWAS Catalog database contained no previous associations with general risk tolerance (or 
similar phenotypes).  
However, we know of one previous study by Day et al.50 that analyzed the same general-risk-
tolerance phenotype measure (which they refer to as “risk-taking propensity”) as the one we 
study, in the first release of the UKB data. Day et. al report one independent lead SNP 
(rs4856591) associated with general risk tolerance in the gene CADM2. This association was 
replicated by Boutwell et al.52 using a proxy SNP available in an independent sample 
(rs1865251) located ~125 kb from the original lead SNP (i.e., rs4856591). 
The original lead SNP from ref.50 is not available in our main reference panel (and therefore not 
available in the summary statistics from our discovery GWAS), but the proxy SNP from ref.52 is 
available. Our discovery GWAS also contains a proximate SNP (rs4856590) only 22 bp away 
from the original lead SNP from ref.50. Both rs1865251 and rs4856590 are genome-wide 
significant in our discovery GWAS. They are “clumped” with our top lead SNP rs993137 (P = 
2.14×10–40), and the LD (r2) between our lead SNP rs993137 and rs1865251 and rs4856590 is 
0.996 and 0.949, respectively. Because its locus is associated with general risk tolerance in a 
previous peer-reviewed publication, we do not consider our lead SNP rs993137 to be a novel 
association. 
We also know of one concurrent GWAS by Strawbridge et al.51 on general risk tolerance (which 
Strawbridge et al. refers to as “risk-taking behavior”). Strawbridge et al. also analyzed the same 
phenotype measure as the one we and Day et al.50 study, but used a somewhat different set of 
individuals than Day et al. in the first release of the UKB data. They identified one independent 
lead SNP on chromosome 6 (i.e., rs9379971) in addition to the previous association in CADM2 
from ref.50 and ref.52. The SNP rs9379971 is genome-wide significant in our discovery GWAS, 
and it is “clumped” with a lead SNP of the discovery GWAS (rs1417998, P = 2.92×10–10).  
Thus, to the best of our knowledge, all of the loci we identified through our GWAS of general 
risk tolerance are novel associations with general risk tolerance, except for our top lead SNP 
rs993137r. We therefore consider 123 of the 124 lead SNPs to be newly identified loci for 
general risk tolerance (and similar phenotypes). We report the novelty of our 124 lead SNPs in 
the column “New locus” in Supplementary Table 3.1.  
3.3.5 Results of the GWAS Catalog lookup of the lead SNPs of the primary GWAS of 
general risk tolerance  
To investigate the potential overlap between general risk tolerance and other phenotypes at the 
loci identified in the discovery GWAS, we performed a lookup for each of our 124 lead SNPs 
(and the SNPs in LD, r2 > 0.6) in the NHGRI-EBI GWAS Catalog database49 (see 
Supplementary Information section 2.11 for details). The results are reported in 
                                                        
r Since we consider the GWAS by Strawbridge et al.51 to be concurrent, we consider our lead SNP rs1417998 to be a 
novel association with general risk tolerance. 
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Supplementary Table 3.3. In total, we found 61 overlaps between our lead SNPs (and the SNPs 
in LD, r2 > 0.6) and the previous associations reported in the GWAS Catalog database. Some of 
our lead SNPs overlap with multiple previous associations: the 61 overlaps involve only 27 of 
our 124 lead SNPs. 
Notably, we found overlaps at five schizophrenia loci, one bipolar disorder locus, four 
educational attainment loci, and two loci associated with cognitive function and information 
processing speed. The multiple overlaps with schizophrenia are consistent with the 16 second-
stage hits we obtained for schizophrenia in the proxy-phenotype analysis (Supplementary Table 
8.1), as well as with our finding of strong joint enrichment for association with schizophrenia (P 
= 3.0×10–9) among our general-risk-tolerance lead SNPs on a non-parametric Mann-Whitney test 
(Supplementary Information section 8). Further, 70% of the 122 general-risk-tolerance lead 
SNPs available in the schizophrenia summary statistics have concordant signs for the two 
phenotypes (P = 8.3×10–6). (We also note that general risk tolerance and schizophrenia are 
moderately and positively genetically correlated (?̂?.= 0.173, SE = 0.021; Supplementary 
Information section 7)). However, we caution that it is possible that this overlap with the 
schizophrenia results is primarily attributable to the fact that the schizophrenia GWAS69 was 
relatively well-powered, rather than to shared genetic etiology between risk tolerance and 
schizophrenia.  
In addition, we found overlaps at one ADHD locus, one extraversion locus, and one brain 
volume (superior frontal gyrus grey matter volume) locus. Other potentially interesting overlaps 
were found at a resting heart rate locus and a motion sickness locus. Several traits associated 
with autoimmune disease also overlap with our lead SNPs: two loci associated with cholangitis, 
one locus associated with ulcerative colitis/atopic dermatitis, and one locus associated with type 
1 diabetes (that locus is also associated with height, age at menarche, and male pattern baldness). 
We also found overlaps at one locus associated with age at menarche, at two loci associated with 
carcinoma, and at one locus associated with breast cancer. 
The remaining overlaps are with seemingly unrelated traits, for example at loci associated with 
tooth development (one locus), gut microbiota diversity (one locus), blood protein levels (one 
locus), blood pressure and type 2 diabetes (one locus), and ear infection (one locus). The genetic 
overlap of general risk tolerance with a large number of traits underlines the possibility of 
widespread pleiotropy in the human genome.  
We note that both the existence and absence of overlaps between any two phenotypes should be 
interpreted with care. The existence of overlaps is not necessarily evidence of a shared genetic 
architecture. For example, a shared tagging variant could be in LD with two different causal 
variants that each only cause one of the traits70. Further, the absence of overlaps may be the 
result of inadequate statistical power in the currently available GWAS for either phenotype.  
3.3.6 General-risk-tolerance lead SNPs in long-range LD regions 
8 of the 15 long-range LD regions identified by Price et al.44 (Supplementary Information 
section 2.9) contain lead SNPs for at least one of our primary or supplementary GWAS (of 
general risk tolerance, adventurousness, the four risky behaviors, and their first PC). We focus 
this section on the two long-range LD regions that contain general-risk-tolerance lead SNPs and 
that are notable because they also contain lead SNPs for all or most of our other six main GWAS 
phenotypes: the long-range LD regions ~83.4 to 86.9 Mb on chromosome 3 (Extended Data 
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Fig. 3.4) and ~25.3 to 33.4 Mb on chromosome 6 (Extended Data Fig. 3.4). These two regions 
are both among the five notable genomic regions we highlighted in Supplementary 
Information section 3.2. Those two regions contain 10 of the 124 general-risk-tolerance lead 
SNPs. We also report a third long-range LD region (~135.5 to 138.8 Mb on chromosome 5) that 
contains two general-risk-tolerance lead SNPs (but no lead SNPs for the other phenotypes), and 
below in Supplementary Information section 3.4 we present the five remaining long-range LD 
regions that we identified in our other six main GWAS. Only one long-range LD region (i.e., 
chromosome 3, ~83.4 to 86.9 Mb, Extended Data Fig. 3.4) contains lead SNPs for all seven of 
our phenotypes. 
The first notable long-range LD region, spanning ~83.4 to 86.9 Mb on chromosome 3, is 
displayed in a local Manhattan plot in Extended Data Fig. 3.4 and was discussed in 
Supplementary Information section 3.2. The region is noteworthy because it contains more 
than one lead SNP for all of our GWAS, and it contains six lead SNPs for general risk tolerance, 
of which three are located within the CADM2 gene (~85.0 to 86.2 Mb), two are located ~76 kb 
and ~115 kb upstream of CADM2, and one is located ~547 kb downstream of CADM2, closer to 
the gene VGLL3. (The gene VGLL3, ~86.9 to 87.0 Mb on chromosome 3, is ~69.8 kb 
downstream of the long-range LD region.) As we discussed in Supplementary Information 
section 3.2, the long-range LD region contains only one gene—CADM2, which covers ~1.2 Mb 
of the ~3.5 Mb long-range LD region. CADM2 was the most significantly associated gene in the 
MAGMA gene analysis (Bonferroni-corrected P = 1.09×10–50, Supplementary Table 12.3), and 
it contains our strongest association with general risk tolerance (rs993137, P = 2.14×10–40). The 
GWAS Catalog database49 reports many genome-wide significant associations within the long-
range LD region, including age at menarche, BMI, educational attainment, and information 
processing speed. Most of the previous associations within the long-range LD region are 
annotated to CADM2, which encodes a synaptic cell adhesion molecule55, and is related to 
synapse formation56 and brain plasticity57. 
The second long-range LD region (~25.3 to 33.4 Mb on chromosome 6) covers all the Human 
Leukocyte Antigen (HLA) genes55. It was also discussed in Supplementary Information 
section 3.2, and it is displayed in a local Manhattan plot in Extended Data Fig. 3.4. It contains 
four lead SNPs located in (or in close proximity to) four different genes: HIST1H2AC, 
HIST1H2BD, TRIM27, and C4B, of which the first three are significant in the MAGMA gene 
analysis after Bonferroni-correction (Supplementary Table 12.3). The region is notable because 
it contains lead SNPs for all our other main GWAS, except drinks per week for which we 
identified a suggestively associated SNP (rs6937318, P = 3.83×10–7). As we discussed in 
Supplementary Information section 3.2, the region contains ~250 genes, and the MAGMA 
gene analysis found ~30 significant genes in the region after Bonferroni-correction (however, 
none of the actual HLA genes are significant, Supplementary Table 12.3). The GWAS Catalog 
database49 reports more than a thousand genome-wide significant associations across hundreds of 
traits within the long-range LD region (~25.3 to 33.4 Mb on chromosome 6), including 
Alzheimer’s disease, autism spectrum disorder, educational attainment, and schizophrenia. 
We also identified a third long-range LD region (~135.5 to 138.8 Mb on chromosome 5) that 
contains two lead SNPs associated with general risk tolerance within the genes CTNNA1 and 
ETF1, but the region does not contain lead SNPs for any of our other main GWAS.  
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3.3.7 General-risk-tolerance lead SNPs in candidate inversions  
Of the 154 genomic segments deemed highly prone to inversion polymorphisms (i.e., the 154 
“candidate inversions,” described in Supplementary Information section 2.9), we identified 44 
that contain lead SNPs for at least one of our GWAS. 13 of these 44 candidate inversions contain 
a total of 30 general-risk-tolerance lead SNPs. This section focuses on four of the 13 candidate 
inversions that we find noteworthy because they contain lead SNPs for general risk tolerance as 
well as for most of our other main GWAS. Three of these four candidate inversions are among 
the five notable genomic regions we highlighted in Supplementary Information section 3.2. 
(Below, in Supplementary Information section 3.4, we discuss three other of the 44 candidate 
inversions of the 44, which are notable because they are shared across four of our GWAS, 
excluding general risk tolerance.) The four candidate inversions that we discuss in this section 
span ~124.6 to 132.7 Mb on chromosome 7 (Extended Data Fig. 3.4), ~7.89 to 11.8 Mb on 
chromosome 8 (Extended Data Fig. 3.4), ~70.1 to 74.4 Mb on chromosome 16, and ~49.1 to 
55.5 Mb on chromosome 18 (Extended Data Fig. 3.4). Only one of these candidate inversions 
(i.e., ~49.1 to 55.5 Mb on chromosome 18, Extended Data Fig. 3.4) contains lead SNPs for all 
our GWAS.  
The first candidate inversion is on chromosome 7 (~124.6 to 132.7 Mb). We discussed it in 
Supplementary Information section 3.2 and we display it in a local Manhattan plot in 
Extended Data Fig. 3.4. This candidate inversion is notable because it contains lead SNPs for 
all our GWAS, except automobile speeding propensity (for which the strongest association is 
almost genome-wide significant (rs141450, P = 7.88×10–8)). The candidate inversion contains 
one lead SNP for general risk tolerance, two lead SNPs for adventurousness, one for drinks per 
week, one for ever smoker, one for number of sexual partners, and one for the first PC of the 
risky behaviors. As we discussed in Supplementary Information section 3.2, the candidate 
inversion contains ~50 genes, and five of those were significant after Bonferroni correction in 
the MAGMA gene analysis (Supplementary Table 12.3). The GWAS Catalog database49 
reports previous associations with traits such as alcohol dependence, educational attainment, and 
schizophrenia. 
The second candidate inversion spans ~7.89 to 11.79 Mb on chromosome 8. We discussed it in 
Supplementary Information section 3.2 and we display it in a local Manhattan plot in 
Extended Data Fig. 3.4. This candidate inversion is notable, because it contains associations for 
all our GWAS, except drinks per week and the first PC of the risky behaviors. (The strongest 
association with drinks per week within the candidate inversion is rs574968044, P = 5.64×10–4, 
and the strongest association with the first PC of the risky behaviors is rs2898249, P = 1.27×10–
7.) The candidate inversion contains 15 lead SNPs for general risk tolerance, five for 
adventurousness, one for automobile speeding propensity, two for ever smoker, and four for 
number of sexual partners. As we discussed in Supplementary Information section 3.2, the 
candidate inversion contains ~20 genes, of which practically all were significant after Bonferroni 
correction in the MAGMA gene analysis (Supplementary Table 12.3). The GWAS Catalog 
database49 reports genome-wide associations in the candidate inversion with many behavioral 
phenotypes, including extraversion, neuroticism, schizophrenia, and chronotype. 
The third candidate inversion is on chromosome 18 (~49.1 to 55.5 Mb) and was also discussed in 
Supplementary Information section 3.2. It contains lead SNPs for all our GWAS, and it 
contains more than one lead SNP for all our GWAS except drinks per week, for which it contains 
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only one. We display the region in a local Manhattan plot in Extended Data Fig. 3.4. The 
candidate inversion contains three lead SNPs for general risk tolerance, two for adventurousness, 
two for automobile speeding propensity, one for drinks per week, three for ever smoker, eight for 
number of sexual partners, and four for the first PC of the risky behaviors. As we discussed in 
Supplementary Information section 3.2, among the ~20 genes within the candidate inversion, 
we find only one gene—TCF4 (Bonferroni-corrected P = 5.51×10–9)—significant after 
Bonferroni correction in the MAGMA gene analysis (Supplementary Table 12.3). TCF4 plays 
an important role in nervous system development, and mutations in the gene are known to cause 
the rare Pitt-Hopkins syndrome55. The syndrome is characterized by distinct facial features, 
intellectual disability, delayed motor skills, and epilepsy, among many other symptoms59–61. The 
GWAS Catalog database49 reports genome-wide significant associations mapped to TCF4 with 
schizophrenia and reports previous genome-wide associations within the candidate inversion 
with traits such as autism spectrum disorder, ADHD, depression, educational attainment, 
schizophrenia,  and subcortical brain region volumes. 
A fourth candidate inversion is on chromosome 16 (~70.1 to 74.4 Mb) and contains more than 
one lead SNP for the GWAS of general risk tolerance, ever smoker, number of sexual partners, 
and the first PC of the risky behaviors. (The strongest association with adventurousness within 
the candidate inversion is rs9929242 (P = 2.21×10–6), the strongest association with automobile 
speeding propensity is rs2158268 (P = 3.35×10–6), and the strongest association with drinks per 
week is rs11648570 (P = 1.50×10–7).) The candidate inversion contains ~35 genes, of which 2 
are significant after Bonferroni correction in the MAGMA gene analysis (Supplementary Table 
12.3): CHST4 (Bonferroni-corrected P = 4.69×10–3) and CMTR2 (Bonferroni-corrected P = 
0.024). CHST4 is involved in normal cell function via carbohydrate sulfotransferase55, and 
CMTR2 is involved in methyltransferase55. There is also one additional gene ~458 kb upstream 
of the candidate inversion—NFAT5—that is significant after Bonferroni correction in the 
MAGMA gene analysis (Bonferroni-corrected P = 4.66×10–3). It is notable because it plays a 
central role in gene transcription during immune response55, consistent with the significant 
estimate of the category “Immune/Hematopoietic” in the partitioning of the SNP heritability into 
functional categories with LD Score regression (Supplementary Information section 12). The 
candidate inversion contains genome-wide significant associations in the GWAS Catalog 
database49 with total cholesterol, prostate cancer, and stroke, among other phenotypes. 
The remaining nine of the 13 candidate inversions that contain general-risk-tolerance lead SNPs 
each contain only one general-risk-tolerance lead SNP, and the overlap with the other GWAS is 
low.  
3.3.8 General-risk-tolerance lead SNPs in LD with 1000 Genomes structural variants 
In addition, 24 of the 124 lead SNPs are located within, or in strong LD with another variant 
within, 23 different 1000G structural variants. All candidate inversions that contain general-risk-
tolerance lead SNPs, as well as these 1000G structural variants, are reported in Supplementary 
Table 3.1.  
3.4 Results of the supplementary GWAS 
Our six supplementary GWAS—of adventurousness, the four risky behaviors, and of the first PC 
of the four risky behaviors—identified a total of 741 lead SNPs. We consider 730 of these 741 
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lead SNPs to be novel associations for these phenotypes. The association results are reported in 
Supplementary Table 3.2. We identified 167 lead SNPs for adventurousness, 42 for automobile 
speeding propensity, 85 for drinks per week, 223 for ever smoker, 118 for number of sexual 
partners, and 106 for the first PC of the risky behaviors.  
The results are displayed in Manhattan plots in Extended Data Fig. 3.1 and in Q-Q plots in 
Extended Data Fig. 3.2. The genomic inflation factors (𝜆]^) across the phenotypes ranges from 
1.254 to 1.470, and the estimated LD Score regression intercepts were in the range of 1.026 to 
1.051, consistent with polygenicity and low levels of confounding from population 
stratification42,68. The estimated effect sizes (the 𝛽ZK’s) reported in Supplementary Table 3.2 are 
expressed in phenotype standard deviation units per effect-coded allele. (The phenotype standard 
deviations are reported in Supplementary Table 1.2).  
3.4.1 GWAS of adventurousness 
We identified 167 lead SNPs associated with adventurousness. The strongest associations were 
found within, or in close proximity to, the genes CADM2 (rs10433500, P = 9.31×10–84), SATB1 
(rs13090941, P = 3.26×10–21), and FOXP2 (rs10228494, P = 1.23×10–19). 47 of the 167 lead 
SNPs are also lead SNPs, or in LD with a lead SNP (r2 > 0.1), for general risk tolerance. 52 of 
the 167 lead SNPs are also lead SNPs, or in LD with a lead SNP (r2 > 0.1), for the four risky 
behaviors, and their first PC. 
To the best of our knowledge, there are no previous studies with genome-wide significant 
associations for adventurousness, and we consider all of our lead SNPs to be novel associations. 
We report the novelty of our adventurousness lead SNPs (and of the lead SNPs of the other 
supplementary GWAS) in the column “New locus” in Supplementary Table 3.2. 
18 of the 167 lead SNPs are distributed across three of the 15 long-range LD regions identified 
by Price et al.44, of which two are the long-range LD regions that we describe above in 
Supplementary Information section 3.2 on chromosome 3 (~83.4 to 86.9 Mb) and 
chromosome 6 (~25.3 to 33.4 Mb). Remarkably, 16 of these 18 lead SNPs are located within the 
long-range LD region on chromosome 3. Most of these 16 SNPs are located within, or in 
proximity to, the CADM2 gene, but three of them are closer to the gene VGLL3 (which is located 
~69.8 kb downstream of the long-range LD region). The third long-range LD region, on 
chromosome 8 (~111.9 to 114.9 Mb), does not contain lead SNPs for any of our other six main 
GWAS. 
There is also a total of 24 lead SNPs located within 16 candidate inversions, as well as 29 lead 
SNPs located within, or in strong LD with another variant within, 29 different 1000G structural 
variants. All candidate inversions that contain adventurousness lead SNPs, as well as these 
1000G structural variants, are reported in Supplementary Table 3.2. 
3.4.2 GWAS of automobile speeding propensity 
We identified 42 lead SNPs associated with automobile speeding propensity. The strongest 
association was found within the gene CADM2 (rs17516256, P = 9.9×10–21). Seven of the 42 
lead SNPs are also lead SNPs, or in LD with a lead SNP (r2 > 0.1), for general risk tolerance. 17 
of the 42 lead SNPs are also lead SNPs, or in LD with a lead SNP (r2 > 0.1), for at least one of 
the other main phenotypes we analyze, excluding the first PC of the risky behaviors. 
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To the best of our knowledge, there are no previous studies with genome-wide significant 
associations for automobile speeding propensity, so we consider all of our lead SNPs to be novel 
associations (Supplementary Table 3.2). 
Eight of the 42 lead SNPs are distributed across two of the long-range LD regions identified by 
Price et al.44. Those two regions are the two long-range LD regions we described above in 
Supplementary Information section 3.2 and that are shared across general risk tolerance and 
all or most of our GWAS. Three of the eight lead SNPs are in the region on chromosomes 3 
(~83.4 to 86.9 Mb), and the other five are in the region on chromosome 6 (~25.3 to 33.4 Mb). 
The three lead SNPs located in the long-range LD region on chromosome 3 (~83.4 to 86.9 Mb) 
are all within the CADM2 gene.  
There is also a total of 24 lead SNPs located within 16 candidate inversions, and seven lead 
SNPs are located within, or in strong LD with another variant within, 7 different 1000G 
structural variants. All candidate inversions that contain automobile speeding propensity lead 
SNPs, as well as these 1000G structural variants, are reported in Supplementary Table 3.2. 
3.4.3 GWAS of drinks per week 
We identified 85 lead SNPs associated with drinks per week. The strongest and most notable of 
these associations is located within the alcohol dehydrogenase 1B gene on chromosome 4 
(ADH1B, rs1229984, P = 7.8×10–202). Multiple genome-wide significant associations were also 
found within, or in close proximity to, other alcohol dehydrogenase genes—ADH1A 
(rs62307263, P = 3.42×10–11), ADH1C (rs113659074, P = 9.93×10–23), and ADH7 
(rs114112910, P = 1.08×10–8). Four of the 85 lead SNPs are also lead SNPs, or in LD with a lead 
SNP (r2 > 0.1), for general risk tolerance. 21 of the 85 lead SNPs are also lead SNPs, or in LD 
with a lead SNP (r2 > 0.1), for at least one of the other main phenotypes we analyze, excluding 
the first PC of the risky behaviors. 
Following the procedure described in Supplementary Information section 2.10, we found that 
the lead SNPs located within, or in close proximity to, the genes ADH1A, ADH1B, ADH1C, 
ADH7, GCKR, and KLB, have previously been associated with alcohol consumption (or similar 
phenotypes), and we therefore do not consider associations annotated to these genes to be novel 
associations with drinks per week (Supplementary Table 3.2).  
Two of the 85 lead SNPs are located within the same long-range LD region on chromosome 3 
(~83.4 to 86.9 Mb) that contains lead SNPs for all our GWAS phenotypes (Supplementary 
Information section 3.2), and both lead SNPs are located within CADM2. Unlike for the six 
other main phenotypes we analyze, there are no lead SNPs for drinks per week in the long-range 
LD region spanning ~25.3 to 33.4 Mb on chromosome 6, but the region contains a suggestive 
association at rs6937318 (P value = 3.83×10–7). However, as can be seen in Extended Data Fig. 
3.4, the general level of association is much lower for drinks per week in that long-range LD 
region in comparison with the other main phenotypes we analyze. 
15 lead SNPs are located across 15 candidate inversions. Of these, none is located within the 
candidate inversion spanning ~7.89 to 11.8 Mb on chromosome 8, unlike for general risk 
tolerance, adventurousness, ever smoker, and number of sexual partners. (The strongest 
association with drinks per week within that candidate inversion is rs574968044, (P = 5.64×10–
4).) Just as for the long-range LD region on chromosome 6 (~25.3 to 33.4 Mb), the general level 
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of association is much lower for drinks per week in the candidate inversion on chromosome 8 in 
comparison with the other main phenotypes, as can be seen in Extended Data Fig. 3.4. 
15 lead SNPs are located within, or in strong LD with another variant within, 20 different 1000G 
structural variants (some lead SNPs are in strong LD with SNPs in multiple structural variants). 
All candidate inversions that contain drinks per week lead SNPs, as well as these 1000G 
structural variants, are reported in Supplementary Table 3.2. 
3.4.4 GWAS of ever smoker 
We identified 223 lead SNPs associated with ever smoker. The strongest associations are located 
within, or in close proximity to, the genes NCAM1 (rs7938812, P = 7.1×10–48), ZEB2 (rs961414, 
P = 6.99×10–28), REV3L (rs240955, P = 3.84×10–23), NT5C2 (rs7092200, P = 7.44×10–22), CLU 
(rs11783093, P = 7.44×10–22), TMEM182 (rs1368550, P = 1.08×10–21), and CADM2 
(rs34495106, P = 2.23×10–20). There are three additional lead SNPs located within, or in close 
proximity to, CADM2. 22 of the 223 lead SNPs are also lead SNPs, or in LD with a lead SNP (r2 
> 0.1), for general risk tolerance. 59 of the 223 lead SNPs are also lead SNPs, or in LD with a 
lead SNP (r2 > 0.1), for at least one of the other main phenotypes we analyze, excluding the first 
PC of the risky behaviors. 
Following the procedure described in Supplementary Information section 2.10, we found that 
the two lead SNPs located within the genes NCAM1 and BDNF have previously been associated 
with smoking behavior. We therefore do not consider those two loci to be novel associations 
with ever smoker (Supplementary Table 3.2).  
Previous GWAS on nicotine dependence71 and number of cigarettes per day (CPD)29,71 report 
genes in the nicotine receptor gene family (i.e., the CHRN family29) as some of their strongest 
associations. In our results, none of the nicotine receptor genes (CHRN) contained any lead 
SNPs, consistent with the theory that the ever smoker phenotype is more strongly mediated by 
risk tolerance and social influences than by vulnerability to nicotine addiction72.  
14 lead SNPs are located in six of the long-range LD regions identified by Price et al.44. These 
include the long-range LD regions ~83.4 to 86.9 Mb on chromosome 3 and ~25.3 to 33.4 Mb on 
chromosome 6, which were also found to contain lead SNPs for general risk tolerance and most 
of our other GWAS phenotypes (Supplementary Information section 3.2). The four remaining 
long-range LD regions are on chromosome 1 (~48.2 to 52.2 Mb), chromosome 2 (~134.7 to 
138.2 Mb), chromosome 12 (~111.0 to 113.5 Mb), and chromosome 20 (~32.5 to 35.0 Mb). 
24 lead SNPs are located within 16 candidate inversions, and there are 56 lead SNPs located 
within, or in strong LD with another variant within, 69 different 1000G structural variants (some 
lead SNPs are in strong LD with SNPs in multiple structural variants). All candidate inversions 
that contain ever smoker lead SNPs, as well as these 1000G structural variants, are reported in 
Supplementary Table 3.2. 
We also performed a replication of the eight genome-wide significant SNPs from the GWAS of 
ever smoker by the TAG consortium29 in our GWAS in the UKB only (and not in our meta-
analyses of our UKB GWAS with the TAG summary statistics, as our replication sample must be 
independent of the TAG sample). All eight SNPs have concordant signs, and all are highly 
significant. Specifically, six of the eight SNPs are genome-wide significant (P value < 5×10–8) in 
our GWAS of ever smoker in the UKB (rs6265, P = 1.1×10–14; rs4923457, P = 2.3×10–11; 
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rs4923460, P = 1.8×10–11; rs4074134, P = 2.6×10–11; rs6484320, P = 2.1×10–11; rs879048, P = 
1.2×10–11), and the two remaining SNPs are suggestively significant (rs1013442, P = 1.5×10–7; 
rs1304100, P = 1.2×10–7). It should be noted that the eight SNPs reported in the TAG consortium 
results are not independent, and if we apply our locus definition from Supplementary 
Information section 2.8, then the SNP rs6265 would be the only lead SNP, and the other seven 
SNPs would be clumped to that SNP. rs6265 is one of the lead SNPs in our GWAS of ever 
smoker (which combines the UKB GWAS with the TAG GWAS; n = 518,633), and its P value 
in that GWAS is 3.92×10–18. 
3.4.5 GWAS of number of sexual partners 
We identified 118 lead SNPs associated with number of sexual partners, and the strongest 
associations are located within, or in close proximity to, the genes C14orf177 (P = 4.61×10–19) 
and FURIN (P = 5.76×10–17). Two lead SNPs are within, or in close proximity to, CADM2 
(rs2163971, P = 4.6×10–14; rs9856718, P = 2.68×10–8). 28 of the 118 lead SNPs are also lead 
SNPs, or in LD with a lead SNP (r2 > 0.1), for general risk tolerance. 63 of the 118 lead SNPs 
are also lead SNPs, or in LD with a lead SNP (r2 > 0.1), for at least one of the other main 
phenotypes we analyze, excluding the first PC of the risky behaviors. 
Following the procedure described in Supplementary Information section 2.10, we determined 
that none of the loci we found to be associated with number of sexual partners have been 
previously associated with any similar phenotype, and we therefore consider all of our 
associations with number of sexual partners to be novel (Supplementary Table 3.2). 
Six lead SNPs are located within the two long-range LD regions on chromosome 3 (~83.4 to 
86.9 Mb) and chromosome 6 (~25.3 to 33.4 Mb) that are shared across general risk tolerance and 
all or almost all other GWAS (see Supplementary Information section 3.2). 
25 lead SNPs are located within 14 candidate inversions, and 23 lead SNPs are located within, or 
in strong LD with another variant within, 33 different 1000G structural variants (some lead SNPs 
are in strong LD with SNPs in multiple structural variants). All candidate inversions that contain 
lead SNPs for number of sexual partners, as well as these 1000G structural variants, are reported 
in Supplementary Table 3.2. 
3.4.6 GWAS of the first PC of the four risky behaviors 
We identified 106 lead SNPs associated with the first PC of the four risky behaviors. The 
strongest association is located in the gene MAPT on chromosome 17 (rs62062288, P = 1.02×10–
29), and that gene contains lead SNPs for the GWAS of automobile speeding propensity, drinks 
per week, and number of sexual partners (but not for general risk tolerance, adventurousness, or 
ever smoker). The second strongest association is in CADM2 (rs6790699, P = 5.99×10–27), our 
top gene associated with general risk tolerance, which also contains lead SNPs for all our main 
GWAS. The three next strongest associations are in NCAM1 (rs2155290, P = 4.11×10–24, top 
locus for ever smoker), ADH1B (rs1229984, P = 3.70×10–22, top locus for drinks per week), and 
FOXP1 (rs4676964, P = 7.80×10–18). This latter gene (FOXP1) is also strongly associated with 
the phenotypes automobile speeding propensity and number of sexual partners.  
18 of the 106 lead SNPs are also lead SNPs, or in LD with a lead SNP (r2 > 0.1), for general risk 
tolerance. 89 of the 106 lead SNPs are also lead SNPs, or in LD with a lead SNP (r2 > 0.1), for at 
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least one of the other main phenotypes we analyze. We note that a high level of overlap with the 
results of the GWAS of the four risky behaviors was to be expected, given that the first PC of the 
risky behaviors was obtained from a principal component analysis of the four risky behaviors. 
We know of no previous GWAS of the first PC of the risky behaviors (or of similar phenotypes), 
and we consider all of our lead SNPs to be novel associations (Supplementary Table 3.2). 
Seven of the 106 lead SNPs are located within the long-range LD region on chromosome 3 
(~83.4 to 86.9 Mb), and three lead SNPs are located within the long-range LD region on 
chromosome 6 (~25.3 to 33.4 Mb), both shared with the general-risk-tolerance GWAS and all or 
most of our other main GWAS (see Supplementary Information section 3.2). One additional 
lead SNP is located within a long-range LD region on chromosome 2 (~134.7 to 138.2 Mb). 
20 lead SNPs are located within 14 candidate inversions. Of these, none is located within the 
chromosome 8 candidate inversion spanning ~7.89 to 11.8 Mb. The strongest association with 
the first PC of the risky behaviors within that candidate inversion is rs2898249 (P = 1.27×10–7), 
which we consider suggestive. Also, as can be seen from Extended Data Fig. 3.4, the general 
level of association within the candidate inversion on chromosome 8 (~7.89 to 11.8 Mb) is more 
similar to the phenotypes for which there are lead SNPs in the candidate inversion than to drinks 
per week (for which the candidate inversion does not contain any lead SNPs). 
20 lead SNPs are located within, or in strong LD with another variant within, 24 different 1000G 
structural variants (some lead SNPs are in strong LD with SNPs in multiple structural variants). 
3.4.7 Long-range LD regions and candidate inversions that contain lead SNPs for 
the supplementary GWAS phenotypes 
Our seven main GWAS identified lead SNPs located in eight long-range LD regions and 44 
candidate inversions (defined in Supplementary Information section 2.9). In Supplementary 
Information section 3.2, we focused on the two long-range LD regions and on the three 
candidate inversions that contain lead SNPs for general risk tolerance and for all or most of our 
six other GWAS phenotypes, and above in this subsection (Supplementary Information 
section 3.4) we have briefly presented the long-range LD regions and candidate inversions that 
contain lead SNPs for each of the six supplementary phenotypes. We now focus on three 
candidate inversions that are notable because they contain lead SNPs for four of the six other 
GWAS (but not for general risk tolerance). The remaining 37 identified candidate inversions and 
the remaining six long-range LD regions have little overlap across the GWAS and are reported in 
Supplementary Tables 3.1 and 3.2. 
The first of the three additional candidate inversions that are notable because they are shared 
across four supplementary GWAS is located on chromosome 11 (~112.5 to 113.5 Mb). It 
contains one lead SNP for drinks per week, four for ever smoker, one for number of sexual 
partners, and one for the first PC of the risky behaviors. The strongest association with general 
risk tolerance within the candidate inversion is rs78168664 (P = 1.47×10–4). The GWAS Catalog 
database 49 reports a few previous phenotypes with associations in the region, which include 
bone ultrasound measurement, cardiac muscle measurement, and gut microbiota. 
The second additional candidate inversion is on chromosome 16 (~12.0 to 14.8 Mb) and contains 
one lead SNP for drinks per week, one lead SNP for ever smoker, one lead SNP for number of 
sexual partners, and one lead SNP for the first PC of the four risky behaviors. The strongest 
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association with general risk tolerance within the candidate inversion is rs2866323 (P = 1.36×10–
5). The GWAS Catalog database49 reports notable previous associations with traits such as age at 
menarche, human standing height, and schizophrenia.  
The third candidate inversion is on chromosome 17 (~43.6 to 44.3 Mb) and contains one lead 
SNP for automobile speeding propensity, one for drinks per week, one for number of sexual 
partners, and two lead SNPs for the first PC of the risky behaviors. The strongest association 
with general risk tolerance within the candidate inversion is rs2866323 (P = 1.86×10–4). The 
candidate inversion covers only four genes, including the gene MAPT (~43.9 to 44.1 Mb on 
chromosome 17). SNPs in and around MAPT have previously been associated with many 
neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease and 
frontotemporal dementia55. However, most of those previous associations are located outside the 
candidate inversion on chromosome 17 (~43.6 to 44.3 Mb), and MAPT is not significant after 
Bonferroni correction in the MAGMA gene analysis (Supplementary Table 12.3). 
3.4.8 GWAS Catalog lookup of the lead SNPs from the supplementary GWAS 
To investigate the overlap of our six supplementary GWAS phenotypes with previous GWAS of 
other phenotypes, we performed a lookup for each of the lead SNPs (and the SNPs in LD, r2 > 
0.6) in the NHGRI-EBI GWAS Catalog database49, as described in Supplementary 
Information section 2.11. We report the results in Supplementary Table 3.3. For the six 
GWAS, we find in total 939 overlaps distributed across 130 lead SNPs. Since the six phenotypes 
are genetically correlated, they tend to share lead SNPs (or loci where the lead SNPs for each 
phenotype are in LD, r2 > 0.1), and as expected we find similar overlaps with other traits across 
the six phenotypes. Each of the six phenotypes have at least one overlap with all of the following 
phenotypes or phenotype categories: schizophrenia; educational attainment or cognitive 
performance (e.g. intelligence, information processing speed, cognitive function); BMI (body 
mass index) (or related anthropometric traits); circulating lipids (e.g. triglycerides, cholesterol, 
lipids); blood pressure or coronary artery disease (including arterial stiffness); and lung disease 
(e.g. interstitial lung disease, COPD, asthma).  
Most of the six GWAS also have lead SNPs that overlap with the following phenotypes or 
phenotype categories: autoimmune diseases (e.g. Crohn’s, rheumatoid arthritis, psoriasis, 
vitiligo); various cancers (e.g. breast cancer, lung cancer) or tumor formation; brain volume; 
bipolar disorder; age at menarche; Alzheimer’s disease (driven by the MAPT-locus located in a 
candidate inversion on chromosome 17, ~43.6 to 44.3 Mb); height; Parkinson’s disease; and 
attention hyperactivity deficit disorder.  
The amount of overlap with schizophrenia seems particularly striking: in total, 19 distinct loci 
from our six additional GWAS overlap with loci associated with schizophrenia. We also 
observed many overlaps between general risk tolerance and schizophrenia (Supplementary 
Information section 3.1). 
As discussed in Supplementary Information section 3.3, we note that both the existence and 
the absence of overlaps between any two phenotypes should be interpreted with care, and that the 
existence of overlaps is not necessarily evidence of shared genetic architecture70.  
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4 Testing for population stratification 
Population stratification can be an important source of bias in GWAS. As per our analysis plan30, 
every cohort in our GWAS included the ten (or more) top principal components (PCs) of the 
genetic-relatedness matrix (GRM) in their analyses, and some also used mixed-linear models. 
These procedures should, in principle, control for population stratification. Nonetheless, some 
population stratification and confounding bias could still remain after these controls73.  
In this section, we report the results of two tests of population stratification that are based on two 
different sets of assumptions. The first test is the LD Score intercept test42, which allows us to 
quantify the amount of stratification that is present in our estimates. The second is a sign test that 
compares the signs of GWAS estimates to the signs of the estimates of a within-family (WF) 
GWAS in an independent replication cohort. We applied the first test to the summary statistics of 
the discovery and replication GWAS of self-reported general risk tolerance and to the summary 
statistics of the supplementary GWAS; we applied the second test to the summary statistics of 
the discovery GWAS of self-reported general risk tolerance. 
4.1 LD Score intercept test 
The LD Score intercept test uses GWAS summary statistics for all measured SNPs. Unlike the 
Genomic Control (GC) method, which assumes that confounding bias (e.g., due to population 
stratification and cryptic relatedness) is responsible for inflation in the GWAS 𝜒" statistics, the 
LD Score regression method can disentangle inflation that is due to true polygenic signal 
throughout the genome (which affects the slope of the LD Score regression) from inflation that is 
due to confounding biases such as cryptic relatedness and population stratification (which affects 
the intercept of the regression). 
We used the LDSC software 42 to estimate the intercepts in LD Score regressions with the 
summary statistics of our discovery and replication GWAS of general risk tolerance. We also 
estimated LD Score regressions with the summary statistics from the supplementary GWAS.  
For each phenotype, we used the “eur_w_ld_chr/” files of LD scores computed by Finucane et 
al.74 and made available on https://github.com/bulik/ldsc/wiki/Genetic-Correlation, accessed on 
March 14, 2016. These LD scores were computed with genotypes from the European-ancestry 
samples in the 1000 Genomes Project; only HapMap3 SNPs with MAF > 0.01 were included in 
the LD Score regressions. Because GC will tend to bias the intercept of the LD Score regression 
downward, we did not apply GC to the summary statistics prior to estimating the LD Score 
regressions. 
Extended Data Fig. 4.1 shows LD Score regression plots for our discovery and replication 
GWAS and for the supplementary GWAS.  
For our discovery GWAS, we estimated a LD Score intercept of 1.040 (SE = 0.012); for the 
replication GWAS, we estimated a LD Score intercept of 1.002 (SE = 0.069). The mean 𝜒" 
statistics for all the SNPs in the two LD Score regressions are 1.848 and 1.031, respectively. The 
mean 𝜒" statistics reflect the average strength of the GWAS associations between the SNPs and 
each phenotype. Under the null hypothesis that there is no confounding bias and that the SNPs 
have no causal effects on the phenotypes, the mean 𝜒" statistics would be 1. Thus, mean 𝜒" 
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statistics greater than 1 indicate that some SNPs are associated with the phenotypes, either 
because they are in LD with causal SNPs or because of confounding bias. 
One measure of stratification bias is given by the ratio qrstuvtws)*xyzzzz)* , which describes the share of 
the inflation in the mean 𝜒" statistic (𝛸"zzzz) that is due to stratification. This ratio is 0.048 (SE = 
0.014) for the discovery GWAS and 0.071 (SE = 0.221) for the replication GWAS. These 
estimates imply that only a small part of the observed inflation in the mean 𝜒" statistics from our 
discovery and replication GWAS is accounted for by confounding bias (due to population 
stratification, cryptic relatedness, or other confounds) rather than polygenic signal. This suggests 
that the bulk of the inflation in the 𝜒" statistics from the discovery and replication GWAS is 
attributable to true polygenic signal throughout the genome, and that population stratification is 
unlikely to be a major concern for the analyses we present in this paper.  
Supplementary Table 4.1 contains the full set of LD Score regression results for the discovery 
GWAS, the replication GWAS, the meta-analysis of the discovery and replication GWAS, and 
the supplementary GWAS. Although the LD Score intercepts from these regressions are often 
significantly larger than 1, the share of inflation in 𝛸"zzzz that is due to stratification remains small 
(ranging from 0.047 to 0.071), which allows us to conclude that confounding bias is likely to 
account for no more than a small part of the inflation in these GWAS’ mean 𝜒" statistics. 
As mentioned in Supplementary Information section 2.7, rather than applying the usual GC 
correction, we followed the increasingly common practice of adjusting the standard errors of our 
GWAS estimates for the possible effects of population stratification by inflating them by the 
square root of our estimates of the intercepts from the LD Score regressions42. For the discovery 
and the replication GWAS of general risk tolerance, the meta-analysis of the discovery and 
replication GWAS of general risk tolerance, and the GWAS of ever smoker, each of which 
combines several cohorts, we inflated the standard errors at the meta-analysis level only. 
4.2 GWAS/WF GWAS sign test for the general-risk-tolerance GWAS 
As a simple test of whether the results of our general-risk-tolerance GWAS are driven entirely by 
stratification or whether they capture some genetic signal, we performed a sign test that 
compares the signs of the estimates from our discovery GWAS of general risk tolerance 
(excluding all full siblings from the UKB cohort, as described below) to the signs of the 
estimates from within-family (WF) GWAS of general risk tolerance in the independent STR1, 
STR2, and UKB-siblings cohorts. The UKB-siblings cohort was defined in the same way as the 
full UKB cohort, but only includes individuals with at least one full sibling in the UKB.  To 
avoid overfitting (i.e., to ensure that the two sets of signs originate from GWAS that were 
conducted using independent cohorts), we reran our discovery GWAS after excluding all 
individuals with at least one full sibling in the UKB.  
If the discovery GWAS estimates are driven by stratification, then they should be independent of 
the signs of the WF GWAS estimates (which are immune to stratification) and therefore the two 
sets of signs should only have a concordance of roughly 50%. A significantly higher degree of 
sign concordance would suggest that at least some of the signal from the GWAS comes from true 
genetic effects. 
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4.2.1 Background 
We followed the method outlined in Okbay et al. (2016)18. Here, we summarize the main 
assumptions and procedures that are described in more detail in that paper. 
We first let 𝛽ZK denote the estimate corresponding to SNP 𝑗 from the discovery GWAS excluding 
the full siblings from the UKB, and let 𝛽Z}~,K denote the WF GWAS estimate corresponding to 
SNP 𝑗. The WF GWAS estimate is obtained in a sample of sibling pairs, from a regression of 
sibling differences in general risk tolerance on sibling differences in genotypes and in controls. 
Since WF regressions are not biased due to stratification, and under the assumption that the WF 
effect size of each SNP is equal to the true population effect size, we can decompose the GWAS 
and WF GWAS estimates as: 𝛽ZK = 𝛽K + 𝑠K + 𝑈K	𝛽Z}~,K = 𝛽}~,K + 𝑉K, 
where 𝛽K and 𝛽}~,K are the true underlying GWAS and WF GWAS parameters for SNP 𝑗, 𝑠K is 
the bias due to stratification (defined to be orthogonal to 𝛽K and 𝑈K), and 𝑈K and 𝑉K are the error 
terms in the estimates due to sampling variation, with E(𝑈K) = E(𝑉K) = 0. Note that if 𝛽ZK and 𝛽Z}~,K are estimated in independent samples, then 𝑈K and 𝑉K will be independent. 
Under the null hypothesis that the GWAS contains no genetic signal (i.e., 𝛽K = 𝛽}~,K = 0 for all 𝑗) the sign of 𝛽Z}~,K will be random with equal odds of being positive or negative and will be 
independent of the sign of 𝛽ZK. This means that among a set of 𝑀 independent SNPs, the number 
of SNPs that have concordant signs, denoted C, follows a binomial distribution: 𝐶~Binomial(𝑀, 0.5). 
We can thus measure the observed sign concordance and use this known distribution to formally 
test the null hypothesis. We tested this against the one-sided alternative hypothesis that 𝛽}~,K and 𝛽K are not equal to zero and that their estimates thus have concordant signs. We conducted one-
sided tests, because there is no reason to suspect that the signs would be discordant. 
4.2.2 The GWAS and WF GWAS data 
For this analysis, WF GWAS estimates were obtained in the STR1 (STR-Twingene), STR2 
(STR-SALTY), and UKB-siblings cohorts. These estimates were then combined using a sample-
size weighted meta-analysis. The STR1, STR2, and UKB-siblings cohorts include 674, 680, and 
16,330 sibling pairs, respectively. This gave us a total WF sample size of 17,684 sibling pairs 
(35,368 individuals).  
The GWAS estimates are those from the discovery GWAS excluding all full siblings from the 
UKB, with a total sample size of 901,908. 
Not every SNP from the GWAS results was available in the WF samples. To maximize power, 
we restricted our SNPs for each sign test to those that were available in both the GWAS results 
and in the three WF cohorts. Additionally, to ensure the quality of the WF GWAS estimates, we 
restricted our SNPs to those with MAF ≥ 0.05 in every WF cohort and with imputation quality 
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(INFO) above 95% in every WF cohort and above 99% in the discovery GWAS. Applying these 
filters left 2,005,496 SNPs in the intersection of the discovery and WF GWAS. 
Then, we applied PLINK’s37 clumping algorithm to the GWAS results with the 1000 Genomes 
phase 3 EUR reference panels to obtain a subset containing approximately independent SNPs. 
For this command, we used a threshold of P = 1 for lead SNPs and a LD threshold of r2 > 0.1 in 
a 1,000,000 kb windowt. We obtained 48,979 approximately independent SNPs with results 
available for both the GWAS and the WF GWAS.  
4.2.3 Bayesian estimation of the posterior distribution of the SNPs’ true effect sizes 
Following Okbay et al. (2016)18, we conducted simulations to benchmark the results of our sign 
tests. To do so, we first obtained estimates of the distribution of the SNPs’ true effect sizes (the 𝛽K’s).  
We define 𝛽K,std as the coefficient from the regression where both the phenotype and the 
genotype have been standardized to have mean zero and unit variance. We further assume that 
the effect sizes are drawn from a mixture distribution of a Gaussian and a point mass at zero: 𝛽K,std	~	𝑁(0, 𝜏") with	probability	𝜋0 otherwise,  
where 𝜏" is the variance of non-null SNPs and 𝜋 is the fraction of non-null SNPs in our data. 
This distributional assumption implies that the variance of effect sizes is inversely proportional 
to the variance of the unstandardized genotypesu. By the Central Limit Theorem, we note that the 
estimation error of the GWAS estimate of 𝛽K,std is approximately normally distributed. We use 𝜎K" to denote the variance of this error and note that our assumptions imply that 𝜎K" ≈ 1/𝑛. This 
means the distribution of 𝛽ZK,std is: 𝛽ZK,std	~	𝑁V0, σK" + 𝜏"X with	probability	𝜋𝑁(0, σK") otherwise.  
Because we have a closed-form distribution, we can use the discovery GWAS summary statistics 
to estimate its parameters: the probability of a SNP being null 𝜋 and the variance of the non-null 
effect sizes 𝜏" (as mentioned above, σK" ≈ 1/𝑛). 
As shown in Okbay et al. (2016)18, given these parameters, the posterior probability that SNP 𝑗 
with estimated effect size 𝛽ZK,std is non-null is: 
                                                        
s This smaller reference suffices for this analysis because we only used SNPs with MAF ≥ 0.05 in every WF cohort 
(and thus we do not use our main reference panel for this analysis). 
t Note that the threshold of 𝑃 = 1 means that this algorithm does not filter SNPs by P value but rather continues to 
include SNPs until there is no SNP remaining that is sufficiently uncorrelated with the selected SNPs. We also 
highlight that this procedure does not choose an arbitrary set of SNPs but instead prioritizes those whose estimates 
are more significant. 
u To see this, note that 𝛽K,std	=	𝛽K ∙ Var(𝑆𝑁𝑃K) (where 𝑆𝑁𝑃K is the unstandardized genotype at SNP j and can take 
values 0, 1, or 2). Because we assume that the distribution of 𝛽K,std is the same for all SNPs, it follows that Var(𝛽K) 
will be larger for SNPs whose unstandardized genotypes have lower variance.  
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𝑝, K =
𝜋QσK" + 𝜏" 𝜙⎝⎛ 𝛽
ZKQσK" + 𝜏"⎠⎞1 − 𝜋𝜎K 𝜙 £𝛽ZK𝜎K¤ + 𝜋QσK" + 𝜏" 𝜙⎝⎛ 𝛽
ZKQσK" + 𝜏"⎠⎞
. 
And the posterior distribution of non-null SNPs is: V𝛽K|𝛽ZK, 𝛽K ≠ 0X~𝑁 £ 𝜏"σK" + 𝜏" 𝛽h , σK"𝜏"σK" + 𝜏"¤. 
Following Okbay et al., we estimated the parameters 𝜋, 𝜏", and 𝑝,K using the summary statistics 
from the discovery GWAS (including the full siblings in the UKB cohort). This generated a 
posterior distribution of the true effect size of each SNP given the estimated effect sizes. 
4.2.4 Simulations 
We used a simulation procedure whereby we drew, for each of the 𝑀 approximately independent 
SNPs, “true” effect sizes from the resulting posterior distributions as well as estimation errors, 
and we repeated the simulation 1,000 times.  
We let 𝐸(𝐶) denote the expected number of concordant signs under the alternative hypothesis 
that the SNPs have effect sizes given by the true 𝛽K’s. The quantity 𝐸(𝐶) provides a benchmark 
for the sign test. If the actual fraction of concordant SNPs matches the expected fraction 𝐸(𝐶)/𝑀 
and is significantly larger then 50%, then we can be reasonably confident that most of the 
GWAS estimates are not driven by stratification. 
We estimated 𝐸(𝐶) using the following method. For each of the 1,000 simulations, we generated 
discovery and WF GWAS estimates for each SNP j by adding Gaussian noise to the “true” effect 
size 𝛽K drawn from the posterior distribution. We obtained the following quantities: 𝛽Z]}§¨,K = 	𝛽K +	𝜀K	𝜎O]}§¨,K 𝛽Z}~,K = 	𝛽K +	𝛿K𝜎O}~,K, 
where 𝜀K and 𝛿K	are independent draws from a standard normal distribution and 𝜎O]}§¨,K	and 𝜎O}~,K are the standard errors of the coefficients for SNP j from the discovery and WF GWAS, 
respectively.  
Let 𝐶Z«	be the number of SNPs with matching discovery and WF GWAS signs in simulation k. 
We obtained our estimate of 𝐸(𝐶) by averaging 𝐶Z« across the 1,000 simulations: 𝐸¬(𝐶) = 11000 ­ 𝐶Z«.*+++«®*  
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In addition, we estimated the standard deviation of 𝐶 by using the formula for the sample 
standard deviationv: 
SDJ(𝐶) = ± 1999 ­ ²𝐶Z« − 𝐸¬(𝐶)³"*+++«®* . 
 
4.2.5 Results of the sign test 
Supplementary Table 4.2 reports the results of a range of sign tests we conducted. We 
conducted four sign tests, all of which compared the signs of the estimates from the discovery 
GWAS of risk tolerance (excluding all full siblings from the UKB) to the signs of the estimates 
from the meta-analysis of the WF GWAS in the UKB-siblings, STR1, and STR2 cohorts. Before 
each sign test, we pruned the list of independent clumped SNPs based on the P values obtained 
in the discovery GWAS.  Each sign tests corresponds to one of the following four P value 
cutoffs: 1 (all SNPs included), 0.05, 0.005, and 0.0005.  
As can be seen from Supplementary Table 4.2, we strongly reject the null hypothesis of no sign 
concordance for all of the sign tests. All four sign tests are significant at the 5 × 10–*+ level.  
Note that all of the sign tests we conducted are well powered to reject the null hypothesis of no 
sign concordance. Based on these sign tests, we can be reasonably confident that at least some of 
the GWAS estimates are not driven by population stratification. 
Supplementary Table 4.2 also reports the expected number of concordant signs for each of the 
four sign tests that were conducted. For each test, the observed number of concordant signs is 
similar to, but nonetheless significantly smaller than, the expected number of concordant signs 
predicted by the simulation. This discrepancy might be the result of our assumptions about the 
SNPs’ true effect sizes (the 𝛽K’s). It is also possible that our estimate of the posterior distribution 
of 𝛽K is overly optimistic. 
Another possibility is the following. Our simulation procedure assumes that the true effect sizes 
are the same for both the discovery and WF GWAS, and we use the discovery GWAS summary 
statistics to estimate the posterior distribution of 𝛽K. However, it is possible that the true WF 
GWAS effect sizes are smaller than the true GWAS effect sizes. This could arise, for example, if 
genetic effects were mediated by the family environment (for instance, if parents successfully 
attempted to make their children more similar to each other in terms of their risk tolerance by 
partly counteracting their genetic propensity for risk tolerance). If this were the case, our 
simulation procedure would overestimate the expected number of concordant signs. 
                                                        
v This procedure should yield unbiased estimates of the expected value and the standard deviation of 𝐶, conditional 
on the estimated posterior distribution of the true effect sizes. Because we used an independent set of SNPs, both the 
expected value and the standard deviation of 𝐶 are additive functions of the SNP-level probabilities of sign 
concordance, and this holds even though the simulation does not take the LD between the SNPs into account. 
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4.3 Discussion 
We have presented the results of two tests of population stratification that rely on different sets 
of assumptions. The LD Score intercept test relies on stronger assumptions and allows us to 
quantify how much population stratification is present in our estimates. Our results from this test 
—for our discovery and replication GWAS of general risk tolerance and for our supplementary 
GWAS—imply that only a small part of the observed inflation in the mean 𝜒" statistics is likely 
to be accounted for by confounding bias rather than polygenic signal.  
 
Our results from the second test, the sign test, allow us to strongly reject the null hypothesis that 
the coefficients from our discovery GWAS of general risk tolerance are driven by stratification. 
All four sign tests are significant at the 5 × 10)*+ level.  
 
In sum, both the LD Score intercept tests and the sign tests allow us to conclude that our results 
are unlikely to be driven by population stratification. We can be reasonably confident that the 
bulk of the variation in the GWAS estimates is attributable to true polygenic signal.  
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5 Out-of-sample replication of the lead SNPs from our discovery 
GWAS of general risk tolerance  
To assess the credibility of the results of our discovery GWAS of self-reported general risk 
tolerance, we attempted to replicate the associations of the lead SNPs from that GWAS in an 
independent replication GWAS of self-reported general risk tolerance. 
As described in Supplementary Information section 2.1, the replication GWAS included 10 
cohorts, with a combined sample size of 35,445. To assess the replicability of the lead SNPs 
from our discovery GWAS, we followed the procedure outlined in Supplementary Information 
section 1.8 of Okbay et al. (2016)16 and conducted binomial tests to assess whether the 
associations of the lead SNPs from our discovery GWAS replicate in an independent replication 
GWAS. We conducted two binomial tests. First, we conducted a binomial sign test to assess 
whether the directions (i.e., the signs) of the effects of the lead SNPs are concordant across the 
discovery and the replication GWAS. Second, we conducted a binomial test to assess whether a 
significantly large fraction of the lead SNPs are significant at the 5% level on one-sided tests 
(i.e., with concordant signs and significant at the 10% level on two-sided tests) in the replication 
GWAS.  
We benchmarked these results against a plausible alternative hypothesis, where we predicted the 
number of concordant signs and significant SNPs in the replication GWAS given a posterior 
estimate of the true distribution of effect sizes. This allowed us to determine whether the results 
of the two aforementioned binomial tests match what we would expect if the lead SNPs were all 
true positives.  
5.1.1 Constructing the set of lead and proxy-lead SNPs 
We used the 124 independent lead SNPs from our discovery GWAS of general risk tolerance to 
construct a set of lead and proxy-lead SNPs that are available in the replication GWAS summary 
statistics. We first identified the subset of the 124 lead SNPs that were directly available in the 
replication GWAS summary statistics and had a sample size of at least one-half the maximum 
sample size in that GWAS. We identified 122 such SNPs. Next, for each of the remaining two 
SNPs, we determined whether there exists a suitable “proxy-lead SNP” that satisfies three 
conditions: (1) the SNP is in high LD (r2 > 0.8) with the original SNP (we used PLINK37 and our 
main reference panel to compute LD); (2) the SNP is available in the summary statistics of both 
the discovery GWAS and replication GWAS; and (3) the SNP has a sample size of at least one-
half the maximum sample size in the replication GWAS. If more than one proxy-lead SNP 
satisfied these three condition for one original SNP, we selected the one in highest LD with the 
original SNP as the proxy-lead SNP for the analyses. We identified one such proxy-lead SNP. 
We combined that proxy-lead SNP with those that were directly available in the replication 
GWAS to create the set of 123 lead and proxy-lead SNPs.    
5.1.2 Binomial replication tests 
We conducted two binomial tests of the null hypothesis that none of the lead SNPs are associated 
with risk tolerance. Rejecting this null provides evidence that our lead SNPs contain at least 
some truly associated SNPs. Under the null, we would expect that 50% of the lead SNPs have 
concordant signs and 5% are significant at the 5% level on the one-sided tests (i.e., significant at 
the 10% level, with concordant signs) in the replication GWAS. For both binomial tests, we used 
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one-sided tests of the null hypothesis because we are specifically interested in testing for a larger 
share of concordant or significant SNPs relative to the null share.  
Because the lead SNPs are located in independent loci, the number of lead SNPs that have 
concordant signs or that are significant in the replication GWAS under the null can be modeled 
as a series of coin flips, where the probability of a “success” is 0.5 for sign concordance and 0.05 
for the one-sided tests at the 5% level of significance. It follows that under the null hypothesis, k 
(which we define as the total number of concordant or significant SNPs) is distributed 𝑘	~	Binomial(𝑀, 𝜋), where M is the total number of lead SNPs and π is the probability of 
encountering a concordant or significant SNP (i.e., 0.5 for sign concordance or 0.05 for the one-
sided tests at the 5% level of significance). Knowing the distribution of k allows us to perform 
tests of the null hypothesis. The results of these tests are presented below.  
5.1.3 Expected replication record 
In addition to the test of the null hypothesis described above, we also benchmarked our 
replication record against an estimate of a plausible replication record.  
As for the sign test in Supplementary Information section 4.2, we followed the procedure 
outlined in Okbay et al. (2016)16 and conducted a Bayesian analysis to obtain estimates of the 
posterior distribution of the SNPs’ true effect sizes (the 𝛽K’s), given their GWAS estimates. That 
procedure is described in more detail in Supplementary Information section 4.2 and in Okbay 
et al. (2016)16. 
To compute the expected sign concordance and its variance under the posterior distribution of 
the SNPs’ true effect sizes, we proceeded as in Supplementary Information section 4.2, except 
that we used the set of lead and proxy-lead SNPs (instead of the ~50,000 approximately 
independent SNPs) and replaced the within-family GWAS by the replication GWAS. 
To compute the expected replication record and its variance at the 5% level under the posterior 
distribution of the SNPs’ true effect sizes, we proceeded as in Supplementary Information 
section 4.2, except that we replaced 𝐶Z« with 𝑅¬«, where 𝑅¬« is defined as the number of SNPs in 
simulation k where the simulated replication effect is a significant replication of the simulated 
discovery effect.  
5.1.4 Replication results 
Out of the 123 lead or proxy-lead SNPs, 94 have concordant signs in the replication GWAS. 
Under the null hypothesis that the lead SNPs from our discovery GWAS are all null, we would 
expect 50% of the SNPs (i.e., 61.5 SNPs) to have concordant signs in the replication GWAS. 
Based on the results from our binomial test of sign concordance, we strongly reject the null 
hypothesis of 50% concordance (P = 1.7×10-9). Our expected replication record is that 95.9 (SD 
= 4.6) of the 123 SNPs would have matching signs, which matches our actual replication record 
very closely. 
Out of the 123 lead or proxy-lead SNPs, 23 are significant at the 5% level on one-sided tests (i.e., 
significant at the 10%, with concordant signs) in the replication GWAS. Under the null 
hypothesis that the lead SNPs from our discovery GWAS are all null, we would expect 5% of the 
SNPs (i.e. 6.15 SNPs) to reach significance at the 5% level on the one-sided tests in the 
replication GWAS. We strongly reject this null hypothesis (P = 4.5×10-8). Consistent with this, 
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our expected replication record is that 24.7 (SD = 4.4) SNPs would be significant at the 5% level, 
which again matches our actual replication record very closely.  
The replication record of our lead and proxy-lead SNPs is shown in Extended Data Fig. 5.1, and 
the summary statistics for the 123 lead or proxy-lead SNPs are reported in Supplementary 
Table 3.1.  
In sum, our actual replication record matches our expected replication record for both the sign 
and significance binomial tests. Moreover, both binomial tests strongly reject the null hypothesis 
that none of our lead SNPs are true associations. We also note that under our Bayesian model of 
true effect sizes, the posterior probability that a SNP is causal is above 99% for all of our 124 
lead SNPs. Coupled with our empirical replication results, this suggests that most if not all of the 
lead SNPs we identified are true positives. 
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6 Estimation of genome-wide SNP heritability 
Risk tolerance (both self-reported and experimentally elicited) has been found to be moderately 
heritable in twin studies, with heritability estimates ranging from 20% to 60%2,7,8. In this section, 
we employ three different methods to obtain estimates of the SNP heritability of our primary and 
supplementary GWAS phenotypes. A phenotype’s SNP heritability is the fraction of the 
phenotype’s variance that is accounted for by the additive genetic effects of a set of SNPs.  
6.1 Methods to estimate genome-wide SNP heritability 
We used three methods, GCTA75, LD Score regression42, and Heritability Estimator from 
Summary Statistics (HESS)76, to estimate the genome-wide SNP heritability (ℎ]"). The GCTA 
method estimates the heritability of a phenotype directly from the individuals’ genotypic data, 
while the LD Score and HESS methods use GWAS summary statistics as inputs.  
For comparability across phenotypes and methods, for the LD Score and HESS methods, we 
used summary statistics from the UKB GWAS only for all phenotypes except adventurousness. 
For the adventurousness phenotype, we only report estimates that were obtained using the LD 
Score regression and HESS methods using the 23andMe summary statistics, because this 
phenotype is not available in the UKB and we did not have access to the individual-level 
genotypic data from the 23andMe cohort (and so could not obtain estimates with the GCTA 
method). 
We emphasize that, for general risk tolerance and ever smoker, our main GWAS also analyzed 
data from cohorts other than the UKB, so the heritability estimates we report in this section are 
different from those that would have been obtained using the summary statistics from our main 
GWAS. (Table 1 reports HESS h2 estimates obtained by using summary statistics from our main 
GWAS of the seven phenotypes.) 
6.1.1 The GCTA method 
The GCTA method is based on restricted maximum-likelihood estimation and uses the genetic 
relationship matrix (GRM) to estimate the SNP heritability. Under the  assumptions discussed in 
Yang et al. (2011)75, the method leads to unbiased estimates of the genome-wide SNP 
heritability. However, it is computationally intensive, and it is thus necessary to limit the number 
of SNPs and individuals included in the analysis in order to be computationally feasible. 
Therefore, we restricted the GCTA analysis to a random subset of 30,000 individuals out of the 
full sample from the discovery GWAS. We thereafter dropped one individual in each pair of 
individuals with a cryptic relatedness exceeding 0.025, to obtain a set of unrelated individuals. 
For comparability we used the same initial subset of 30,000 individuals for the GCTA estimation 
for all phenotypes, though the sample size varies slightly across phenotypes because of missing 
phenotypic observations. The final sample sizes for each phenotype are presented in 
Supplementary Table 6.1. In total 646,855 directly genotyped SNPs with MAF > 0.01 were 
included in the GCTA heritability estimation. 
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6.1.2 The LD Score regression method 
Under the assumptions discussed in Bulik-Sullivan et al. (2015)42, a SNP’s GWAS 𝜒" statistic is 
linearly related to its LD score, defined as the sum of the squared correlation coefficients 
between any single SNP and all the other SNPs. The slope of the LD Score regression (of the 
SNPs GWAS 𝜒" statistics on their LD scores and an intercept) can be rescaled to obtain an 
estimate of the heritability explained by the SNPs included in the LD Score analysis by dividing 
the slope by the sample size divided by the number of SNPs, i.e., by n/M. We used the 
“eur_w_ld_chr/” files of LD scores computed by Finucane et al.74 and made available on 
https://github.com/bulik/ldsc/wiki/Genetic-Correlation, accessed on March 14, 2016. These LD 
scores were computed with genotypes from the European-ancestry samples in the 1000 Genomes 
Project. Only HapMap3 SNPs with MAF > 0.01 were included in the LD Score regression; for 
every phenotype, ~1.3 million SNPs were used for the LD Score heritability estimation. Since 
Genomic Control (GC) will tend to bias the intercept of the LD Score regression downward, we 
did not apply GC to the summary statistics prior to estimating the LD Score regressions. 
6.1.3 The HESS method 
The HESS estimator can be described in brief as an analytical variance decomposition method 
that, unlike the GCTA and LD Score regression methods, assumes that the SNP effect sizes are 
fixed effects rather than random effects. The method assumes that the SNPs are randomly 
distributed in the population and requires a pre-specified SNP covariance matrix as input. The 
SNP covariance matrix can be estimated in the sample of interest if individual genotypic data is 
available, or with an external reference panel such as the 1000 Genomes77. As Shi et al.76 show 
using simulations, heritability estimates from LD Score regression are sensitive to the true 
proportion of causal SNPs, and the HESS estimator yields more accurate heritability estimates 
than LD Score regression under a wider range of proportions of truly causal SNPs. We used the 
reference panel distributed with the HESS software for the calculation of the covariance matrix. 
That panel is the European subsample of the 1000 Genomes phase 3 version 5 reference panel, 
restricted to common variants (MAF > 0.05), which is the same as the reference panel used for 
the construction of the LD Scoresw. For every phenotype, a total of ~4.9 million SNPs were used 
in the HESS heritability estimation. As with the LD Score regressions, we did not apply GC prior 
to estimating heritability with HESS. 
6.2 Results of genome-wide SNP heritability estimation 
The results of the genome-wide SNP heritability estimations are reported in Supplementary 
Table 6.1 and displayed in Extended Data Fig. 6.1. The estimated heritabilities of our primary 
and supplementary GWAS phenotypes range from 0.055 to 0.173.  
For self-reported general risk tolerance, we obtained a GCTA heritability estimate of ℎ¬]^¶§"  = 
0.085 (SE = 0.018), a LD Score heritability estimate of ℎ¬·¸	¨v¹ut"  = 0.055 (SE = 0.002), and a 
HESS heritability estimate of ℎ¬º»¨¨"  = 0.063 (SE = 0.003). Of all estimated phenotype, the 
                                                        
w While the same reference panel was used for the construction of the LD scores, as indicated above HapMap3 SNPs 
with MAF > 0.01 were included in the LD score regression. 
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highest estimated heritability was for the first PC of the risky behaviors: ℎ¬]^¶§"  = 0.173 (SE = 
0.025), ℎ¬·¸	¨v¹ut"  = 0.114 (SE = 0.004), and ℎ¬º»¨¨"  = 0.156 (SE = 0.004). 
The methods yield broadly consistent results. For all phenotypes, the heritability estimates are 
similar across the three methods, although the GCTA heritability estimates are generally the 
highest and the LD Score regression estimates are generally the lowest. 
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7 Genetic correlations 
To assess whether the genetic variants that influence general risk tolerance tend to be the same 
and to have similar effect sizes as those that influence plausibly related phenotypes, we use 
bivariate LD Score regression24 to estimate pairwise genetic correlations for autosomal SNPs 
between self-reported general risk tolerance and a number of pre-selected phenotypes. We also 
verify that the genetic correlation for general risk tolerance between males and females is 
statistically indistinguishable from one (thereby justifying our approach of pooling the data 
across the sexes in the rest of our analyses) and that the genetic correlation between the 
discovery and replication GWAS of general risk tolerance is also statistically indistinguishable 
from one. 
7.1 Methodology 
Under some assumptions, bivariate LD Score regression24 produces unbiased estimates of 
genetic correlation, even in the presence of sample overlap. Under these assumptions the method 
merely requires GWAS summary statistics and an “LD score” (the amount of genetic variation 
tagged by a SNP) reference panel.  
Bivariate LD Score regression utilizes the following moment condition:   
(6) 𝐸¼𝑧*K𝑧"K½ = 𝐼𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡 + a𝑁*𝑁"𝑀 𝐶𝑜𝑣.ℓK, 
where 𝑧«K is the z-statistic of SNP j from the GWAS of trait k (k = 1, 2), Intercept is the 
regression intercept, Nk is the sample size of the GWAS of trait k, M is the number of SNPs 
included in the GWAS, 𝐶𝑜𝑣. is the genetic covariance between traits 1 and 2, and ℓK is the LD 
score of SNP j. The slope parameter from a regression of ?̂?*Á?̂?"Á on a𝑁*𝑁"ℓÁ can therefore be 
used to estimate the genetic covariance between the two traits. From separate, univariate LD 
Score regressions of traits 1 and 2, we can also back out estimates of the respective heritabilities 
of the two traits, ℎ.*" 	and	ℎ."" , and obtain an estimate of the genetic correlation as follows: 
(7) ?̂?. = 	𝐶𝑜𝑣J .Qℎ¬.*" ℎ¬."" . 
We used the scores computed by Finucane et al.74, which use genotypic data from the European-
ancestry samples in the 1000 Genomes Project and only HapMap3 SNPs (eur_w_ld_chr, see 
https://github.com/bulik/ldsc/wiki/Genetic-Correlation, accessed on March 14, 2016). As is 
common in the literature, we restrict our analyses to SNPs with MAF > 0.01; this guarantees all 
analyses are performed using a set of SNPs that are imputed with reasonable accuracy across all 
contributing cohorts. The standard errors are estimated by the LDSC software using a block 
jackknife over the SNPs.  
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7.2 Pre-selected phenotypes 
For our bivariate LD Score analyses, we considered a wide range of phenotypes. First, we 
considered our supplementary GWAS phenotypes. These include adventurousness, our four main 
risky behaviors (automobile speeding propensity, drinks per week, ever smoker, and number of 
sexual partners) and their first PC (see Supplementary Table 7.1A1). We also analyzed 
additional risky behavior phenotypes for which we ran additional GWAS with only the first 
release of UKB data (for details regarding the methodology and phenotype definitions, see the 
Appendix at the end of this section); these include age first had sexual intercourse, teenage 
conception (females only), and use of sun protection (see Supplementary Table 7.1A2). 
Further, we analyzed additional risky behaviors for which we were able to obtain summary 
statistics from previously published well-powered GWAS. We include the risky behaviors age 
tobacco smoking onset (among ever-smokers)29 cigarettes per day (among ever-smokers)29, 
former tobacco smoker (among ever-smokers)29 lifetime cannabis use78, and self-employed79 
(Supplementary Table 7.1A3).  
Second, we include the cognition phenotypes cognitive performance80, educational attainment16, 
and intracranial volume81  (Supplementary Table 7.1B). Third, we selected the anthropometric 
phenotypes BMI82 and height83 (Supplementary Table 7.1C). Fourth, we analyzed the 
neuropsychiatric phenotypes ADHD53, Alzheimer’s disease84, anxiety disorders85,x, autism 
spectrum disorder86, bipolar disorder87, depressive symptoms18, and schizophrenia69 
(Supplementary Table 7.1D).  
Fifth, we analyzed the five personality phenotypes that make up the five-factor personality model 
(agreeableness, conscientiousness, extraversion, neuroticism, and openness to experience) using 
GWAS summary statistics provided by 23andMe and previously analyzed by Lo et al. (2016)88 
(Supplementary Table 7.1E). Also known as the Big Five, these traits constitute the most 
widely used taxonomy of personality traits in psychology. The Big Five have roots in Allport & 
Odbert’s lexical hypothesis89, which states that individual differences are encoded in language90. 
This is in contrast to economic preferences such as risk aversion, which are measures of 
individual heterogeneity that arise in a utility maximization framework.  
Recent work in economics has highlighted the importance of personality for economic outcomes, 
particularly in education, crime, health, and the labor market91. However, little is known about 
the relationship between the Big Five and economic preferences. In the most comprehensive 
study of its kind to date, Becker et al. (2012)3 find highly significant positive correlations for 
self-reported risk aversion with openness (0.28) and extraversion (0.26), and negative 
correlations with conscientiousness (-0.04), agreeableness (-0.14), and neuroticism (-0.09)3.    
We also ran GWAS using the first release of UKB data for the socioeconomic phenotypes 
household income and Townsend deprivation index (see Supplementary Table 7.1E; for details 
regarding the methodology and phenotype definitions, see again the Appendix at the end of this 
section). Finally, we evaluated the genetic correlation between risk and longevity92. 
                                                        
x Otowa et al.85 used two phenotype measures in their GWAS of anxiety disorders: one is based on a categorical 
case-control designation for having any anxiety disorder diagnosis, and the other is based on continuous factor 
scores derived by combining information across clinical phenotypes. Our analyses are based on the case-control 
measure. 
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7.3 Results: Genetic correlation between general risk tolerance and pre-
selected phenotypes 
To estimate the genetic correlations between general risk tolerance and each of the above 
phenotypes, we used the summary statistics from the meta-analysis of the discovery and 
replication GWAS. The estimates of the genetic correlations are shown in Supplementary 
Table 7.1 and in Fig. 2.  
7.3.1 Adventurousness and risky behaviors 
First, we examine the genetic correlation between adventurousness and general risk tolerance. 
Then, we return to our other supplementary GWAS phenotypes and their genetic correlations 
with general risk tolerance. These results are reported in Supplementary Table 7.1A1. As 
expected, the estimated genetic correlation with adventurousness is high and statistically 
significant (?̂?.= 0.834, SE = 0.011). The correlation with automobile speeding propensity is 
moderately high  and highly statistically significant (?̂?.= 0.448, SE = 0.021), consistent with 
individuals with more risk-tolerance increasing alleles being more likely to exceed the 
automobile speed limit. For drinks per week the genetic correlation is positive and highly 
statistically significant (?̂?.= 0.254, SE = 0.021), and the genetic correlation is comparable for 
ever smoker (?̂?.= 0.246, SE = 0.022), implying that higher risk tolerance is genetically associated 
with more risky health behaviors. The genetic correlation estimates are highly significant for 
number of sexual partners (?̂?.= 0.520, SE = 0.019). Finally, the genetic correlation for the first 
PC of these four risky behaviors, which can be interpreted as a general factor of risky behavior, 
is interestingly both moderately high in absolute value and highly statistically significant (?̂?.= 
0.500, SE = 0.018). Thus, all of our supplementary GWAS phentoypes are significantly 
genetically correlated in the expected direction with the primary general-risk-tolerance 
phenotype. 
Next, let us turn to the three additional UKB risky behaviors (for which we ran GWAS using 
only the first release of UKB data) and their genetic correlations with general risk tolerance. The 
results are reported in Supplementary Table 7.1A2. The genetic correlation estimates are highly 
significant for age first had sexual intercourse (?̂?.= -0.332, SE = 0.032) and teenage conception 
(?̂?.= 0.246, SE = 0.049). Together with our results of number of sexual partners, this implies that 
that higher risk tolerance is genetically associated with more risky sexual behavior; this is also 
consistent with a finding from a recent GWAS of age at first sexual intercourse50. Use of sun 
protection has an insignificant genetic correlation with general risk tolerance, and we suspect that 
this phenotype may be more highly correlated with skin pigmentation and predisposition to skin 
cancer than to general risk tolerance.  
All seven of our statistically significant genetic correlation estimates for the aforementioned 
risky behaviors have signs that are in the direction that would be expected based on the 
corresponding phenotypic correlations, and the absolute values of the estimates are higher than 
those of these phenotypic correlations. 
Lastly, Supplementary Table 7.1A3 reports the estimates for the risky behaviors for which we 
were able to obtain summary statistics from previously published, well-powered GWAS. One of 
the three cigarette-related phenotypes is moderately and significantly genetically correlated with 
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general risk tolerance: former tobacco smoker (among ever-smokers) (?̂?.= -0.131, SE = 0.055). 
However, age of tobacco smoking onset (among ever-smokers) and cigarettes per day (among 
ever-smokers) are not significantly genetically correlated with general risk tolerance. These 
results suggest that, while higher risk tolerance may be genetically associated with some risk-
related smoking behaviors such as smoking initiation (as suggested by the significant genetic 
correlation with ever smoker) and cessation, risk tolerance may not necessarily be genetically 
correlated with smoking addiction (as captured by cigarettes per day).  
For lifetime cannabis use, the genetic correlation is positive and highly statistically significant 
(?̂?.= 0.313, SE = 0.057), implying that risk tolerance is genetically associated with risk-seeking 
cannabis use behavior. The genetic correlation estimate for self-employed is significant and large 
in magnitude (?̂?.= 0.672, SE = 0.259), implying that higher risk tolerance is genetically 
associated with a common proxy for entrepreneurship. The point estimate for this phenotype is 
the highest among any of the phenotypes tested. However, in interpreting this correlation it is 
important to note that the LD Score regression heritability of the self-employment phenotype is 
low and not significantly different from zero: 0.0126 (SE = 0.0106). Indeed, the standard errors 
on the estimate are quite large (SE = 0.259). This might be due to the fairly small sample size of 
the self-employment GWAS (n = 50,627).  
All 11 of our statistically significant genetic correlation estimates for the risky behaviors have 
signs that imply higher risk tolerance is associated with riskier behaviors.  
7.3.2 Cognition phenotypes 
Two of the three cognition phenotypes are significantly, though weakly, genetically correlated 
with general risk tolerance: educational attainment (?̂?.= 0.099, SE = 0.022) and intracranial 
volume (?̂?.= 0.144, SE = 0.059). These results are consistent with the well-established positive 
correlation between risk preferences and cognition and educational attainment in the 
literature2,4,93. 
7.3.3 Anthropometric phenotypes  
Height is not significantly genetically correlated with general risk tolerance. BMI, on the other 
hand, is significantly, albeit weakly, positively correlated (?̂?.= 0.053, SE = 0.021).  
7.3.4 Neuropsychiatric phenotypes 
Among the neuropsychiatric traits, we find moderate (and highly significant) genetic correlations 
with ADHD (?̂?.= 0.247, SE = 0.033), anxiety disorders, (?̂?.= 0.214, SE = 0.089), autism 
spectrum disorder (?̂?.= -0.105, SE = 0.050), bipolar disorder (?̂?.= 0.214, SE = 0.035) and 
schizophrenia (?̂?.= 0.173, SE = 0.021). The positive and significant genetic correlation with 
ADHD is consistent with the significant effect of our polygenic score of general risk tolerance on 
ADHD in an independent sample (Supplementary Information section 10). We do not, 
however, find significant genetic correlations with either Alzheimer’s disease or depressive 
symptoms.  
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7.3.5 Personality phenotypes  
Agreeableness and conscientiousness are not significantly correlated with general risk tolerance. 
However, the genetic correlations between general risk tolerance and extraversion (?̂?.= 0.505, SE 
= 0.027), neuroticism (?̂?.= -0.420, SE = 0.038), and openness (?̂?.= 0.332, SE = 0.031), are 
moderately high in absolute value and highly significant. The direction of the genetic correlation 
between general risk tolerance and all five personality traits is in line with the literature on the 
phenotypic correlations of these traits outlined above3. Our results for extraversion, neuroticism, 
and openness are also in line with the signs of the significant coefficients on the polygenic score 
for general risk tolerance in regressions of each of these personality phenotypes on the score, as 
highlighted in Supplementary Information section 10 (although our predictive power for these 
traits is quite low).  
7.3.6 Socioeconomic phenotypes and longevity  
The genetic correlation estimates for both household income (?̂?.= 0.215, SE = 0.033) and for 
Townsend score (?̂?.= 0.185, SE = 0.047) are positive and significant, implying that higher risk 
tolerance is genetically associated with higher earnings and social deprivation. The genetic 
correlation with Townsend score is higher than even the phenotypic correlation. We do not find a 
significant genetic correlation with longevity.  
7.3.7 Summary of Findings 
In sum, general risk tolerance tends to be genetically correlated with adventurousness and with 
the risky behaviors involving automobile speeding propensity, substance use, sexual activity, and 
self-employment. Importantly, our estimates have signs that are consistent with higher self-
reported risk tolerance being associated with riskier behavior. General risk tolerance is also 
genetically correlated with the neuropsychiatric phenotypes ADHD, anxiety disorders, autism 
spectrum disorder, bipolar disorder, and schizophrenia, but not with Alzheimer’s disease or 
depressive symptoms, and with the personality phenotypes extraversion, neuroticism, and 
openness, but not with agreeableness or conscientiousness. 
Our results also point toward distinctions in the genetic correlation between general risk 
tolerance and externalizing and internalizing behaviors and disorders. Externalizing behaviors 
and disorders are those in which individuals tend to express maladaptive thoughts and feelings 
toward others or their environment, while internalizing behaviors and disorders are those in 
which individuals tend to express thoughts and feelings inward. Overall, we find significant 
genetic correlations with behaviors and disorders typically classified as externalizing94, such as 
substance abuse (smoking cigarettes, cannabis use, and drinking) and ADHD as well as thought 
disorders related to externalizing disorders such as bipolar disorder and schizophrenia. 
Conversely, we find little evidence of significant genetic correlation with internalizing behaviors 
or disorders, such as depression. We also find evidence confirming the well-documented 
phenotypic correlation between risk taking and cognitive performance and educational 
attainment (e.g., in the domain of financial risk taking2,4,93). 
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7.4 Other results 
7.4.1 Genetic correlation between males and females 
Phenotypically, more than 33% of males in the UKB are categorized as risk tolerant (based on 
their answers to the general-risk-tolerance question), whereas only approximately 18% of 
females are categorized as risk tolerant. To test the extent to which the genetics of general risk 
tolerance differs between males and females, we conducted GWAS of general risk tolerance in 
the first release of UKB data, separately for males and females. We followed the same 
methodology and QC protocol for these two sex-specific GWAS as for our discovery GWAS of 
general risk tolerance and our GWAS of the four main risky behaviors and their first PC in the 
full release of UKB data, except that we only used the first release of UKB data and we only 
used SNPs with MAF > 0.005 instead of MAF > 0.001; the latter does not affect the analyses 
reported in this section, as we restrict these analyses to SNPs with MAF > 0.01. Supplementary 
Table 7.2 reports the SNP-based heritabilities and other relevant summary statistics from the LD 
Score regressions. General risk tolerance is similarly heritable for males (h2 = 0.066, SE = 0.009) 
and females (h2 = 0.053, SE = 0.101), and the difference is not statistically significant. We then 
used bivariate LD Score regression to calculate the genetic correlation between these two 
samples, and obtained an estimate of ?̂?. = 0.9489 (SE = 0.1351). We cannot reject perfect genetic 
correlation between the sexes, thereby justifying our approach of pooling males and females in 
our other analyses. The phenotypic differences between males and females can therefore either 
be the result of (1) factors (which could be biological or environmental) that act across gender 
independently of genotypes, or (2) the sex chromosomes (which we do not analyze here). 
7.4.2 Genetic correlation between the discovery and replication GWAS  
We estimated the genetic correlation between our discovery and our replication GWAS of 
general risk tolerance. We find a high genetic correlation that cannot be statistically 
distinguished from unity (?̂?.= 0.8344, SE = 0.1289), suggesting the genetic underpinnings of 
general risk tolerance do not vary much between our discovery and replication samples. 
As discussed in Supplementary Information sections 1 and 3.3, we also estimated the genetic 
correlation between: (1) the UK Biobank general-risk-tolerance GWAS and the 23andMe 
general-risk-tolerance GWAS; (2) the UK Biobank general-risk-tolerance GWAS and the 
replication GWAS; (3) the 23andMe general-risk-tolerance GWAS and the replication GWAS; 
and (4) the discovery and replication GWAS of general risk tolerance. For (1) we find a 
moderately high, positive genetic correlation (?̂?.= 0.767, SE = 0.021) that is distinguishable from 
unity. For (2) we find a moderately high, positive genetic correlation (?̂?.= 0.828, SE = 0.135); for 
(3) we find (?̂?.= 0.759, SE = 0.126). Finally, for the final correlation (4), we find (?̂?.= 0.834, SE 
= 0.129). The last three correlations are all indistinguishable from unity.  
7.5 Comparison of the genetic and phenotypic correlations 
In Supplementary Table 1.3 we show phenotypic correlations for our primary GWAS 
phenotype, general risk tolerance, and for our five supplementary phenotypes whose GWAS 
included data from the UKB: automobile speeding propensity, drinks per week, ever smoker, 
number of sexual partners, and the first PC of these four risky behaviors (the GWAS of our other 
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supplementary phenotype, adventurousness, used 23andMe data only). Panel A shows values 
calculated naively assuming Pearson correlation coefficients for all of our variables using the 
“pwcorr” command in Stata. In the first column, we show test-retest correlations between the 
first and the second measurements if each phenotype in the UKB, to give a sense of the test-
retest reliability of each phenotype. In the subsequent correlation matrix, coefficients below the 
diagonal are uncorrected Pearson coefficients. Above the diagonal, we adjust the correlation 
estimate for each pair of variables for measurement error by dividing it by the square root of the 
product of the two test-retest correlations for the two variablesy. 
In Panel B, we recalculate Panel A, but this time we use the polychoric package in Stata to allow 
the correct estimation of tetrachoric (between two ordinal variables) or polyserial correlations 
(between an ordinal and a continuous variable). Again, uncorrected correlation coefficients are 
below the diagonal, while correlations corrected for measurement error are above the diagonal.  
In summary, both correcting for measurement error (Panel A and B, above the diagonals) and 
specifying the correct type of correlation coefficient (Panel B) raises the value of the correlation 
estimates, so that our highest estimates are in Panel B, above the diagonal. While some 
correlations are quite high (especially between the first PC phenotype and the other phenotypes), 
the others remain relatively low, including for the correlations between general risk tolerance and 
the five supplementary phenotypes. 
In Supplementary Table 7.1, Panel A1, we compare the genetic correlations with general risk 
tolerance to the phenotypic correlations with general risk tolerance. Even after specifying the 
correct type of correlation (Pearson or polyserial) and adjusting for measurement error, most 
genetic correlations remain considerably higher than the phenotypic correlations.  
These results are relevant to the ongoing debate about the extent to which risk tolerance is a 
“domain-general” versus “domain-specific” trait. Low phenotypic correlations among measures 
of risky behaviors in various domains have led some researchers to conclude that risk tolerance 
is highly domain-specific95,96. The comparatively large genetic correlations we estimate support 
the view that a general factor of risk tolerance partly accounts for cross-domain variation in risky 
behavior6,97 and imply that this factor is genetically influenced, while the lower phenotypic 
correlations suggest that environmental factors are more important contributors to domain-
specific behavior. 
 
 
 
 
  
                                                        
y This is a standard method to correct for measurement error attenuation in the correlation estimates (see, e.g., 
https://en.wikipedia.org/wiki/Correction_for_attenuation). 
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7.6 Appendix: GWAS of other risky behaviors and of socioeconomic 
phenotypes using the first release of UKB data 
While we used existing published GWAS results for most phenotypes, we conducted our own 
GWAS using the full release of UKB data for our four main risky behaviors and their first PC. 
We describe the coding of our four main risky behaviors and their first PC in Supplementary 
Information section 1.2 (for phenotypic correlations of these five behaviors see Supplementary 
Table 1.3). We also conducted our own GWAS using only the first release of UKB data for five 
phenotypes: age first had sexual intercoursez (n = 98,956), teenage conception among females (n 
= 40,077), use of sun protection, household income (n = 97,059), and Townsend deprivation 
indexaa score (n = 112,192). Throughout these analyses we dropped participants who answered 
“Do not know” or “Prefer not to answer” and averaged data across two assessment visits when 
possible.   
The five remaining UKB phenotypes for which we ran GWAS in only the first release of UKB 
data were coded as follows: 
• Age first had sexual intercourse: UKB respondents were asked “What was your age when 
you first had sexual intercourse? (Sexual intercourse includes vaginal, oral or anal 
intercourse)?” We dropped anyone reporting “Never had sex” or an age of first sexual 
encounter at less than 12 (given the high likelihood of associated abuse or misreporting). 
We then normalized the measure separately for males and females.  
• Teenage conception among females: UKB females who bore at least one child were 
asked “How old were you when you had your FIRST child?” We recoded this variable 
into a case-control binary variable. Females reporting age of first live birth between 13 
and 20 (inclusive) were coded as cases (n = 6,285), while females reporting higher ages 
of first live birth were coded as controls (n = 33,792). Childless females were dropped. 
• Use of sun protection: UKB respondents were asked “Do you wear sun protection (e.g. 
sunscreen lotion, hat) when you spend time outdoors in the summer?”; eligible responses 
ranged from “1. Never/rarely” to “4. Always,” and also included “5. Do not go out in 
sunshine.” We dropped all participants who answered “5. Do not go out in sunshine” and 
normalized the resulting categorical variable separately for males and females.  
• Household income: UKB respondents were asked “What is the average total income 
before tax received by your HOUSEHOLD?”; eligible responses were “1. Less than 
£18,000,” “2. £18,000 to £30,999,” “3. £52,000 to £100,000,” “5. Greater than 
£100,000.” We normalized the resulting categorical variable.  
• Townsend deprivation index score: This score measures local social deprivation based on 
the preceding national census output areas; a higher score implies more social 
deprivation. Each participant was assigned a score corresponding to the output area in 
                                                        
z Day et al.50 report results from a GWAS of age of first sexual encounter. We conduct similar analyses ourselves 
here. We treat the phenotype slightly differently by separately normalizing phenotypes among males and females, 
and then conducting our GWAS on the combined sample. 
aa Hill et al.245 report results from GWAS for household income and the Townsend deprivation index in the UKB. 
We ran our own analyses because we could not find the summary statistics from their GWAS in the public domain. 
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which their postcode is located. The score is calculated by the UKB immediately prior to 
each participant joining the dataset. We normalized the scores for our analysis.  
We followed the same methodology and QC protocol for these five additional GWAS as for our 
discovery GWAS of general risk tolerance and our GWAS of the four main risky behaviors and 
their first PC in the full release of UKB data (see Supplementary Information section 2), 
except that we only used the first release of UKB data and we only used SNPs with MAF > 
0.005 instead of MAF > 0.001 (the latter does not affect the analyses reported in this section, as 
we restrict these analyses to SNPs with MAF > 0.01). Supplementary Table 7.2B reports the 
various statistics outputted by LD Score regressions for each of these five additional GWAS. The 
third column shows estimates of the SNP-based heritabilities. All five phenotypes have a higher 
SNP-based heritability than general risk tolerance, except Townsend score. The sexual activity 
phenotypes exhibit particularly high heritabilities. Age first had sexual intercourse has the 
highest SNP-based heritability: 0.167 (SE = 0.009). The only estimate of the LD Score 
regression intercept that is significantly different from one is for household income, for which 
the intercept is 1.035 (SE = 0.008). By comparison, the mean 𝜒" statistics for the SNPs in the LD 
Score regressions are larger than 1.10 for three of the five GWAS, including household income 
for which the mean 𝜒" statistic is 1.198 (the exceptions are teenage conception and Townsend 
score, for which the mean 𝜒" statistics are 1.074 and 1.094, respectively). These estimates imply 
that only a small part of the observed inflation in the mean 𝜒" statistics of the GWAS is likely to 
be accounted for by confounding bias (due to population stratification, cryptic relatedness, or 
other confounds), rather than by polygenic signals. Additional details for these five additional 
GWAS are available upon request. 
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8 Proxy-phenotype analyses 
8.1 Introduction  
We conducted proxy-phenotype analyses80 to search for additional SNPs that affect phenotypes 
that are plausibly related to general risk tolerance. These analyses allow us to test whether SNPs 
that are strongly associated with a “first-stage” phenotype are enriched for association with a 
related “second-stage” phenotype, and potentially to identify new SNPs associated with the 
second-stage phenotype. Proxy-phenotype analyses leverage the fact that, if the first- and 
second-stage phenotypes are genetically correlated, SNPs associated with the first-stage 
phenotype should have a higher probability of being associated with the second-stage phenotype, 
compared to what we would expect by chance. 
In our study, the first-stage phenotype is always general risk tolerance, and the first-stage 
analysis was conducted in our discovery GWAS. We consider eight primary second-stage 
phenotypes: age of smoking onset, cigarettes per day (CPD), smoking cessation (which compares 
former smokers to current smokers), lifetime cannabis use, self-employment status (an indicator 
of whether an individual is self-employed or not), ADHD, bipolar disorder, and schizophrenia. 
We chose these second-stage phenotypes for the following two reasons. First, summary statistics 
from GWAS of these phenotypes that did not include the UKB are publicly available or could be 
obtained. Second, these phenotypes are plausibly related to general risk tolerance: the first five 
phenotypes are risky behaviors and all eight are at least moderately genetically correlated with 
general risk tolerance (Supplementary Information section 7.3). We also used height as a 
negative control. 
8.2 Methodology  
8.2.1 Data and Setup 
We used our discovery GWAS of general risk tolerance as our first-stage analysis. The second-
stage lookups were all performed using summary statistics from previous GWAS. We obtained 
the summary statistics from the following sources: The Tobacco and Genetics Consortium 
(2010)29 for the three tobacco smoking phenotypes, the International Cannabis Consortium 
lifetime for cannabis use (Stringer et al. 2016)78, the Gentrepreneur Consortium for self-
employment (van der Loos et al. 2013)79, the Psychiatric Genomics Consortium for ADHD, 
bipolar disorder, and schizophrenia (Demontis et al. 2017, Sklar et al. 2011, and Ripke et al. 
2014, respectively)53,69,87, and the GIANT consortium for height (Wood et al. 2014)83. Our 
methodology follows Okbay et al. (2016)18 and involves two main stages.  
8.2.2 Stage 1: Constructing the set of lead and proxy-lead SNPs 
The first stage involves constructing the set of lead SNPs from the first-stage analysis. Unlike 
Okbay et al., we only used the lead SNPs (i.e., the independent SNPs with P values < 5 × 10)Â) 
from our discovery GWAS of general risk tolerance as candidate SNPs for the second stagebb. 
For brevity, we illustrate the steps involved for cigarettes per day (CPD), but analogous 
procedures apply for each of the other second-stage phenotypes. Our discovery GWAS of 
general risk tolerance identified 124 lead SNPs. Of these, 52 SNPs were directly available in the 
CPD summary statistics, whereas 72 were either not available or their GWAS sample sizes were 
                                                        
bb Okbay et al. used all SNPs with a P value less than 1 × 10)k, rather than just the lead SNPs. 
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too small to meet our inclusion criterion: to ensure the quality of the estimates for the second-
stage SNPs, we limit our lookup procedure to second-stage SNPs with GWAS sample sizes of at 
least one-half of the maximum sample size for that GWAS. For each of these 72 SNPs, we 
determined whether there exists a suitable “proxy-lead SNP” that satisfies three conditions: (1) 
the SNP is in high LD (r2 > 0.8) with the risk-tolerance associated SNP; (2) the SNP is available 
in the summary statistics of both the discovery GWAS of general risk tolerance and the GWAS 
of CPD; and (3) the SNP has a CPD sample size of at least one-half the maximum sample size in 
the CPD GWAS. To determine the set of SNPs in high LD with the risk-associated SNP, we 
employ PLINK37 with our main reference panelcc. A proxy-lead SNP was available for an 
additional 44 of the 72 SNPs (with r2’s ranging from 0.80 to 1.00, with a mean r2 = 0.94). 
Whenever more than one proxy was available for a SNP, we chose the proxy with the largest r2. 
Ties were broken by choosing the closest SNP to the original lead SNP in base pair distance. Our 
final list of lead and proxy-lead SNPs for CPD therefore contained 52 + 44 = 96 SNPs. 
8.2.3 Stage 2, part 1: SNP lookup and search for previously identified significant loci  
We individually tested each of the k lead and proxy-lead SNPs for experiment-wide significance 
by examining whether each is significantly associated with the second-stage phenotype, using a 
Bonferroni-corrected significance level of 0.05/k (for CPD, k = 96). We refer to the lead and 
proxy-lead SNP that reached Bonferroni-corrected significance in the second stage as “second-
stage hits.”  
For each second-stage hit, we then identified the set of SNPs in the second-stage hit’s locus by 
identifying the SNPs in a 1,000 kb window around the corresponding first-stage lead SNP and 
with r2 > 0.1 with that corresponding first-stage lead SNP (we used PLINK37 and our main 
reference panel to compute LD). We then checked if any of these SNPs are genome-wide 
significant in the second-stage summary statistics. This allowed us to determine whether the 
second-stage hits tag genomic regions that were previously found to be genome-wide significant 
in the GWAS of the second-stage phenotype.   
8.2.4 Stage 2, part 2: Testing the set of lead and proxy-lead SNPs for enrichment and 
sign concordance 
For each second-stage phenotype, we performed a non-parametric Mann-Whitney test67 of joint 
enrichment to test whether the set of lead and proxy-lead SNPs have a P value distribution that is 
significantly different from the P value distribution of a randomly-chosen, matched set of 
“comparison SNPs” in the second-stage summary statistics. Because we expect the second-stage 
phenotypes to be highly polygenic, with many SNPs having weak but true associations, it would 
have been inappropriate to test the null hypothesis that the P value distribution of the lead and 
proxy-lead SNPs is uniform. For each lead and proxy-lead SNP, the comparison SNPs are 
randomly selected from among the set of SNPs that have a minor allele frequency within one 
percentage point of the lead or proxy-lead SNPdd. As in Okbay et al. (2016)18, we generated 
1,000 comparison SNPs for each of the k lead or proxy-lead SNPs, and compared the P value 
distribution for this group of k × 1000 SNPs with that of the k lead or proxy-lead SNPs.  
We also conducted a sign test to assess whether the lead and proxy-lead SNPs have effects in the 
predicted (or concordant) direction in the second stage. For cigarettes per day (CPD), lifetime 
                                                        
cc Throughout this section, we employ our main reference panel to compute the LD between SNPs. 
dd The matched SNPs are drawn with replacement from the set of SNPs in the second-stage summary statistics that 
excludes the Y lead or proxy-lead SNPs. 
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cannabis use, self-employment status, ADHD, bipolar disorder, and schizophrenia (for which a 
higher phenotype value corresponds to more risk taking, and which we estimated to be positively 
genetically correlated with general risk tolerance) we classified a SNP as having an effect “in the 
predicted direction” if the sign of its effect is concordant with that for general risk tolerance. For 
age of smoking onset and smoking cessation (for which a higher phenotype value corresponds to 
less risk taking, and which we estimated to be negatively genetically correlated with general risk 
tolerance) we classified a SNP as having an effect “in the predicted direction” if the sign of its 
effect is discordant with that for general risk tolerance. For example, a SNP that increases 
general risk tolerance and decreases the age of smoking onset has an effect in the predicted 
direction. For ADHD, bipolar disorder, schizophrenia, and height, we did not predict the 
direction of the SNPs’ effects; we simply conducted a sign test to establish whether SNPs’ 
effects are more likely to be sign concordant with those for general risk tolerance than expected 
by chance. 
8.3 Results from proxy-phenotype enrichment analyses 
Q-Q plots for the lead and proxy-lead SNPs in each second-stage phenotype are shown in 
Extended Data Fig. 8.1. These plots show results from the sign test mentioned above and 
highlight any second-stage hits. Further details on each of the lead and proxy-lead SNPs are 
reported in Supplementary Table 8.1, which reports summary statistics from the first and 
second stages for the lead SNPs associated with general risk tolerance and their proxies.   
8.3.1 Do risk-tolerance-associated SNPs predict smoking behaviors? 
For CPD, 52 lead SNPs are directly available in the second-stage summary statistics, and we 
identified 44 proxy-lead SNPs. Out of 96 lead or proxy-lead SNPs, 51 (53.1%) have signs in the 
predicted direction (P = 0.31). There are no second-stage hits. Moreover, the Mann-Whitney test 
of joint enrichment fails to reject the null hypothesis that the P values of the lead and proxy-lead 
SNPs are drawn from the same P value distribution as a set of randomly-selected SNPs (P = 
0.88).  
For age of smoking onset, 52 lead SNPs are directly available in the second-stage summary 
statistics, and we identified 45 proxy-lead SNPs. Of a total of 97 lead or proxy-lead SNPs, 54 
(55.7%) have signs in the predicted direction (P = 0.15). There were again no second-stage hits, 
and the Mann-Whitney test of joint enrichment fails to reject the null (P = 0.48).  
For smoking cessation, 53 lead SNPs are directly available in the second-stage data, and we 
identified 44 proxy-lead SNPs. Of a total of 97 lead or proxy-lead SNPs, 61 (62.9%) have signs 
in the predicted direction (P = 0.007). There were no second-stage hits. The Mann-Whitney test 
of joint enrichment fails to reject the null (P = 0.11).   
8.3.2 Do risk-tolerance-associated SNPs predict lifetime cannabis use? 
For lifetime cannabis use, 117 lead SNPs are directly available in the second-stage data, with no 
additional proxy-lead SNPs. Of these lead SNPs, 76 out of 117 (65.0%) have signs in the 
predicted direction (P = 8 × 10)k). One SNP, rs993137, reaches Bonferroni-corrected 
significance (P = 1.7 × 10)k, before Bonferroni correction) and is thus a second-stage hit, and 
the sign of the effect of this SNP is in the predicted direction. This SNP does not tag any 
previously identified genome-wide hit for lifetime cannabis use, and is thus a novel association. 
The Mann-Whitney test of joint enrichment fails to reject the null hypothesis (P = 0.13).  
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Interestingly, rs993137 falls within the CADM2 gene, which was found to be significantly 
associated with lifetime cannabis use in a gene-based test by Stringer et al. (2016)78. Stringer et 
al. also note that CADM2 has previously been associated with body mass index (BMI), 
processing speed, and autism disorders; these phenotypes themselves have been previously 
associated with cannabis use98–100. It is noteworthy that CADM2 contains lead SNPs for all our 
primary and supplementary GWAS. The NHGRI-EBI GWAS Catalog database49 reports 
previous associations with age at menarche, cognitive function, and educational attainment, 
among other phenotypes, as well as those mentioned by Stringer et al. (2016). 
8.3.3 Do risk-tolerance-associated SNPs predict self-employment? 
For self-employment, 56 lead SNPs are directly available in the second-stage data, along with 43 
proxy-lead SNPs. Of a total of 99 lead or proxy-lead SNPs, 64 (64.6%) have signs in the 
predicted direction (P = 0.002). There is one second-stage hit, SNP rs7387531 (P = 1.1 × 10)k, 
before Bonferroni correction), and the sign of its effect is in the predicted direction.ee,ff To our 
knowledge, no robust association has previously been reported between a genetic variant and 
self-employment; thus, if the association with rs7387531 is robust, this would be the first genetic 
variant to be found to be significantly associated with self-employment.  
Lastly, the Mann-Whitney test of joint enrichment fails to reject the null hypothesis (P = 0.49). 
The significant SNP rs7387531 is located within a candidate inversion on chromosome 8 (~7.89 
to 11.79 Mb), and that candidate inversion contains lead SNPs for our GWAS of general risk 
tolerance, adventurousness, automobile speeding propensity, ever smoker, and number of sexual 
partners. The NHGRI-EBI GWAS Catalog database49 reports SNP associations within the 
breakpoints of the candidate inversion with many other phenotypes, among them are 
neuroticism, extraversion, schizophrenia, and chronotype. 
8.3.4 Do risk-tolerance-associated SNPs predict ADHD? 
For ADHD, 116 lead SNPs are directly available in the second-stage data, with one additional 
proxy-lead SNP. Of a total of 117 lead or proxy-lead SNPs, 74 (63.2%) SNPs have concordant 
signs (P = 0.003). There are four second-stage hits (rs10905461, P = 5.0 × 10)Å before 
Bonferroni correction; rs3764002, P = 2.4 × 10)k; rs7783012, P = 4.4 × 10)Æ; and rs786250, P 
= 2.6 × 10)Å) and all of these have concordant signs. These SNPs are all in new loci: none of 
them tag any previously identified genome-wide associations for ADHD. The Mann-Whitney 
test of joint enrichment rejects the null hypothesis of no-enrichment (P = 0.008). 
None of the four Bonferroni-significant SNPs are located within any of the long-range LD 
regions and candidate inversions in which we found lead SNPs for all or most of our primary and 
supplementary GWAS (Supplementary Information section 3.2). 
We also note that ADHD is significantly associated with our polygenic score of general risk 
tolerance (Supplementary Information section 10) and, as with all second-stage traits we 
                                                        
ee In an ex post analysis, we looked up rs7387531 in the summary statistics of the replication GWAS of self-
employment from van der Loos et al. (2013)79. rs7387531’s association with self-employment did not replicate (P = 
0.061 on a two-sided test, but with the wrong sign). However, this replication attempt was severely underpowered: 
the replication sample was small, comprising only the STR cohort (n  =  3,271). Further, rs7387531 had an R2 of 
~0.004% in the discovery GWAS of general risk tolerance; due to the winner’s curse, the true R2 is likely to be 
smaller than that, and the R2 of rs7387531 on self-employment could be even smaller. 
ff We assume that higher general risk tolerance leads to a higher probability of being self-employed. For the opposite 
view, see ref.246. 
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analyze here (except height), it is also significantly genetically correlated with general risk 
tolerance.  
8.3.5 Do risk-tolerance-associated SNPs predict bipolar disorder? 
For bipolar disorder, 47 lead SNPs are directly available in the second-stage data, with 49 
additional proxy-lead SNPs. Of a total of 96 lead or proxy-lead SNPs, 64 (66.7%) SNPs have 
concordant signs (P = 7.1 × 10)k). There are no second-stage hits. The Mann-Whitney test of 
joint enrichment fails to reject the null hypothesis of no-enrichment (P = 0.87).  
8.3.6 Do risk-tolerance-associated SNPs predict schizophrenia? 
For schizophrenia, 122 lead SNPs are directly available in the second-stage data, with no 
additional proxy-lead SNPs. Of a total of 122 lead or proxy-lead SNPs, 85 (70.0%) SNPs have 
concordant signs (P = 8.3 × 10)Æ). There are sixteen second-stage hits, and 13 of these have 
concordant signs. Four of these SNPs do not tag any loci that were previously identified in 
published GWAS on schizophrenia (rs13327339, P = 4.8 × 10)Å before Bonferroni correction; 
rs1374197, P = 4.8 × 10)Å; rs2357023, P = 4.0 × 10)k; and rs3764002, P = 3.8 × 10)k); two 
of these four SNPs (rs1374197 and rs2357023) have concordant signs. rs3764002 was also a 
second-stage hit for ADHD.  
Four of the 16 Bonferroni-significant SNPs are located within long-range LD regions or a 
candidate inversion in which we found lead SNPs in all or most of our primary and 
supplementary GWAS (Supplementary Information section 3.2). The SNP rs3849046 is 
located within a long-range LD region on chromosome 5 (~135.4 to 138.4 Mb) in which we 
found two lead SNPs for general risk tolerance, but no lead SNPs for any other main GWAS.  
The SNP rs1417998 is located in the long-range LD region on chromosome 6 (~25.3 to 33.4 Mb) 
that covers the HLA-complex, and that region contains lead SNPs for all our GWAS except 
drinks per week (for which it contains a suggestive association). The SNPs rs624244 and 
rs1531518 are both located within a candidate inversion on chromosome 18 (~49.1 to 55.5 Mb), 
and that region is noteworthy because it contains lead SNPs for all our main GWAS. 
The Mann-Whitney test of joint enrichment rejects the null hypothesis of no-enrichment (P = 3.0 × 10)È) relative to randomly selected SNPs. Although schizophrenia has been shown to be 
very polygenic101, the Mann-Whitney test rejects the hypothesis that the observed enrichment is 
due to polygenic inflation of test statistics over the entire genome. However, it is possible that 
the overlap between risk tolerance and schizophrenia is explained by enrichment of broad classes 
of SNPs (e.g., functionally important or conserved regions), rather than specific shared 
pathways. This is because the Mann-Whitney null distribution is only matched on minor allele 
frequency; however, the null sample could be further matched based on other attributes (e.g., LD 
score, functional annotations) to examine whether the joint enrichment is accounted for by these 
attributes.  
These 16 second-stage hits for schizophrenia, together with the strong enrichment of the general-
risk-tolerance lead SNPs in the schizophrenia GWAS as well as the high sign concordance of 
their effects on schizophrenia, suggest that part of the genetic signal for schizophrenia and 
general risk tolerance may be concentrated in the same genomic regions. We also note that five 
of our general-risk-tolerance lead SNPs are located in loci that had been found by previous 
GWAS to be associated with schizophrenia (as we detail in Supplementary Information 
section 3.3). 
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8.3.7 Do risk-tolerance-associated SNPs predict height? 
For height, 57 lead SNPs are available in the data, along with 42 proxy-lead SNPs. Out of these 
99 lead or proxy-lead SNPs, 53 (53.5%) have concordant signs (P = 0.27), and eight are second-
stage hits. Four of these eight SNPs have concordant sign, and all tag loci with previously 
identified genome-wide associations. The Mann-Whitney test of joint enrichment rejects the null 
hypothesis that the second-stage P values are drawn from a null distribution (P = 1.4 × 10)Å) 
and reveals much enrichment (as can be seen from Extended Data Fig. 8.1).  
These result for height partially contradicting our initial framing of height as a negative control. 
Such enrichment in the absence of genetic correlation between two traits could be due to a 
number of reasons102, including an enrichment of all polygenic traits for certain regions in the 
genome (e.g., functional or evolutionary conserved regions). As discussed above, the Mann-
Whitney null distribution does not account for this form of regional polygenic enrichment. We 
do not further explore this here, but we note that this may be an interesting question for future 
research. 
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9 Multi-trait Analysis of GWAS (MTAG) 
9.1 Introduction 
Because many phenotypes are genetically correlated24,70, information contained in the GWAS of 
different but related phenotypes can be used to increase detection and the predictive power of our 
analysis. We used Multi-trait Analysis of GWAS (MTAG)103 to increase the precision of the 
estimates of our GWAS of self-reported general risk tolerance and to improve our ability to 
detect lead SNPs associated with general risk tolerance. MTAG offers several advantages over 
lookup-based methods, such as the proxy-phenotype method (Supplementary Information 
section 8); MTAG allows for more than two phenotypes, it increases detection power for all 
included phenotypes, and it works even in the presence of sample overlap across the various 
GWAS. 
With MTAG, we leveraged the additional information contained in the GWAS summary 
statistics of six phenotypes related to risk tolerance or risky behavior. The six phenotypes are the 
five supplementary GWAS phenotypes adventurousness, automobile speeding propensity, drinks 
per week, ever smoker, and number of sexual partners, as well as lifetime cannabis use78,gg,hh. We 
selected these six phenotypes because they each plausibly capture a different dimension of risk-
taking behavior, and they all are significantly genetically correlated with general risk tolerance 
(Supplementary Table 7.1, Panels A1 and A3). Additionally, we conducted an additional 
MTAG analysis that also included self-employment79 among those phenotypes, but ultimately 
decided not to include self-employment in our baseline analysis, as we explain below. 
We also used the summary statistics of this MTAG analysis to construct polygenic scores of 
general risk tolerance and evaluate their power in predicting a suite of phenotypes available in 
three validation cohorts (Supplementary Information section 10). 
9.2 Methods 
We used the summary statistics from the meta-analysis of the discovery and replication GWAS 
of general risk tolerance and of the six aforementioned phenotypesii as input for our MTAG 
analysis. 
MTAG builds on the assumption that the correlation in the effect size of a SNP across 
phenotypes is the same for all SNPs. This assumption is strong and often violated; however, 
Turley et al. (2017)103 analytically show that, as long as the SNPs have a non-null association 
with all phenotypes, MTAG is still a consistent estimator with a lower mean squared error than a 
                                                        
gg The summary statistics for most of these phenotypes come from GWAS that were conducted in samples that 
included the UKB and 23andMe cohorts. This should not bias the results because, as mentioned above, MTAG 
works well in the presence of sample overlap across the various GWAS. 
hh We do not use the summary statistics from our sixth supplementary GWAS phenotype, the first PC of the risky 
behaviors, because that would have been redundant given that we already use the summary statistics of the four 
risky behaviors. 
ii As usual, we applied genomic control using the intercepts of LD Score regressions to adjust the summary statistics 
used as input for our MTAG analysis. As the MTAG summary statistics are invariant to any scaling performed on 
the summary statistics used as inputs for the analysis, whether genomic control has been applied to the input 
summary statistics should not affect the results. We did not apply genomic control using the intercepts of LD Score 
regressions to adjust the summary statistics outputted by the MTAG analysis, because the adjustment is already built 
into the MTAG estimates. 
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corresponding GWAS. A problem might arise in MTAG for SNPs that have no effect on one 
phenotype but a sizeable effect on another. This might be the case for SNPs in the proximity of 
genes implicated in a biological process that is specific to one of the phenotypes, but unlikely to 
be implicated for general risk aversion. Such examples might include nicotine or cannabis 
receptors, or alcohol metabolism. We therefore excluded from this analysis all SNPs within 1Mb 
of the genes CHRNA5 and CHRNB3 (nicotinic receptors), CNR1 and CNR2 (cannabinoid 
receptors), and ADH1B (Alcohol Dehydrogenase)jj. 
We imposed a MAF filter of 0.01 and a sample size filter	𝑁 ≥ "m × 𝑃È+(𝑁) to the SNPs for all 
datasets, where 𝑃È+(𝑁) denotes the ninth decile of the sample size of a dataset. MTAG 
automatically limits the analysis to the 5,869,552 SNPs present in all data sets.  
We also considered adding self-employment79 to the seven phenotypes in the MTAG analysis, 
but doing so would have limited the number of shared SNPs to 2,232,479. Below, we also report 
(in parentheses) the results of the MTAG analysis that also included self-employment (and that 
therefore included a total of eight phenotypes). 
We ran MTAG (July 13, 2017 release) and then clumped the resulting MTAG summary statistics 
for the general-risk-tolerance phenotype using our main reference panel33 and PLINK 1.9, with 
the same thresholds we used for the main GWAS analysis (Supplementary Information section 
2.8). These thresholds included a primary P value threshold (5×10–8), a secondary P value 
threshold (1×10–4), an r2 threshold (0.1), and a SNP window defined in kilobases (1,000,000 
kb)kk.  
To assess whether the lead SNPs from the MTAG analysis of general risk tolerance are in loci 
that have not been identified by previous GWAS of risk tolerance, we repeated the steps we had 
followed to assess the novelty of the lead SNPs from our discovery GWAS of general risk 
tolerance (described in Supplementary Information section 2.10). 
9.3 Results 
9.3.1 MTAG summary statistics  
Leveraging the information present in the seven (eight with self-employment) selected 
phenotypes, MTAG increases the number of independent SNPs reaching genome-wide 
significance for general risk tolerance from 124 to 312 (225 with self-employment). 
Supplementary Table 9.1 reports the 312 lead SNPs. 127 of these are in loci that overlap the 
124 loci already identified in our discovery GWAS of general risk tolerance. The top SNP is 
located in the locus in the CADM2 gene on chromosome 3 that has previously been identified by 
Day et al.50 and that has also been associated in a concurrent study on general risk tolerance by 
                                                        
jj It is worth noting that SNPs close to the ADH1B gene were top-hits in recent GWAS of alcohol consumption 
(Clark et al. (2017)247 and Supplementary Table 3.2). By contrast, SNPs in the proximity of the cannabis receptor 
genes were not associated with life-time cannabis use at the genome-wide significant level in the GWAS of lifetime 
cannabis use whose summary statistics we obtained78. SNPs close to the nicotine receptors genes have been found to 
be significantly associated with daily cigarettes smoked but not with ever smoker (TAG et al. (2010)29 and 
Supplementary Table 3.2), although this could be due to the limited statistical power of those GWAS. For 
precautionary reasons, we still drop those SNPs from the MTAG analysis. None of these regions contain top-hits for 
the single-trait GWAS of general risk tolerance, and therefore their exclusion should have little bearing on our 
analysis. 
kk As noted before, we used a very wide SNP window of 1,000,000 kb, which effectively makes the r2 and P value 
thresholds the only binding parameters for the PLINK clumping algorithm. 
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Strawbridge et al.51. A total of 185 of the 312 lead SNPs are novel genome-wide significant 
associations with general risk tolerance that have not been identified by our discovery GWAS, 
by Day et al., or by Strawbridge et al.  
MTAG increases the mean χ" for general risk tolerance from 1.81 to 2.21 (1.89 to 2.23 with self-
employment). To achieve a similar increase in χ", the sample size for the GWAS would have to 
be increased from 975,353 to 1,452,014 (975,353 to 1,346,482 with self-employment). This 
increase in signal can be seen by comparing the Q-Q plots for the MTAG analysis with the seven 
phenotypes and for the meta-analysis of the discovery and replication GWAS of general risk 
tolerance (Extended Data Fig. 9.1a). 
Extended Data Fig. 9.1b displays the Manhattan plots for the MTAG analysis of general risk 
tolerance (top panel) and for the discovery GWAS of general risk tolerance (bottom panel), 
revealing strong similarities. Indeed, the genetic correlation between the summary statistics from 
the MTAG analysis and from the meta-analysis of the discovery and replication GWAS of 
general risk tolerance is very close to unity (?̂?.= 0.959, SE = 0.0025 without self-employment; ?̂?.= 0.975, SE = 0.0016 with self-employment). 
9.3.2 Robustness tests 
MTAG can lead to inflated results if the summary statistics for some of the phenotypes come 
from highly-powered GWAS but have relatively low genetic correlations with the phenotype of 
interest. Here, this might be the case for the ever smoker phenotype, since the summary statistics 
of that phenotype have a mean χ" statistics of 2.006 but a genetic correlation of only 0.28 with 
general risk tolerance. However, we repeated the above MTAG analysis without the ever smoker 
phenotype (and without self-employment), and we still found 299 independent SNPs that reach 
genome-wide significance, 296 of which are either the exact same SNPs or within loci of the 
original MTAG analysis. The remaining three SNPs have P values close to our P value threshold 
of 5×10–8. 
9.3.3 Predictive power of general-risk-tolerance polygenic score constructed with the 
MTAG summary statistics 
We constructed a polygenic score using the summary statistics from the MTAG analysis that 
used the seven selected phenotypes. This score allows us to measure how the increase in signal 
translates into increased out-of-sample predictive power for several measures of risk tolerance, 
personality traits, and risky behaviors in the Add Health and the HRS cohorts. The construction 
of the polygenic score with the LDpred method104 (with the Gaussian mixture weight 0.3), the 
definition of the predicted phenotypes, and the results of these analyses are described in detail in 
Supplementary Information section 10. Comparison of the predictive power of the polygenic 
scores constructed using the MTAG and GWAS summary statistics are reported in Extended 
Data Figs. 10.1-10.2 and in Supplementary Tables 10.1-10.4. As expected, the predictive 
power of the polygenic scores constructed using the MTAG summary statistics is on average 
slightly higher than that of the scores constructed using only the GWAS summary statistics. 
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10 Predictive power of general-risk-tolerance polygenic score 
To assess the out-of-sample predictive power of the genetic variants associated with self-reported 
general risk tolerance, and to gauge the potential for leveraging these associations in empirical 
research in the behavioral sciences, we constructed various polygenic scores (PGS) and used 
them to predict several risk-related phenotypes, personality traits, and real-world measures of 
risky behaviors.  
In this section, we first describe in detail the phenotypes we predicted, which fall in three main 
domains: measures of risk tolerance (including general risk tolerance), personality traits, and 
risky behaviors. To be able to analyze several phenotypes in all of these domains, we used six 
different datasets with contain rich phenotypic information: the Add Health, HRS, NTR, STRll, 
UKB-siblingsmm, and Zurich cohorts. 
Next, we delineate and motivate the methodology that we followed to construct the polygenic 
scores used for prediction. We constructed three polygenic scores in total. Our first two 
polygenic scores were constructed with the LDpred104 method, which accounts for the linkage 
disequilibrium (LD) between SNPs. The first was constructed using the summary statistics from 
the meta-analysis of the discovery and replication GWAS of general risk tolerance; the second 
was constructed using the MTAG summary statistics (for details, see Supplementary 
Information section 9). Our third polygenic score was constructed with the classical method, 
which simply weights SNPs by their GWAS effect size105,106. Due to data access limitations, the 
23andMe cohort could not be included in the meta-analysis whose summary statistics we used to 
construct the polygenic scores in the NTR, STR, and Zurich cohorts. The polygenic score using 
the MTAG summary statistics was only constructed for the Add Health, HRS, and UKB-siblings 
cohorts. 
Across our analyses, we find that the polygenic scores’ predictive power is within the range 
expected according to theory107,108, when we take into account the SNP heritability of general 
risk tolerance and cross-cohort heterogeneity. In addition, our polygenic scores are predictive of 
both general risk tolerance and alternative measures of risk tolerance, such as financial and 
income gamble risk tolerance. Furthermore, the scores are predictive of a wide variety of other 
phenotypes: from personality traits such as openness to experience and behavioral inhibition, to 
real-world economic behaviors such as being an entrepreneur or owning a business, to risky 
health behaviors such as drinking, smoking, or drug use, to precautionary behaviors such as 
having life and health insurance. These results are robust to controlling for educational 
attainment, cognitive performance, and personality traits. Finally, for some of the predicted 
phenotypes, the predictive power of our polygenic scores is comparable to, or even exceeds, the 
predictive power of cognitive performance or educational attainment.  
                                                        
ll The STR1 and STR2 cohorts were merged for the prediction analysis. See Appendix Section 10.5.3 for details. 
mm As mentioned in Supplementary Information section 4, the UKB-siblings cohort was defined in the same way 
as the full UKB cohort, but only includes individuals with at least one full sibling in the UKB. 
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10.1 Phenotype definition 
10.1.1 Risk-tolerance phenotypes 
We predict both general-risk-tolerance measures and several alternative measures of risk 
tolerance. These alternative measures have been developed to elicit risk tolerance in specific 
domains, such as financial investment decisions or career choices. Three such alternative 
measures are available in the cohorts we analyze: “financial risk tolerance,” “income gamble risk 
tolerance,” and “lottery-elicited risk tolerance.” These alternative measures have been shown to 
correlate with non-hypothetical risky behaviors such as smoking and drinking, being self-
employed, or holding a risky investment portfolio1–5. As a negative control, we also predicted 
height in the STR cohort.  
(1) General risk tolerance 
The general-risk-tolerance phenotypes we used are comparable to the measures used in the 
discovery and replication GWAS of general risk tolerance (these measures are described in 
Supplementary Information section 1.2).  
In the STR cohort, the following question adapted from the German Socioeconomic Panel4 was 
asked to the respondents: “How do you see yourself: Are you generally a person who is fully 
prepared to take risks or do you try to avoid taking risks? Please tick a box on the scale, where 
the value 1 means ‘unwilling to take risks’ and the value 10 means ‘fully prepared to take 
risks’.” The sample size for general risk tolerance in the STR cohort is 8,012, and the mean 
response is 4.5 (Supplementary Table 10.1).  
In the Add Health cohort, the latest wave asks respondents who were 24-34 years old the 
following question: “How much do you agree with each statement about you as you generally 
are now, not as you wish to be in the future?: I like to take risks.” Likert-scale response options 
include: [1] strongly agree; [2] agree; [3] neither agree nor disagree; [4] disagree; [5] strongly 
disagree. We reverse coded this variable, so that individuals more likely to take risks were coded 
with a “5” rather than a “1,” and vice versa. In total, we have data available for 4,749 European 
respondents for this variable, and the mean response is 3.0 (Supplementary Table 10.1).  
In the UKB-siblings cohort we have information on self-reported general risk tolerance. All of 
the phenotypes predicted in the UKB-siblings cohort are the same as the UKB measures used in 
our primary and supplementary GWAS. For a detailed description of these phenotypes, see 
Supplementary Information section 1.2. 
(2) Financial risk tolerance 
Financial risk tolerance was measured with the following survey question in the STR cohort10: 
“Are you a person that is fully prepared to take financial risk or do you try to avoid taking 
financial risk? Please tick a box on the scale, where the value 1 means: ‘not at all willing to take 
risks’ and the value 10 means: ‘very willing to take risks’.” 
The sample size for financial risk tolerance in the STR cohort is 8,038, with a mean response of 
3.5 (Supplementary Table 10.1). 
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(3) Income gamble risk tolerance 
The income gamble risk tolerance phenotype is available in the STR and HRS cohorts. In the 
STR cohort the income gamble risk question is109: 
“Imagine the following hypothetical situation. You are the sole provider for your household, and 
you have the choice between two equally good jobs: 
Job A will with certainty give you SEK 25,000 per month after taxes for the rest of your life. 
Job B will give you a 50-50 chance of SEK 50,000 per month after taxes for the rest of your life, 
and a 50-50 chance of SEK X per month after taxes for the rest of your life. 
Which job do you choose?” 
The question was asked three times, and the amount X consecutively takes the values 20,000, 
22,000 and 17,000. At the time, one US dollar was worth approximately seven SEK. A 
respondent receives one point for each time the risky Job B is chosen, so that a value of 0 
indicates the lowest risk tolerance, and a value of 3 indicates the highest risk tolerance.  
The sample size for income gamble risk tolerance in the STR cohort is 7,577, with a mean 
response of 2.0 (Supplementary Table 10.1). 
In the HRS cohort, the income gamble risk question was asked in several waves. Here, we 
summarize how we created the income gamble risk tolerance variable in the HRS cohort. We 
provide further details in the Appendix at the end of this section.  
In the first wave the income gamble risk question is phrased as follows: 
“Suppose that you are the only income earner in the family, and you have a good job guaranteed 
to give you your current (family) income every year for life. You are given the opportunity to take 
a new and equally good job, with a 50-50 chance it will double your (family) income and a 50-50 
chance that it will cut your (family) income by a third. Would you take the new job?” 
If the answer is “yes” to the first question, then the respondent is asked this follow-up question: 
“Suppose the chances were 50-50 that it would double your (family) income, and 50-50 that it 
would cut it in half. Would you still take the new job?” 
If the answer is “no” to the first question, then the respondent is asked this follow-up question: 
“Suppose the chances were 50-50 that it would double your (family) income and 50-50 that it 
would cut it by 20 percent. Would you then take the new job?” 
In the following waves, the question wording is slightly modified, albeit keeping the same 
overall structure (see the Appendix at the end of this section for more details). In order to merge 
the information from different waves, we first coded each variable so that higher values imply 
higher risk tolerance, and then we took the average of the residuals from a separate OLS 
regression of each wave’s phenotype on an intercept and birth year, birth year squared, birth year 
cubed, sex, as well as three interaction terms between sex and the three birth year variables.  
The sample size for income gamble risk tolerance is 7,302 in the HRS cohort, with a mean 
answer of 1.8 (Supplementary Table 10.1). 
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(4) Lottery-elicited risk tolerance 
The lottery-elicited risk tolerance phenotype is only available in the Zurich cohort. It was elicited 
using a method called Multiple Price List (MPL)4,25,110, which is commonly used in studies on 
risk tolerance based on incentivized gambles or lotteries. This phenotype was measured in an 
incentivized computerized experiment, in which respondents were asked lottery questions 
presented in three separate screens, corresponding to three tables. Each screen shows a table with 
20 rows, on which respondents are required to make 20 binary decisions between a fixed lottery 
(option A) and a certain outcome (option B), which changes from row to row.  
In each table, option A offers the possibility to “Win X CHF with a probability of 50% and win 
Y CHF with a probability of 50%.” The following values for X and Y are used for the three 
tables: Table 1: (20, 10) CHF; Table 2: (20, 0) CHF; and Table 3: (50, 20) CHF. (The expected 
values for option A are thus 15, 10, and 35 for the three tables). Option B displays the guaranteed 
win as the interval [X, Y] divided into 20 equal steps presented in descending order on each 
screen. (Between 10 and 19.5 CHF on table 1, between 0 and 20 CHF on table 2, and between 20 
and 48.5 CHF on table 3.) Respondents chose between either option A or B for each of the 20 
rows and the software enforced consistency so that respondents could only switch once from 
option B to option A on each screen. We calculated a screen’s certainty equivalent as the average 
of the two option B wins just above and below the respondents’ switching point. Individual i’s 
lottery-elicited risk tolerance measure was then calculated as the median of the calculated 
relative risk premia (rrp) of the three lottery questions: 
(8) 
𝑚𝑒𝑎𝑠𝑢𝑟𝑒5 = 𝑚𝑒𝑑𝑖𝑎𝑛(𝑟𝑟𝑝5,K) = 𝑚𝑒𝑑𝑖𝑎𝑛 £(𝐵5,K − 𝐸[𝐴K])|𝐸[𝐴K]| ¤,	 
where 𝐸[𝐴K] is the expected value of option A on screen j and 𝐵5,K is the certainty equivalent for 
individual i on screen j. (For the subsamples from Munich and Innsbruck, currencies were 
converted to EURO according to purchasing power.) 
The sample size of the lottery-elicited risk tolerance is 2,610 in the Zurich cohort. 
10.1.2 Personality traits 
Personality traits have been defined as “the relatively enduring patterns of thoughts, feelings, and 
behaviors that reflect the tendency to respond in certain ways under certain circumstances”111. 
Therefore general risk tolerance can be viewed as one of the many traits characterizing an 
individual’s personality, and is certainly very much related to established personality measures 
such as behavioral inhibition (the tendency to have a restrained or fearful response to unfamiliar 
events), openness to experience (the degree of intellectual curiosity, creativity, and preference 
for novelty and variety), or sensation-seeking (the tendency to search for experiences and 
feelings that are varied, novel, complex, and intense). Indeed several studies at the intersection of 
economics and personality psychology document the phenotypic correlation between measures 
of personality traits and general risk tolerance2–4,112–117. Motivated by these findings, we 
investigate the predictive power of our genetic measure of risk tolerance for various phenotypic 
measures of personality traits. 
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A large range of measurements of personality traits is available in our datasets, from the widely 
used five-factor model of personality (the Big Five), to more specific measures like behavioral 
inhibition and locus of control. Below we provide a detailed description of our personality 
phenotypes, and we present the summary statistics in Supplementary Table 10.2. 
(1) Behavioral inhibition 
Behavioral inhibition is defined as a behavioral style characterized by a restrained or fearful 
response to unfamiliar events, both social and non-social, and has been shown to be moderately 
stable over time118. The 16-item Adult Measure of Behavioral Inhibition (AMBI) battery is 
available in the STR cohort (n = 7,608) cohort. An example question is: “Do you feel awkward 
when you are approached by someone new?” Each question is answered on a three-point scale. 
Summing the responses leads to a variable taking values in the interval [0, 32]. We reverse coded 
the variable so that a higher score implies a higher behavioral disinhibition, since we expect 
behavioral disinhibition to be positively correlated with general risk tolerance, as has been found 
in previous studies2.  
(2) Locus of control 
Locus of control is a personality trait defined on a spectrum ranging from internal control, where 
an individual feels that the outcomes of events are contingent on his or her own behavior and 
attributes, to external control, where an individual believes that external forces outside of 
personal control determines the outcome of events. The 12-item locus of control scale is 
available in the STR cohort for 6,777 individuals. It is coded such that higher numbers indicate 
an internal locus of control. An example question is: “Becoming a success is a matter of hard 
work; luck has little or nothing to do with it”119. We expect internal locus of control to be 
positively correlated with general risk tolerance, and this is what has been found in previous 
studies2. 
(3) Big Five personality traits 
Several decades of research in personality psychology beginning in the 1970s have led to a 
widely shared taxonomy of personality traits, known as the Big Five120–122. Identified via factor 
analysis of common language descriptors of personality, these five distinct and independent 
personality characteristics are openness to experience, conscientiousness, extraversion, 
agreeableness, and neuroticism. Such traits have been measured both in the HRS and in the NTR 
cohorts. 
In the HRS cohort, the Big Five personality traits were measured in four waves between 2006 
and 2012, with 26 items in 2006-2008 and 31 in 2010-2012. The original 26 items in 2006 and 
2008 were obtained from the MIDUS survey123. Extraversion, agreeableness, and 
conscientiousness were measured with five items, openness to experience with seven, and 
neuroticism with four. In 2010 and 2012, five items from the International Personality Item 
Pool124 were added for conscientiousness. As is common in the literature, the responses to each 
item were elicited on a four-point scale121. For each trait, scores were constructed by taking the 
mean of all items in the respective category after recoding items to make their direction 
consistent, and then averaged across waves and standardized to have zero mean and unit 
variance. A score was set to missing if more than half of the items in that category had missing 
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values. The resulting sample sizes are 8,253 for openness, 8,268 for conscientiousness, 8,271 for 
extraversion, 8,271 for agreeableness, and 8,264 for neuroticism. Given the limited evidence on 
the sign of the phenotypic correlation between general risk tolerance and the Big Five traits, we 
do not have an ex ante expectation about the signs of their associations with our polygenic score 
of general risk tolerance. 
In the NTR cohort, the NEO Five-Factor Inventory (NEO-FFI) was sent to adult participants in 
three waves in 2003, 2009 and 2013. Each of the five personality traits is measured with 12 
items, and the responses to each of these were given on a five-point Likert scale. Scores were 
standardized to have zero mean and unit variance in each wave and then averaged across waves, 
yielding a sample size of 8,526. 
(4) Sensation seeking 
Sensation seeking is defined by the search for experiences and feelings that are “varied, novel, 
complex and intense,” and by the readiness to “take physical, social, legal, and financial risks for 
the sake of such experiences”125.  
In the NTR cohort, sensation seeking was assessed using a short version of the Zuckerman 
sensation seeking scale (SSS)126–128. The scale consists of 12 items that measure four subdomains 
of sensation seeking. Thrill and adventure seeking (n = 8,649), defined as the desire to engage in 
extreme sports and risky activities; experience seeking (n = 8,185), defined as the desire for 
experiences that engage the mind and senses such as art, travel, food or dress; disinhibition (n = 
8,618), defined as the desire to find release through interactions with other disinhibited people, 
wild parties and sexual disinhibition; and boredom susceptibility (n = 8,621), defined as the 
intolerance to boredom. A combined total score is then constructed as the total sum of all 
subscales. The SSS was measured at six time points between 1991 and 2007. Scores were 
standardized to have zero mean and unit variance in each wave and then averaged across waves.  
(5) Attention-deficit hyperactivity disorder 
We also examined the predictive power of our score for attention-deficit hyperactivity disorder 
(ADHD). ADHD is not a personality trait, but it is nonetheless of interest because it has been 
shown to be phenotypically correlated with risk-taking behaviors, such as starting one’s own 
business129–131. ADHD is a chronic condition of persistent behavioral problems that often begins 
in childhood and persists into adulthood. The fourth edition of the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-IV) defines ADHD as “a persistent pattern of inattention 
and/or hyperactivity-impulsivity that is more frequently displayed and more severe than is 
typically observed in individuals at a comparable level of development.” 
In the NTR cohort, symptoms of ADHD were assessed by the Conners ADHD index132,133 and 
were measured at three occasions in 2004, 2007 and 2013. The scores were standardized to have 
zero mean and unit variance in each wave and averaged across waves, yielding a total of 8,457 
respondents. 
10.1.3 Risky behaviors 
Building on previous studies that demonstrate the predictive power of risk tolerance for various 
behaviors1–5,28, we consider a wide range of phenotypes associated with lifestyle risks. We are 
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interested in two categories of real-world behaviors: risky and precautionary. The first category 
focuses on behaviors that increase an individual’s exposure to unpredictable outcomes and 
includes smoking, drinking, unhealthy food consumption, financial investment, and career 
choices. The second category focuses on behaviors that aim to prevent or curtail potential future 
negative outcomes, and includes investing in health or life insurance as well as preventative 
health care measures such as taking medications and getting regular medical screenings. 
Below we provide a detailed description of our real-world phenotypes. Supplementary Table 
10.3 presents summary statistics. For a more detailed description of measures drawn from the 
STR cohort, see Beauchamp et al. (2015)2. 
(1) Smoking 
Smoking is associated with increased risks of heart disease, stroke, lung cancer (and other types 
of cancers), and other chronic lung diseases134. Smoking has also been shown to be 
phenotypically correlated with risk tolerance1–5.  
In the HRS cohort, we constructed a binary variable for “ever smoker” that equals “1” if an 
individual respondent reported ever having been a tobacco smoker in at least one wave. 57% of 
the 8,617 HRS respondents are coded as ever smokers. 
In the STR cohort, respondents are coded as “ever smokers” if they indicated they currently 
smoke regularly, used to smoke regularly, currently smoke on and off, or used to smoke on and 
off. 53% of the 13,921 respondents in the STR cohort are coded as smokers. 
In the Add Health cohort, respondents are coded as “ever smokers” if they reported having ever 
smoked regularly (i.e., at least one cigarette every day for 30 days) in Wave 4, the latest wave of 
the Add Health data. 52.6% of 4,775 European ancestry respondents were coded as smokers. We 
also constructed a continuous variable for age of smoking initiation among those who were 
coded as smokers, again in Wave 4. The mean age of smoking initiation in the Add Health 
cohort is 16.9, and the variable is defined for 2,493 European respondents. 
In the UKB-siblings cohort we have information on whether the respondent has ever been a 
smoker. For a detailed description of the phenotype used, see Supplementary Information 
section 1.2. 
(2) Drinking 
Similar to smoking, drinking is a risky behavior known to have negative health consequences135 
and has also been correlated phenotypically with risk tolerance1,2. The Add Health, HRS, and 
STR datasets include a rich set of questions on drinking habits. 
In the HRS cohort, we calculated the number of alcoholic drinks per week reported by each 
respondent in each wave, took the average across waves, and normalized the resulting measure in 
a variable with a mean of approximately zero and a variance of approximately onenn. 
Importantly, in waves 1 and 2, respondents were only able to choose among 5 categories: 0 
                                                        
nn The normalized variable is the inverse normal cumulative distribution function (CDF) of the respondents’ 
percentile ranks. Given the discrete nature of the underlying drinking reports, the inverse normal CDF has some 
mass points and does not have a mean of exactly zero and a variance of exactly one. This is true of all the other 
phenotypes that have been normalized. 
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drinks per week, 1 or fewer drinks per week, 1-2 drinks per week, 3-4 drinks per week, or 5 or 
more drinks per week. We coded these as 0, 1, 1.5, 3.5, and 5 drinks per week for each wave, 
respectively. From wave 3 onward, respondents were first asked how many days per week they 
had any alcoholic drinks, and then were asked how many drinks they had on average on each of 
those days. For these waves, we simply multiplied each of these two responses to calculate 
drinks per week. This information was available for 8,652 respondents. 
Similarly, in Add Health we calculated the number of drinks per week for 3,712 European 
respondents in Wave 4. Respondents were asked both how many days they consumed alcohol in 
the last 12 months and how many alcoholic drinks they consumed each time they drank in the 
last 12 months. We multiplied these responses together and divided by 52 to arrive at our final 
drinks per week variable. The average number of drinks per week in Add Health was 5.6.  
In the UKB-siblings cohort we have information on the number of drinks per week. For a 
detailed description of the phenotype used see Supplementary Information section 1.2. Notice 
that drinks per week was normalized in the HRS but not in the Add Health and UKB-siblings 
cohorts, where it is simply reported as a count. 
In the STR cohort, we constructed a binary variable equal to “1” if respondents reported having 
alcoholic drinks more than twice in the past month. Specifically, a first question asks respondents 
if they drank strong beer, wine, or liquor more than twice in the past month. If respondents 
answer in the negative, a follow-up question asks about their frequency of drinking for each type 
alcohol separately, and “twice per month” was one of eight response categories. Overall, we 
classified individuals as alcohol consumers if they answered the first question in the affirmative 
or if their answers to the follow-up questions indicated that they usually drink beer, wine, or 
liquor at least twice a month. 82% of the 12,551 respondents in the STR cohort were coded as 
such. 
The STR dataset contains additional information regarding excessive drinking over the life 
course, which might better capture risky drinking behavior. We constructed a dummy variable 
equal to “1” for respondents who reported any of the following: 1) ever having a period in their 
life when they drank too much; 2) ever having a period in their life when someone else objected 
to their drinking; or 3) ever having a period in their life when they chose drinking instead of 
working, spending time on hobbies, or spending time with family or friends. 8% of the 13,269 
STR respondents were coded as excessive drinkers. 
(3) Cannabis consumption 
Similar to cigarettes and alcohol, cannabis abuse can lead to negative health136 and social 
consequences137, especially during adolescence and early adulthood. Furthermore in 2008, at the 
time of reporting, recreational use of marijuana was illegal in the United States, and therefore its 
consumption carried the additional risk of breaking the law.oo  
                                                        
oo Starting with Oregon in 1973, the possession of marijuana was decriminalized by some states, but remained illegal 
across the United States. Starting with California in 1996, some states legalized the use of marijuana for medical 
purposes. Recreational use was legalized only starting with Colorado in 2012. While the negative health and social 
consequences were still prevalent through the sample, the legal consequences of cannabis consumption varied 
depending on the residence of the respondents, which is unknown to us.  
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Using data from Wave 4 of Add Health, we constructed a binary variable for “ever cannabis” 
that equals “1” if an individual respondent reported having ever used cannabis. 60.0% of the 
4,742 European respondents had a value of “1” for this variable. 
(4) Unhealthy food consumption 
Consumption of fried food is a common risky health behavior that has been linked to 
cardiovascular disease and other negative health consequences138. Questions about fried food 
consumption were asked to a subset of 3,078 respondents in the HRS cohort who participated in 
the 2013 Healthcare and Nutrition Mailout. We looked at propensity to eat fried food either at 
home or as takeout. In reporting how much fried food they consumed, respondents could answer 
“Never,” “Less than once per week,” “1-3 times a week,” “4-6 times a week,” or “Daily.” We 
normalized the measures separately for home and for takeout, resulting in two measures with 
means of approximately zero and variances of approximately one. Our measure of overall 
propensity to eat fried food is the sum of these two normalized measures.  
(5) Number of sexual partners 
As a final measure of risky health behavior, we consider the total number of sexual partners, 
which is a risk factor for contracting sexually transmitted infections (STIs)139,140. In Wave 4 of 
Add Health, respondents were asked with how many female and male partners they had ever 
engaged in any type of sexual activity. We summed the values for female and male partners. The 
mean number of sexual partners for the 4,603 European respondents was 13.5.   
In the UKB-siblings cohort we have information on the number of sexual partners. For a detailed 
description of the phenotype used, see Supplementary Information section 1.2. Notice that 
number of sexual partners was normalized in the UKB-siblings cohort but not in the Add Health 
cohort, where it is simply reported as a count. 
(6) Automobile speeding propensity 
In the UKB-siblings cohort we have information on automobile speeding propensity. For a 
detailed description of the phenotype used, see Supplementary Information section 1.2. 
(7) First PC of risky behaviors 
Following the approach laid out in Supplementary Information section 1.2, we computed the 
first principal component (PC) of our four supplementary risky behaviors (automobile speeding 
propensity, drinks per week, ever smoker, and number of sexual partners) in the full UKB 
sample, and then extracted the individuals comprising the UKB-siblings cohort.  
(8) Financial market participation 
We consider two measures of exposure to financial risk, both of which have been correlated to 
phenotypic measures of risk tolerance1,2,4,28. The first is financial market participation. This 
phenotype captures what economists refer to as the “extensive margin” of financial risk-taking 
behavior (i.e., does one participate in the financial market or not). 
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In the HRS cohort, we coded a dummy variable that equals “1” if a respondent ever reports a 
strictly positive “net value of stocks, mutual funds, and investment trusts” across all available 
waves. Using this measure, 68% of 8,652 HRS respondents participated in financial markets.  
Similarly, in the STR cohort we constructed a variable coded “1” if respondents reported a 
positive value of either stock or bond holdings, using information from the single wave in this 
cohort when assets were reported. Overall, 30% of the 3,285 STR respondents were coded as 
participating in the financial market. 
(9) Equity share and share of financial assets 
Our second measure of exposure to financial risk considers the risk profile of respondents’ total 
wealth. We use the share of respondents’ total wealth held in equity (i.e., stocks) and similar 
risky financial assets. This phenotype captures what economists refer to as the “intensive 
margin” of financial risk-taking behavior (i.e., how much of a person’s wealth is exposed to 
financial market fluctuations). 
In the HRS cohort, we calculated for each wave the ratio of “net value of stocks, mutual funds, 
and investment trusts” over “total wealth including secondary residence.” For each respondent, 
we then averaged this measure across all available waves. This measure roughly reflects the 
amount of total wealth an individual holds in risky financial assets. We note that mutual funds 
and investment trusts might include equities, as well as other risky assets such as bonds and 
derivatives. We refer to this resulting variable as the “share of financial assets.” In total, we 
dropped 50 observations reporting negative equity holdings and two observations for which the 
share of financial asset in a wave exceeds unity. The mean value of the share of financial assets 
variable across the 8,599 respondents is approximately 8%. 
In the STR cohort, we instead calculate equity share as the ratio of the value of assets held in 
stocks to the sum of the value of assets held in property, stocks, bonds, bank, boat, and other 
assets such as jewelry, antiquities, and art. These data are only available for a subset of the 
respondents, because the associated questions were removed from the survey in the later waves 
(in an effort to reduce survey length). The 3,170 respondents in STR cohort held on average 
3.5% of their total wealth in stocks.  
(10) Career choices 
While some careers are relatively secure and provide a steady stream of income, others are 
riskier and have greater income fluctuations. Prominent examples of the latter are owning a 
business or becoming an entrepreneur. 
In order to capture this domain of risk taking, which has been correlated to phenotypic measures 
of risk preferences2,4,5,28, we considered two separate measures in the STR cohort. First, we 
constructed a binary variable equal to “1” if respondents reported ever running their own 
business. 25% of the 7,979 individuals in STR cohort were coded as having ever run their own 
business. 
As a second measure, we consider a self-report of being an entrepreneur, defined as someone 
who “commercializes a new innovation or idea … [and who] has, or plans to have, a number of 
employees and strives to expand the business,” as opposed to a “self-employed person [who] 
owns and runs his/her own company, for instance a restaurant or a law firm, where he/she works 
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[and] … normally does not strive to expand over a certain limit and has 0 or a few employees.” 
This question was asked only of respondents who had reported ever running their own business. 
We constructed a binary variable equal to “1” if respondents reported being entrepreneurs, and 
“0” if the respondents reported being self-employed persons or if they reported never having run 
their own businesses. Based on this measure, 5% of the 7,981 individuals in STR cohort were 
coded as entrepreneurs. 
(11) Preventative healthcare and healthcare utilization 
Focusing now on precautionary behaviors, we first consider choices regarding preventive 
healthcare.   
We constructed an index of preventative health care and health care utilization by combining 
several available measures for 8,648 respondents in the HRS cohort. Specifically we considered 
whether respondents had visited a doctor in the last two years, whether respondents had visited a 
dentist in the last two years, and whether respondents had recently undergone a number of 
specific procedures or screenings. These included cholesterol screening, flu shot, breast exam 
(for females), mammogram (for females), pap smear (for females), and prostate exam (for 
males). We took the simple sum of dummy indicators for having undergone or participated in 
any of these eight healthcare measures. Since not all of these items apply to both sexes, we 
normalized these sums separately for men and women, and then combined the measures, 
obtaining an index with a mean of approximately zero and a variance of approximately one. 
(12) Health insurance 
In order to limit the risk associated with an unexpected negative health event, individuals can 
enroll in health insurance. Prior to the implementation of The Patient Protection and Affordable 
Care Act (popularly known as “Obamacare” or “Healthcare reform”) in the US, this form of risk 
prevention was an individual choice (rather than required by law) for most individuals. In the 
HRS cohort, we measure whether individuals choose to have health insurance. As is the case for 
our other phenotypes, risk tolerance has been shown to predict whether a person has health 
insurance1.  
According to national and state eligibility criteria, some HRS respondents in certain waves were 
automatically granted health insurance (i.e., Medicaid or Medicare recipients and 
CHAMPUS/VA healthcare recipients), and therefore these observations are not used in the 
construction of this measure for these respondents. For the remaining observations, we calculated 
whether each respondent-wave observation responded affirmatively to questions about having 
each of several forms of health insurance (e.g., non-Medicare and non-CHAMPUS/VA federal 
health insurance, health insurance from current or previous employers, health insurance from 
spouse’s current or previous employers, other health insurance). For each respondent, we then 
took the average of non-missing observations across all waves until (and including) the 2011 
wavepp. Our resulting measure indicates the percentage of waves during which a respondent had 
healthcare, among waves during which it was an optional choice. On average, the 8,454 
respondents in the HRS cohort were covered by health insurance 95% of the time. 
                                                        
pp The individual mandate of the Affordable Care Act of 2010 was not yet in effect during 2011, the final wave from 
which we draw these data. 
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(13) Life insurance 
Finally, individuals purchase life insurance to mitigate the negative consequence of their deaths 
for their families and loved ones. Phenotypic risk tolerance has been shown to predict whether a 
person has life insurance1.  
We measured whether respondents are consistently covered by life insurance by calculating the 
percentage of waves during which HRS respondents reported having life insurance. On average, 
the 8,652 respondents in the HRS cohort report being covered by life insurance more than two-
thirds (71%) of the time. 
10.2 Methods 
10.2.1 Polygenic scores 
We constructed three polygenic scores. We constructed our first polygenic score with the 
LDpred104 method, using summary statistics from our GWAS of general risk tolerance; we also 
constructed our second score with the LDpred method, but using the summary statistics of 
general risk tolerance outputted by the MTAG analysis (Supplementary Information section 
9); and we constructed our third score with the classical method, using summary statistics from 
our GWAS of general risk tolerance. We will refer to these scores as LDpred-GWAS, LDpred-
MTAG, and Classical-GWAS scores respectively. 
Due to data access limitations and to avoid overfitting, different cohorts were included in the 
GWAS whose summary statistics were used to construct the scores. In the Add Health and HRS 
cohorts, the summary statistics from the meta-analysis of the discovery and replication GWAS of 
general risk tolerance were used to construct the scores, with no cohort excluded (n = 975,353). 
For the analyses in the NTR and Zurich cohorts, the scores were constructed with the summary 
statistics from a meta-analysis that excluded the 23andMe cohort (due to data access limitations, 
the sample size of the resulting meta-analysis was n = 466,571). For the analysis in the STR 
cohort, we excluded the 23andMe cohort (due to data access limitations) as well as the STR 
cohort itself (to avoid overfitting141) from the meta-analysis whose summary statistics we used to 
construct the scores (the sample size of the resulting meta-analysis is n = 458,558)qq. And for the 
analysis in the UKB-siblings cohort, to avoid overfitting141 we reran our discovery GWAS after 
excluding all individuals in the UKB-siblings cohort from the UKB cohort (the sample size of 
the resulting meta-analysis was n = 937,353). 
The prediction analyses with our LDpred-MTAG score was only conducted in the Add Health, 
HRS, and UKB-siblings cohorts, since these were the only three cohorts for which 23andMe data 
could be used, due to data access limitations.  
Both the LDpred and the classical polygenic scores are calculated as the weighted sum of the M 
individual genotypes: 
(9) 𝑆Z5 = ­𝛽ZKÑK®* 𝑔5K	, 
                                                        
qq We also note that, since the HRS, NTR, and Zurich cohorts do not contain data on general risk tolerance, none of 
these cohorts was included in any meta-analysis of general risk tolerance. 
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where 𝑆Z5 denotes the polygenic score of individual i, 𝛽ZK is the estimated additive effect size of the 
effect-coded allele at SNP 𝑗, and 𝑔5K	is the genotype of individual 𝑖	at SNP j (coded as having 0, 
1, or 2 instances of the effect-coded allele)105.  
For the LDpred scores, the estimated additive effect sizes (the 𝛽ZK’s) are the estimates from the 
summary statistics adjusted for LD between the SNPs. To calculate LDpred scores, an LD 
reference file and a validation reference file must be provided. For HRS, STR, UKB-siblings, 
and the Zurich cohorts we used the 1000 Genomes-imputed data (Phase 1, Version 3) of the 
HRSrr cohort as the reference sample. For the Add Health cohort, we used the HRC (Haplotype 
Reference Consortium) Genomes-imputed data (Version 1.1) of Add Health (n=4,775) as the 
reference sample. For the NTR cohort, the reference sample used for the construction of the 
LDpred scores consists of all five European populations from the 1000 Genomes dataset: Utah 
Residents (CEPH) with Northern and Western European Ancestry, Finnish, British, Iberian, and 
Toscani individuals (n = 381).  
The LDpred method relies on a Gaussian mixture weight that corresponds to the assumed 
fraction of SNPs that are causal. We used the software called LDpred104 to generate a score for 
each of the following mixture weights: 1, 0.3, 0.1, 0.03, 0.01, 0.003, 0.001, 0.0003, and 0.0001, 
using the individuals’ best guess data and using only SNPs in the HapMap consortium phase 3 
release142,143 with a MAF > 0.01 and an imputation quality of more than 0.7. We report only the 
analyses with the LDpred scores constructed with the Gaussian mixture weight 0.3, as these 
scores tended to perform better both across cohorts and predicted phenotypes.  
For the classical polygenic scores, the estimated additive effect size 𝛽ZK for SNP j is the GWAS 
estimate for SNP j. We used the software PLINK37 to produce the classical scores, using the 
individuals’ best guess data; as with the LDpred method, we only use SNPs in the HapMap 
consortium phase 3 release142 with a MAF > 0.01 and an imputation quality of more than 0.7 (the 
prediction results are thus comparable across the two methods)ss.  
We expect our LDpred-GWAS score to have greater predictive power than our Classical-GWAS 
score, since the LDpred method takes into account the non-independence between SNPs. 
Further, since the MTAG summary statistics leverage the additional information contained in the 
GWAS of genetically correlated phenotypes, we expect our LDpred-MTAG score to have the 
greatest predictive power. 
                                                        
rr The HRS genotype data used as a reference sample for the STR and the Zurich cohorts was restricted according to 
the following quality control criteria. We removed 13,973 SNPs that have been flagged as having incorrect 
annotations from the HRS cohort248; we restricted the reference file to SNPs with imputation quality greater than 
0.7, MAF greater than 0.01, SNP call rate greater than 95%; and we removed individuals with a call rate less than 
95%, as well as related individuals and individuals not of North-Western European ancestry. The resulting sample 
contained 7,302 individuals.  
For the HRS and UKB-siblings cohort, we restricted the reference file to HapMap3 SNPs with MAF greater than 
0.01 and SNP call rates greater than 98%; we also removed individuals with a call rate less than 98%, related 
individuals, and individuals not of European ancestry. The resulting sample contained 8,353 individuals. 
ss The classical score is often calculated with an LD-pruning and P value thresholding procedure. The LD-pruning is 
meant to achieve independence between the predictive set of SNPs, and the P value threshold excludes SNPs that 
are not estimated to be significantly associated with the phenotype. This procedure often discards information that 
could increase the predictive power if it were properly accounted for104. Here, we do not use an LD-pruning and P 
value thresholding procedure to drop SNPs prior to constructing the scores. 
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10.2.2 Main prediction exercise 
We ran two separate Ordinary Least Squares (OLS) regressions for each phenotype, cohort, and 
score. The first regression includes only our baseline controls: sex, birth year, birth-year squared, 
birth-year cubed, as well as the interactions between sex and the three birth-year variables, and 
the first ten principal components (PCs) of the cohort-specific genetic relatedness matrix; in the 
NTR and STR cohorts, dummy variables that indicate the different genotype platforms were also 
included. The second regression is identical to the first one, except that it also includes the 
polygenic score. Since the scores have mean zero and unit variance, the estimated coefficients on 
the score represent the change in real-word outcomes associated with a one-standard-deviation 
increase in the polygenic score of general risk tolerance. Our measures of interest are the 
regression coefficients on the scores and the incremental R2 (or pseudo-R2) of the scores, defined 
as the difference between the R2 (or pseudo-R2) of the two regressions. The 95% confidence 
intervals for the incremental R2 estimates are calculated with the bootstrap percentile method, 
with 1,000 bootstrap samples144,145. 
10.2.3 Robustness to inclusion of additional control variables 
Are these polygenic scores of general risk tolerance potentially useful for the empirical 
researcher in the behavioral sciences? Since many social-science datasets contain rich 
information about the individual characteristics of the participants, it is important to understand 
whether the polygenic scores for general risk tolerance are still predictive of risky behaviors even 
after controlling for relevant variables that capture important individual characteristics. For this 
reason, when analyzing real-world risky behaviors, we also estimate the incremental R2 (or 
pseudo-R2) of the scores while controlling for cognitive performance, personality traits, and 
educational attainment in the baseline regression. 
These traits were selected as additional controls because they could plausibly be important 
determinants of risky and precautionary behaviors, and because many of these traits are 
phenotypically correlated with risk tolerance2. This robustness exercise also makes it easier to 
compare our prediction results with the existing literature, which usually controls for some of 
these personal characteristics6,110,146,147.  
Furthermore, we also calculated the incremental R2 for cognitive performance, for personality 
traits, and for educational attainment, defined as the difference between the R2 of a regression 
including only our baseline controls, and another regression including the baseline control and 
the traits of interest. These three incremental R2 values provide the applied researcher with 
interesting benchmark comparisons, and enable us to understand whether the predictive power of 
our polygenic score is comparable to the predictive power of other important individual 
characteristics. 
For the Add Health cohort, we control only for educational attainment and a measure of verbal 
cognition, since information on personality traits is available only for a small subsample of 
individuals. The measure of verbal cognition is a modified version of the Peabody Picture 
Vocabulary Test which was collected in the first wave of Add Health, when participants were 12 
to 20 years old. In this test, respondents have to select the illustration that best fits the meaning of 
the word that an interviewer has just read aloud. This computer-adapted test consisted of eighty-
seven items, and scores were age-standardized. 
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For the HRS cohort, the cognitive performance measure is the average of measures from waves 
2-10. In each of these waves, the cognitive performance measure is the sum of a total word recall 
summary score (based on immediate and delayed word recall tasks) and a mental status summary 
score (based on counting, naming, and vocabulary tasks)tt. The Big Five factors (defined above) 
were used as measures of personality traitsuu, and years of education as a measure of educational 
attainment. 
For the STR cohort, the standardized score on a military conscription test was used as a measure 
of cognitive performance, behavioral inhibition and locus of control were used as measures of 
personality traits, and years of education was used as a measure of educational attainment. The 
cognitive performance measure was merged using conscription data provided by the Military 
Archives of Sweden. Men were required by law to participate in military conscription around the 
age of 18. We use the stanine scores of four subtests of logical, verbal, spatial, and technical 
ability. Following Rietveld et al. (2014)80, we use the first principal component of these four 
stanine scores as the measure of cognitive performance. No measure of cognitive performance is 
available for females. 
Finally, for the UKB-siblings cohort we control for educational attainment, neuroticism, and 
cognition. Our measure of neuroticism follows Okbay et al. (2016)18: it is constructed as a 
respondent’s score on a 12-item version of the Eysenck Personality Inventory Neuroticism scale. 
Individuals must answer at least 10 out of 12 binary-response questions to be included, and 
questions that remain missing will be coded as 0. To obtain a measure of cognition, we used a 
test designed to measure fluid intelligence. The test consists of thirteen logic and reasoning 
questions and has a two-minute time limit. Each respondent took the test up to four times. We 
used the mean of the standardized score across the occasions on which the respondent took the 
test as our measure of cognition. 
10.2.4 Methodology for binary and censored phenotypes 
For the analysis of some real-world risky behaviors, we used specific statistical methods to 
model more accurately the distribution of the dependent variable. For binary outcomes, such as 
engaging in smoking, drinking, or participating in financial markets, we estimated Probit models. 
Instead of the estimated coefficient, which has no clear interpretation in a Probit model, we 
report the average marginal effect of the polygenic score. We report this as ÔÕÖ	(`®*|×]¨,Ø)Ô×]¨ =𝛽Z×]¨ ∙ 𝐸¬¼𝜙(𝑃𝐺𝑆 ∙ 𝛽Z×]¨ + 𝑋𝛽Z)½, where 𝛽Z×]¨ is the estimated coefficient on the polygenic score, 𝜙 
is the Gaussian probability density function, 𝐸¬[∙] takes the sample average, PGS is the polygenic 
score, and X contains the control variables. In the absence of a meaningful R2 measure for the 
Probit model, we used the McFadden pseudo-R2, ²ÛÜ)ÛÝÛÜ ³, where 𝑙+ is the log-likelihood of a 
model with only a constant, and 𝑙Ñ is the log-likelihood of the full model. Our measure of the 
incremental pseudo-R2 is thus Ûß)Ûß,àáâÛÜ , which indicates the difference between the log-likelihood 
of the model controlling for baseline controls and the score  (𝑙Ø,×]¨) and the log-likelihood of the 
model controlling only for the baseline controls  (𝑙Ø), scaled by the log-likelihood of a model 
with only a constant  (𝑙+). 
                                                        
tt In Wave 2, these measures are present only for a subset of respondents (the AHEAD cohort). 
uu See above for a detailed description of the personality variables in the HRS cohort. 
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For equity share and share of financial assets phenotypes, we estimate Tobit models instead of 
OLS regressions, to account for the point mass at zero (due to many respondents in our dataset 
not holding any stocks)vv. The same measure of incremental pseudo-R2, ²Ûß)Ûß,àáâÛÜ ³, is 
reportedww.  
The 95% confidence intervals for all of these estimates are calculated with the bootstrap 
percentile method, with 1,000 bootstrap samples144,145. 
10.3 Results 
Results are presented in Extended Data Figs. 10.1-10.2 and Supplementary Tables 10.1-10.4. 
For each predicted phenotype, cohort, and score, these tables report summary statistics for the 
regression sample, the estimated incremental R2 of the score, and the sign and P value of the 
estimated regression coefficient on the polygenic score. 
Overall, we find that our preferred polygenic score explains 1.01% to 1.78% of the variation in 
general risk tolerance, up to 1.4% of the variation in several personality traits, and up to 1.94% 
of variation in real-world behaviors. As we discuss in Supplementary Information section 
10.4, our incremental R2 estimates from the prediction of general risk tolerance fall within the 
range we expect based on theory107,108. 
Below, we focus our discussion on the results for the LDpred-GWAS score. As mentioned 
above, the results displayed for the LDpred scores are based on a Gaussian mixture weight of 
0.3. We chose this weight because the corresponding scores consistently performed well across 
cohorts and phenotypes in our analyses. The results for the LDpred-MTAG and Classical-GWAS 
scores are generally similar, although the predictive power of the LDpred-MTAG score tends to 
be slightly higher and that of the Classical-GWAS score tends to be slightly lower. 
10.3.1 Risk tolerance 
In the UKB, the incremental R2 of the LDpred-GWAS score is 1.62% (CI: 1.37% - 1.90%). In 
the Add Health cohort we estimate a much smaller predictive power, with incremental R2 of 
1.01% (CI: 0.57% - 1.62%). In the STRxx cohort we estimate an incremental R2 of 1.05% (CI: 
0.64% - 1.50%). Using the summary statistics from the MTAG analysis improves our predictive 
power: the incremental R2 of the LDpred-MTAG score is 1.78% in the UKB-siblings cohort and 
1.07% in the Add Health cohort. 
                                                        
vv The Tobit model is a maximum likelihood estimator proposed by James Tobin249 that assumes a linear relationship 
between regressors 𝑋, a normally distributed error term  𝜀, and a continuous latent variable 𝑦∗. The observed 
dependent variable is 𝑦 = 𝑦∗ whenever 𝑦∗ > 0 but is 𝑦 = 0 otherwise. This model is used to account for censoring 
and a point mass at zero, as is observed for our measures of equity share and of share of financial assets.  
ww Because the Tobit model has a continuous likelihood, the McFadden pseudo-R2 can sometimes be smaller than 
zero or greater than 1, which is nonsensical for an R2 measure. Whenever that happened, such as in the case of share 
of financial assets in the HRS cohort when cognitive performance or educational attainment are controlled for, we 
reported “N.A”. in the table of results.  
xx As mentioned above, due to data access limitations, the summary statistics used to construct the score in the STR 
cohort were based on a meta-analysis that excluded the 23andMe cohort, and therefore had a much smaller GWAS 
sample size (nGWAS of 466,571). 
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The estimated regression coefficients for all scores have the expected sign and are all highly 
statistically significant (with P values < 0.0005), indicating that the scores significantly predict 
general risk tolerance out of sample.  
(1) Alternative measures of risk tolerance 
The predictive power of our polygenic score for alternative measures of risk tolerance is also 
significant, but limited in magnitude. 
For the financial risk tolerance phenotype, the incremental R2 of the LDpred-GWAS score in the 
STR cohort is 0.44%. For the income gamble risk tolerance phenotype, the incremental R2 is 
0.24% in the HRS cohort, and 0.34% in the STR cohort. When predicting either financial risk 
tolerance or income gamble risk tolerance, the coefficients on the LDpred-GWAS scores are 
always highly statistically significant. 
By contrast, we find that our polygenic scores of general risk tolerance do not predict the lottery-
based measure of risk tolerance in the Zurich cohort. For this measure, the incremental R2 is 
0.09% and the coefficient on the score is not distinguishable from zero (P = 0.12).  
The lack of predictive power of our polygenic score for lottery-based risk tolerance is surprising, 
as this phenotype is considered the workhorse of risk preference measurement in economic 
theory110. It is important to note, however, that this null result does not necessarily mean that our 
polygenic score fails to capture variation in economically relevant risk preferences, given its 
predictive power for risky economic behaviors such as entrepreneurship and financial risk 
taking. Indeed, the predictive power of lab-based measures for real world behavior has itself 
come under scrutiny148,149, and lottery-based measures of risk preferences usually have lower 
predictive power than self-reported measures4,6,146,147. Further, recent research in both economics 
and psychometrics has found modest levels of correlations between lottery-elicited measures of 
risk tolerance and the general-risk-tolerance phenotype used in our discovery and replication 
GWAS4,6. Our results thus add to the small but growing body of evidence that lottery-based and 
self-reported measures of risk tolerance may indeed capture different aspects of decision-making 
over uncertainty.  
10.3.2 Personality traits 
Our results provide interesting evidence regarding the complex and interlacing structure of 
personality traits and their relationship to general risk tolerance. Genetic predisposition for risk 
tolerance is predictive of openness to experience, sensation seeking, extraversion, behavioral 
inhibition, and to a lower extent ADHD. Not surprisingly, these domains are the ones that have 
been theoretically and phenotypically connected to an individual’s behavior in new, unexpected, 
and uncertain circumstances. Furthermore, these results corroborate our findings of positive 
genetic correlations between general risk tolerance and openness, extraversion, and ADHD 
(Supplementary Information section 7.3). 
Looking at the Big Five personality traits, our LDpred-GWAS score is predictive of openness to 
experience (with incremental R2 estimates of 1.45% and 0.42% in the HRS and NTRyy cohorts, 
respectively), extraversion (0.94% in HRS and 0.17% in NTR), and to a lower extent 
                                                        
yy As mentioned above, the scores in the NTR cohort were also based on a meta-analysis that excluded the 23andMe 
cohort. 
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agreeableness (0.09% and 0.11%). The estimated coefficients on the LDpred-GWAS scores for 
these three phenotypes always have a P value ≤ 0.4%. In contrast, conscientiousness was never 
predicted by our polygenic score, and neuroticism was significantly predicted in the HRS cohort 
(incremental R2 of 0.31%), but not in the NTR cohort. 
The results described above are broadly consistent with the estimated sign and magnitude of the 
genetic correlations between general risk tolerance and extraversion, openness, and neuroticism 
(Supplementary Information section 7.3).  
Finally, our LDpred-GWAS score was predictive of sensation seeking (with incremental R2 
estimates of 1.13% for the composite sensation seeking phenotype, and ranging from 0.33% to 
0.75% for the four sensation seeking subscales), behavioral inhibition (0.50%), and ADHD 
(0.50%). Furthermore, the estimates of the coefficients on the scores are all highly significant 
and positive, as expected. No score is predictive of locus of control. Using the summary statistics 
from the MTAG analysis does not improve our predictive power substantially. 
10.3.3 Risky behaviors 
(1) Main prediction results 
Supplementary Table 10.3A reports the predictive power of the scores for risky behaviors, 
while Supplementary Table 10.3B reports the predictive power of the scores for precautionary 
behaviors. 
Overall across all our validation cohorts, the predictive power of the LDpred-GWAS scores is 
low but positive across a wide range of risky and precautionary behaviors, with incremental R2 
estimates ranging from 0.02% to 1.36%. Although most incremental R2 estimates are low, the 
estimated coefficients on the LDpred-GWAS score have the expected sign for 22 of the 25 
regressions we ran (P = 8× 10)Å), and are always in the expected direction whenever the 
estimated coefficient is significant at the 5% level (16 of the 25 measures, P = 2 × 10)*Å)zz. 
Our LDpred-GWAS score are predictive of economic behaviors such as being an entrepreneur 
(1.36%) or owning a business (0.57%), as well as health behaviors such as number of sexual 
partners (0.65% and 0.79% in Add Health and UKB-siblings), automobile speeding propensity 
(0.59%), ever using cannabis (0.37%), smoking (incremental R2 ranging from 0.10% to 0.25% 
depending on cohort and phenotype), drinking (incremental R2 ranging from 0.02% to 0.19%, 
depending on cohort and phenotype), and the first PC of risky behaviors (0.96%). For 
precautionary behaviors, both life and health insurance coverage are significantly predicted by 
our LDpred-GWAS scores, with an incremental R2 of 0.17% and 0.10%, respectively. In 
contrast, our scores are not significantly predictive of financial market participation, equity share 
or share of financial asset, age of smoking initiation, fried food consumption, and preventative 
health care utilization.  
Several results stand out. The estimated coefficient imply that a one-standard-deviation increase 
in the polygenic score is associated with a 1.6 percentage points higher probability of being an 
entrepreneur, 3.4 percentage points higher probability of having owned a business, 2.2 additional 
                                                        
zz These P values refer to the probability of finding this many concordant signs or significant coefficients; they are 
derived from one-tailed binomial tests (the first coming from 25 coin flips with probability of 0.5; the second from 
25 coin flips with probability of 0.05). 
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lifetime sexual partners, 3.5 percentage points higher probability of ever having smoked 
marijuana, and a 2 to 3 percentage points higher probability of ever being a smoker. 
Using the MTAG summary statistics to construct the LDpred scores in the Add Health, HRS, 
and UKB-siblings cohorts generally increases our predictive power. For example, the 
incremental R2 estimates for the first PC of risky behaviors and for number of sexual partners 
double, to 1.96% and 1.53% respectively. In the case of ever using cannabis, the incremental R2 
increases by ~0.40% relative to using the LDpred-GWAS and Classical-GWAS scores.  
(2) Robustness to inclusion of additional control variables 
To further assess the potential for using polygenic scores in empirical research, we investigated 
whether the predictive power of our polygenic scores is robust to including in the regressions 
additional control variables for cognitive performance, personality traits, and educational 
attainment. We obtained very similar point estimates but larger confidence intervals than in the 
regressions that do not include these additional variables. Supplementary Table 10.4 displays 
these results. Note that, due to missing observations in the additional control variables, the 
sample sizes decrease (in particular, the samples for the STR cohort includes males only, as the 
cognitive performance measure is only available for males). The pattern of results is nonetheless 
very similar, though the confidence interval of the estimated coefficients and incremental R2 
values generally increase, reducing our ability to distinguish them from zero. Above and beyond 
the measures of personal characteristics, our polygenic scores of risk tolerance are still 
significantly predictive of being an entrepreneur, owning a business, the first PC of risky 
behaviors, the number of sexual partners, automobile speeding propensity, ever using marijuana, 
ever being a smoker, being an excessive drinker and drinks per week (in the STR and UKB-
siblings cohorts only), and having health or life insurance. Just as for the results displayed in 
Supplementary Table 10.3, LDpred scores constructed using either the GWAS or the MTAG 
summary statistics are usually more predictive than Classical-GWAS scores. 
Furthermore, the predictive power of our polygenic scores for many risky behaviors is 
comparable in magnitude to that of cognitive performance, personality, and educational 
attainment. The estimated 95% confidence intervals of the incremental R2 of our polygenic 
scores almost always contain the estimated incremental R2 of cognitive performance, educational 
attainment, or personality traits. 
10.3.4 Height as a negative control 
Neither the LDpred-GWAS nor the Classical-GWAS scores significantly predict height in the 
STR cohort (Supplementary Table 10.1). In the UKB-siblings cohort, the incremental R2 are 
indistinguishable from zero but, given the large sample size, the coefficients of the LDpred-
GWAS and LDpred-MTAG scores are statistically different from zero. These observations, 
combined with the above results, suggest that our scores capture some true polygenic signal for 
general risk tolerance and that our above results are not artifacts of our estimation procedure or 
of chance. 
 94 
10.4 Expected predictive power of general-risk-tolerance polygenic score 
As mentioned before, the predictive power of our polygenic scores is within the range expected 
according to theory, when cross-cohort heterogeneity of the GWAS and predicted phenotypes’ 
SNP heritabilities are taken into account. Daetwyler et al.107 have developed a theoretical 
formula for the expected predictive power of a polygenic score, when predicting the phenotype 
whose GWAS summary statistics were used to construct the score in an independent cohort. The 
formula assumes independent SNPs, equal heritability of the phenotype in the discovery and 
validation cohorts, and perfect genetic correlation of the phenotype across cohorts. Daetwyler et 
al.107 show that, under those assumptions, the expected predictive power of a polygenic score is 
equal to: 𝐸(𝑅") = ℎ" å 11 + 1/𝜆ℎ"æ 
where ℎ" is the SNP heritability of the phenotype (which is assumed to be the same in the 
validation cohort and in the GWAS whose summary statistics are used to construct the score), 
and 𝜆 = 𝑛]}§¨/𝑀 is the ratio of the sample size in the discovery GWAS (𝑛]}§¨) and the 
effective number of SNPs evaluated in the validation cohort (M). For the discovery meta-analysis 
we use in our Add Health (nGWAS = 975,353) and UKB-siblings (nGWAS = 937,353) analyses, h2 is 
0.041 when estimated by LD Score regression (Supplementary Table 4.1) and 0.045 when 
estimated using HESS (Table 1); in the STR cohort (nGWAS = 458,558), h2 is 0.055 when 
estimated by LD Score regression and 0.063 when estimated by HESS (Supplementary Table 
6.1)aaa; and a reasonable value for M is 60,000, which is the midrange of 50,000 to 70,000 
suggested by Wray et al. 2013141. 
Given a range of h2 values between 0.041 and 0.045 (0.055 and 0.063 for the STR cohort), this 
formula suggests an expected predictive power between 1.60% to 1.86% in the UKB-siblings 
cohort, 1.64% to 1.90% in the Add Health cohort, and between 1.63% and 2.05% in the STR 
cohort. Our estimated incremental R2’s for general risk tolerance are 1.62% (CI: 1.37% – 1.90%) 
in the UKB-siblings cohort and ~1.0% in both the Add Health and STR cohorts—slightly less 
than what we would expect given the Daetwyler formula. 
One explanation for the relative underperformance of our polygenic scores is cross-cohort 
heterogeneity. To account for this, De Vlaming et al.108 generalize the Daetwyler formula by 
allowing for unequal heritability between the prediction (ℎw") and discovery cohorts (ℎ"¸ ) and 
imperfect genetic correlation (rg < 1), while still assuming independent SNPs. With these 
generalizations, the expected predictive power of a polygenic score becomes:  𝐸(𝑅") = 𝑟."ℎw" £ 11 + 1/𝜆ℎ"¸ ¤. 
As before, we let ℎw" and  ℎ"¸  range between 0.041 and 0.045 (0.055 and 0.063 for the STR 
cohort). For the UKB-siblings cohort, we estimate a genetic correlation of 0.93 between the 
                                                        
aaa These heritability estimates for the STR cohort are those for the UKB cohort only (and not those for the meta-
analysis of the UKB and replication cohorts whose summary statistics were used to construct the scores in the STR 
cohort). These estimates are higher because they are not attenuated by cross-cohort heterogeneity, unlike the 
heritability estimates for the GWAS whose summary statistics were used in the Add Health and UKB-siblings 
analyses. 
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discovery and validation cohorts (using the full UKB GWAS instead of a GWAS of the UKB-
siblings subset to increase precision of this estimate). For the Add Health and STR cohorts, 
where sample sizes are too low to permit direct estimation of the genetic correlation, we consider 
rg values between 0.7 and 0.9. 
The expected incremental R2 now ranges between 1.51% and 1.61% for the UKB-siblings 
cohort, 0.80% to 1.54% for the Add Health cohort, and between 0.80% and 1.66% for the STR 
cohort. The observed predictive power of our score is now consistent with what we would expect 
in theory. This demonstrates the importance of considering cross-cohort heterogeneity when 
forming expectations of the performance of polygenic scores.  
De Vlaming et al.108 additionally allows for imperfect genetic correlations between individual 
cohorts within the discovery sample. When we account for this within-discovery sample 
heterogeneity (using the estimated genetic correlations reported in Supplementary Information 
section 7.4.2, which range from 0.76 to 0.83), our expected R2 ranges become 1.44%% – 1.67% 
for the UKB-siblings cohort, 0.84% – 1.62% for the Add Health cohort, and 0.80% – 1.67% for 
the STR cohort. These ranges remain consistent with our observed R2 estimates.bbb  
Lastly, our polygenic score performs consistently better in the UKB-siblings validation cohort 
than in the Add Health and STR validation cohorts, given our expected R2 values. This 
discrepancy could be explained by cross-cohort heterogeneity that we were unable to account 
for. For example, we have assumed throughout that ℎw" = ℎ"¸ ; however, the heritability of risk 
tolerance may be systematically lower in the Add Health and STR cohorts, where direct 
heritability estimation was not possible. 
Thus, while polygenic scores constructed from our GWAS results can already aid the study of 
some related phenotypes, future research would benefit from the collection of measures of risk 
tolerance that are more similar across cohorts.   
                                                        
bbb We do not account for imperfect genetic correlations between cohorts within our replication meta-analysis; these 
cohorts only account for 3.5% of the individuals in our discovery meta-analysis and are unlikely to affect our results. 
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10.5 Appendix: definition of the income risk gamble variable in the HRS 
cohort and merger of the STR1 and STR2 cohorts 
10.5.1 Income gamble risk tolerance in the HRS cohort 
In the HRS cohort the income gamble risk question was slightly modified after the first wave109. 
In the first wave, respondents were first asked the following question: 
“Suppose that you are the only income earner in the family, and you have a good job guaranteed 
to give you your current (family) income every year for life. You are given the opportunity to take 
a new and equally good job, with a 50-50 chance it will double your (family) income and a 50-50 
chance that it will cut your (family) income by a third. Would you take the new job?” 
Respondents who answered “yes” to the first question were asked this follow-up question: 
“Suppose the chances were 50-50 that it would double your (family) income, and 50-50 that it 
would cut it in half. Would you still take the new job?” 
Respondents who answered “no” to the first question were asked this follow-up question: 
“Suppose the chances were 50-50 that it would double your (family) income and 50-50 that it 
would cut it by 20 percent. Would you then take the new job?” 
In the original variable coding, the variable was coded as 1 if the respondent accepted the new 
job with the risk of cutting income by half, and a value of 4 if the respondent always chose to 
stay with the job with a guaranteed income. We reverse coded the original phenotype so that a 
higher value implies higher risk tolerance.  
The income gamble risk tolerance question was not asked in waves 2 and 3. In wave 4 and all 
subsequent waves, the initial question was: 
“Suppose that you are the only income earner in the family. Your doctor recommends that you 
move because of allergies, and you have to choose between two possible jobs. The first would 
guarantee your current total family income for life. The second is possibly better paying, but the 
income is also less certain. There is a 50-50 chance the second job would double your total 
lifetime income and a 50-50 chance that it would cut it by a third. Which job would you take -- 
the first job or the second job?” 
If the first job was chosen as the answer to the initial question, then this follow-up question was 
asked: 
“Suppose the chances were 50-50 that the second job would double your lifetime income and 50-
50 that it would cut it by twenty percent. Would you take the first job or the second job?” 
If the first job was chosen as the answer to the follow-up question, then a second follow-up 
question was asked: 
“Suppose the chances were 50-50 that the second job would double your lifetime income and 50-
50 that it would cut it by 10 percent. Would you take the first job or the second job?” 
If instead the second job was chosen as the answer to the initial question, then a different follow-
up question was asked:   
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“Suppose the chances were 50-50 that the second job would double your lifetime income, and 
50-50 that it would cut it in half. Would you take the first job or the second job?” 
If the first job was chosen as the answer to the follow-up question, then a second follow-up 
question was asked: 
“Suppose the chances were 50-50 that the second job would double your lifetime income and 50-
50 that it would cut it by seventy-five percent. Would you take the first job or the second job?” 
In the original variable coding, the respondent is given a value of 1 if the respondent accepts the 
second job with the risk of cutting the income by seventy-five percent, and a value of 6 if the 
respondent always chooses to stay with the job with a guaranteed income. Again, we reverse 
coded the responses so that a higher value corresponds to a higher risk tolerance. Further, since 
this survey measure has two additional response categories relative to the measure used in the 
first wave, we converted this survey measure’s responses to the 4-point scale that disregards the 
second follow-up questions; a value of 5 or 6 corresponds to 4, a value of 4 corresponds to 3, a 
value of 3 corresponds to 2, and value 1 or 2 corresponds to 1.  
We constructed the income gamble risk tolerance phenotype as the average response across 
waves, as follows. We first computed the residuals for wave w as 
(10) 
𝑦ç,5 = 𝑿𝒊𝜷𝒘 + 𝜖ç,5, 𝜖ç̂,5 = 𝑦ç,5 − 𝑿𝒊𝜷𝒘 
where 𝑦ç,5 is income gamble risk tolerance in wave 𝑤 for individual 𝑖 and 𝑿𝒊 contains the 
intercept and the control variables (birth year, birth year squared, birth year cubed, sex, as well as 
three interaction terms between sex and the three birth year variables). We then calculated the 
average residual across waves as 𝜖5̂ = 𝜖ç̂,ëzzzzz. To ensure this averaged residual is not associated 
with any of the control variables in 𝑿𝒊 either, we computed residual 𝑝5 as 
(11) 
𝜖5̂ = 𝑿𝒊𝜷 + 𝜂5, 𝑝5 = 𝜖5̂ − 𝑿𝒊𝜷,  
and used this residual 𝑝5 is used as the phenotype for the prediction in the HRS cohort. The 
sample size for income gamble risk tolerance is 7,302 in the HRS cohort (Supplementary Table 
10.1). 
10.5.2 Merging the STR1 and STR2 cohorts 
Since the STR1 and STR2 cohorts have been genotyped with different genotyping arrays (for 
details, see Supplementary Table 2.1), we kept them separate for the GWAS of general risk 
tolerance (Supplementary Information section 2). However, we merged the cohorts for the 
prediction analyses. First, we constructed and standardized the polygenic scores and calculated 
the 10 genetic principal components (PCs) separately in the STR1 and STR2 cohorts. We then 
merged the individual-level data by pooling the polygenic scores into a single variable. Two 
separate sets of PCs were used, imputing the value 0 for the 10 PCs of STR2 for the individuals 
in the STR1 cohort, and vice versa. In all the prediction analyses in the merged STR cohort, we 
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included a dummy variable indicating whether the individual belonged to the STR1 or STR2 
cohort. 
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11 Testing hypotheses about specific genes and gene sets 
Earlier studies have shown that risk tolerance and related individual characteristics are 
moderately heritable7,150, thus providing a motivation to investigate the biological and molecular 
bases of this heritability. Indeed, there is a voluminous literature that links specific biological 
pathways (i.e. brain regions, neuronal populations, hormones, receptors, and neurotransmitters) 
to decision making and behavior. Different research designs and proxies for biological pathways 
have been used, all with specific advantages and disadvantages (see, for example, Nave et al. 
(2015)151 for a review of studies on the role of oxytocin on trust).  
One part of this literature is candidate gene studies that have attempted to leverage insights from 
psychology and biology to derive hypotheses that could be tested using specific genes as proxies 
for biological pathways. Although the hypothesis-based approach seems intuitively reasonable, it 
is now widely accepted that findings from candidate gene studies on human behavior often fail to 
replicate. The reasons for this include very small effects of common genetic variants on human 
behavior, small sample sizes in candidate gene studies that led to underpowered statistical tests, 
publication bias, and insufficient controls for correlations between genotypes and relevant 
environmental conditions15,16,18,20,152–155. 
We systematically reviewed the prior literature on biological pathways that have been 
hypothesized to be linked to risk tolerance. Then, we used MAGMA156 on the summary statistics 
from the meta-analysis of the discovery and replication GWAS of general risk tolerance (n = 
975,353; as usual, we applied genomic control using the intercept of the LD Score regression to 
these summary statistics prior to the analyses) to re-evaluate the findings of this literature.  
In addition, since risk tolerance has been hypothesized to be under recent evolutionary 
pressure157–159, we tested whether a set of genes previously identified as having been under 
evolutionary pressure in Europeans is associated with general risk tolerance. 
11.1 Literature review 
11.1.1 Search algorithm 
We conducted a comprehensive literature review on biological pathways that may influence risk 
tolerance. Consistent with our GWAS, we restricted our review to research involving healthy 
individuals. Thus, we excluded studies that focused on neuropathologies, addictions, or other 
disorders. However, we included articles using animal models to study risk tolerance because the 
investigated biological mechanisms may have similar effects on human behavior. Our search 
algorithm employed a relatively broad definition of risk tolerance and included psychometric as 
well as behavioral measures (e.g. self-reported risk tolerance, choices between monetary 
lotteries, or gambling tasks). Risk tolerance among animals was typically measured by observing 
choices between probabilistic food options or by quantifying risk-assessment behavior during 
exploration. Following the analysis plan for our GWAS of general risk tolerance, we considered 
impulsivity and novelty-seeking as conceptually different traits and excluded them from this 
literature review. We included all proxies of biological pathways that are tested in the literature, 
including candidate genes, molecules represented by specific receptors, pharmacological 
interventions that are used to manipulate specific pathways (e.g., nasal oxytocin spray, 
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neurotransmitter receptor blockers, agonists, antagonists), as well as very distal proxies like the 
2D:4D digit ratio. 
We employed two parallel approaches to translate these criteria into search algorithms: first, we 
used a “bottom-up” approach and searched for studies investigating the relationship between risk 
taking and any biological pathway. The “bottom-up” search criterion we used was:  
 
(“risky behavior” OR “risk-aversion” OR “risk preference” OR “risk-taking” OR 
“risk-seeking”) AND (“GWAS” OR “gene” OR “SNP” OR “allele” OR “genetic” 
OR “candidate” OR “hormones” OR “neurotransmitter” OR “neuropeptide” OR 
“biology” OR “biological pathway”).  
 
We also conducted a “top-down” search which specifically cued our search criterion with 
biological pathways that were mentioned in the prior literature on risk tolerance. This “top-
down” search criterion was:  
 
(“risky behavior” OR “risk-aversion” OR “risk preference” OR “risk-taking” OR 
“risk-seeking”) AND (“catecholamines” OR “monoamines” OR “dopamine” OR 
“adrenaline” OR “noradrenaline” OR “norepinephrine” OR “glutamate” OR 
“serotonin” OR “GABA” OR “BDNF” OR “testosterone” OR “acetylcholine” OR 
“NMDA” OR “AMPA” OR “testosterone” OR “estradiol” OR “progesterone” OR 
“cortisol” OR “glucocorticoid” OR “vasopressin” OR “oxytocin” OR “ghrelin” OR 
“leptin”). 
 
We used both of these algorithms in two different search engines; the ISI Web of Knowledge and 
Google Scholar. Both search engines yielded highly overlapping results. 
We screened approximately 1,000 articles and found 132 which matched our criteria, spanning 
different scientific fields (from management to neuroscience), different models (e.g. human or 
rodent), different risk measures (from psychometric to behavioral measures), different biological 
pathways (e.g. monoamines, sex hormones), and different approaches (from genotyping to 
pharmacological manipulations). We included articles regardless of whether the reported results 
were statistically significant or not.  
11.1.2 Results of the literature review 
The results of our literature review are compiled in Supplementary Table 11.1. Overall, the 
literature on biological mechanisms for risk tolerance is relatively recent: most studies were 
published after 2003. However, earlier work on related concepts that were excluded by our 
selection criteria (such as novelty seeking) exists.  
Three main biological mechanisms comprising five biological pathways have been tested by this 
literature. The first of these is the relationship between risk tolerance and sex hormones, 
especially testosterone and estrogens.  Testosterone and estrogens are the two primary steroid sex 
hormones in humans. They are principally (but not exclusively) synthesized in the ovaries 
(estrogen) and testicles (testosterone), and are responsible for the development and regulation of 
the male (testosterone) and female (estrogen) reproductive system and secondary sex 
characteristics. The link between those hormones and risk taking is generally motivated by (and 
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discussed as corroborating of) the observed behavioral and attitudinal differences between males 
and females. A large part of the literature testing the relationship between risk tolerance and sex 
hormones uses the distal 2D:4D digit ratio to approximate prenatal testosterone levels. Some 
studies use measures of sex hormones that are derived from saliva or blood samples.  
The second frequently examined biological mechanism is the relationship with the 
neurotransmitters dopamine and serotonin. Those two monoamines have been repeatedly 
implicated in behavior and decision-making: dopamine plays a major role in reward-motivated 
behavior and in addiction, whereas serotonin is implicated in mood. Studies testing the 
associations between these monoamine pathways and risk tolerance typically test genetic 
variants implicated in the synthesis or the signaling pathways of these neurotransmitters (e.g., 
DRD4, SERT or 5-HTTLPR). Alternatively, pharmacological manipulations are used including 
blockers, agonists, or antagonists of specific dopamine or serotonin receptors.  
The third main biological pathway tested by the literature involves cortisol. Cortisol is another 
steroid hormone belonging to the glucocorticoid class, and is notably produced in response to 
stress. Cortisol triggers gluconeogenesis (the formation of glucose), and activates anti-stress and 
anti-inflammatory pathways. Studies testing the associations between the cortisol pathways and 
risk tolerance typically use a biochemical quantification of cortisol level in salivary or blood 
samples as an independent measure.  
In sum, our literature review highlighted five main biological mechanisms potentially 
underpinning the risk-tolerance phenotype: the testosterone, estrogen, dopamine, serotonin and 
cortisol pathways.  
11.2 Gene analysis and competitive gene-set analyses with MAGMA 
We used MAGMA156 together with the summary statistics from the meta-analysis of the 
discovery and replication GWAS of self-reported general risk tolerance to re-evaluate the 
findings of this literature.  
We conducted several types of analyses based on these results. First, for all five mechanisms we 
constructed gene sets, based on external databases of biological function, and tested these gene 
sets for association with risk tolerance. Second, for two of those pathways (dopamine and 
serotonin), there are a significant number of candidate gene studies in humans. These candidate 
gene studies most commonly test a specific subset of genes and genetic variants (SNPs or 
structural variants) within the dopamine and serotonin pathways. We therefore built a gene set 
from 15 of the 17 most commonly tested genes of those two pathways (Supplementary Table 
11.4) in order to re-evaluate the associations of those candidate genes with risk tolerance. Third, 
we tested specific SNPs in these 15 genes that have been tested in the prior candidate gene 
literature. Lastly, we tested whether a set of genes that has been identified as having been under 
selection among Europeans was enriched for association with general risk tolerance.  
MAGMA can perform two types of analyses: a gene analysis and a competitive gene-set 
analysis. For a given gene, a MAGMA gene analysis tests the joint association of all the SNPs in 
the gene with the phenotype. This aggregation of the SNPs reduces the number of tests compared 
to a SNP-based analysis, which results in an increase in statistical power and may lead to the 
detection of joint effects of multiple weaker SNP associations that would otherwise be missed. A 
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disadvantage of gene analysis is that it is uninformative about the direction of the effect, as it 
simultaneously tests multiple SNPs that can have opposite effects within a gene. 
For a given gene set, a MAGMA competitive gene-set analysis tests whether the genes in the 
gene set are more strongly associated with general risk tolerance than the other genes in the 
genome. Gene sets are groups of genes that share certain characteristics (e.g., biological or 
functional characteristics). Like a gene analysis, a competitive gene-set analysis has increased 
statistical power relative to a SNP-based analysis, as it involves fewer tests. Moreover, a gene-set 
analysis allows tests of specific biological hypotheses by defining appropriate gene-sets, and 
may provide direct insights into the underlying biological pathways or cellular functions of the 
phenotype. MAGMA uses a regression framework that compares the mean association of the 
genes in the gene set with the mean association of all other genes in the genome (equivalent to a 
one-sided two-sample t-test). To account for possible LD between genes, MAGMA uses a gene 
correlation matrix, which was based on the European ancestry samples from the 1000 Genomes 
project phase 177. Additional covariates are included in the regression to correct for any 
confounding effects of gene size and gene density (gene size, log gene size, gene density, log 
gene density).  
11.2.1 Competitive gene-set analysis with MAGMA: Testing gene sets related to 
dopamine, serotonin, testosterone, estrogen, and glucocorticoids 
As mentioned in Supplementary Information section 11.1, not all of the biological pathways 
that were studied in the previous literature on risk tolerance were studied using candidate genes 
as proxies for these pathways. Furthermore, the candidate genes (e.g. DRD4) that were studied 
are not the only genes that are involved in the respective biological pathways (e.g. dopamine). 
Thus, to begin with, we constructed and tested gene sets that represent the five major biological 
pathways that were previously studied in the context of risk tolerance. (We note that we also 
performed ex post MAGMA gene set analyses for GABA and glutamate neurotransmitters. We 
describe these analyses in Supplementary Information section 12.5.) 
We selected all gene sets related to the five major biological pathways (dopamine, serotonin, 
testosterone, estrogen and cortisol) from the Molecular Signature Database (MSigDB, v5.1)160, 
and from the gene sets compiled by Hawrylycz et al. (Nature Neuroscience 2015)161. There were 
38 gene sets related to the five pathways, from which we removed four duplicate gene sets. The 
remaining 34 gene sets had much overlap within each biological pathway, and we therefore 
merged all the gene sets belonging to a given pathway, resulting in five gene sets corresponding 
to each of the five pathways (dopamine, serotonin, testosterone, estrogen and glucocorticoids 
(cortisol)). We report both the initial and the merged gene sets in Supplementary Table 11.2. 
We conducted a competitive gene-set analysis with MAGMA to test each of these five gene sets 
for association with risk tolerance. We applied a resampling-based P value adjustment162 using 
10,000 permutations to correct for multiple testing (as we conducted a test for each of the five 
gene sets). 
None of these five gene sets showed a significant association with general risk tolerance after 
correction for multiple testing (the lowest corrected P value was 0.27, Supplementary Table 
11.3).  
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11.2.2 Gene analysis and competitive gene-set analysis with MAGMA: Testing 
candidate genes from the prior literature 
We used MAGMA to conduct a gene analysis to test the candidate genes identified in our 
literature review for association with general risk tolerance, employing all of the SNPs in our 
GWAS summary statistics within the physical location of the genes being tested. 15 of the 17 
candidate genes that we identified in the literature review were autosomal, and were thus eligible 
for testing (since our GWAS of general risk tolerance was restricted to autosomal SNPs). In 
addition to the gene analysis, we conducted a competitive gene-set analysis with MAGMA to 
test whether the genes in the gene set comprising these 15 genes are more strongly associated 
with general risk tolerance than the other genes in the genome.  
From the gene analysis, none of the genes showed a significant association with general risk 
tolerance after Bonferroni correction to correct for multiple testing (the 15 genes are not in LD; 
Supplementary Table 11.4). From the competitive gene-set analysis, the set of 15 candidate 
genes was also not significantly associated with risk tolerance (P = 0.55, Supplementary Table 
11.4). 
Our MAGMA competitive gene-set analysis of the cortisol, dopamine, serotonin, estrogen, and 
testosterone gene sets has some likely limitations. First, the statistical power of MAGMA 
competitive gene-set analyses barely increases with increasing sample sizes163. Second, 
important effects of numerous single SNPs in a gene or gene set may be overshadowed by the 
high average P values of other SNPs in the gene or gene set. Third, only specific pathways 
within the tested gene sets might be relevant, and merging many pathways into major cortisol, 
dopamine, serotonin, estrogen, and testosterone gene sets decreased our statistical power to 
discover specific pathways. In Supplementary Information section 12.7.4, we further discuss 
these limitations in the context of our ex post MAGMA competitive gene-set analysis of four 
glutamate and GABA gene sets; that analysis also returned null results, despite the fact that our 
Gene Network and DEPICT analyses both point to a role for glutamate and GABA 
neurotransmitters.  
Importantly, however—and unlike for glutamate and GABA—none of the bioinformatics 
analyses we report in Supplementary Information section 12 point to the cortisol, dopamine, 
serotonin, estrogen, and testosterone pathways or related genes either. Further, as reported above 
none of the 15 commonly-tested candidate genes were significant in our MAGMA gene analysis 
after Bonferroni correction for 15 tests; by contrast, our MAGMA gene analysis of ~18,000 
genes identified several glutamate and GABA genes that were significant after Bonferroni 
correction for ~18,000 tests (Supplementary Information section 12.2). Moreover, as we 
discuss in Supplementary Information section 11.2.4 just below, none of the SNPs tagging the 
15 most commonly-tested autosomal candidate genes within the dopamine and serotonin 
pathways have non-negligible effects on general risk tolerance. Therefore, while our MAGMA 
competitive gene-set analysis may suffer from some limitations, other analyses we conducted 
also fail to point to a role for the cortisol, dopamine, serotonin, estrogen, and testosterone 
pathways, and instead point to a role for glutamate and GABA neurotransmitters.  
11.2.3 Replication of specific SNPs tested in the prior candidate gene literature 
As a complement to the MAGMA gene-based tests, we also tested the individual SNPs that have 
been tested for association with risk tolerance in the previous literature and that are located 
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within the 15 autosomal genes tested with MAGMA. We used the summary statistics from the 
meta-analysis of the discovery and replication GWAS of general risk tolerance for these tests. 
Out of the 15 autosomal genes, three have been tested in the previous literature for association 
with alleles of an underlying structural variant, and we treat these separately below, where we 
looked up a total of 18 SNPs available in our GWAS summary statistics for these three genes. 
The remaining 12 autosomal genes contained 75 SNPs that were individually tested in the 
previous literature, of which 74 were available in our meta-analysis of the discovery and 
replication GWAS of general risk tolerance. Thus, our GWAS summary statistics contain the 
majority of candidate SNPs within these genes that were tested in the previous literature, and we 
performed Bonferroni-correction for testing 92 candidate SNPs.  
Out of the 74 previously tested SNPs within the 12 autosomal genes, two replicated with 
Bonferroni-corrected P values less than 0.05. The SNPs were rs36339 (in the gene SLC1802; 
Bonferroni-corrected P = 0.004), and rs174699 (in the gene COMT; Bonferroni-corrected P = 
0.034). The R2’s of rs36339 and rs174699 in the summary statistics of our discovery GWAS of 
general risk tolerance are 0.00185% and 0.00141%, respectively. By comparison, the smallest R2 
among the lead SNPs from our discovery GWAS of general risk tolerance is almost twice as 
large, at 0.0032% (rs1935571). The effects of rs36339 and rs174699 are considerably smaller 
than what could be found at the genome-wide significance level with our current discovery 
sample of 939,908 individuals, and they are several orders of magnitude smaller than what 
candidate gene studies in the existing literature—with typical sample sizes rarely exceeding a 
few hundred to a few thousand individuals—could have found. The sample sizes required to 
have 80% statistical power to detect the effects of rs36339 and rs174699 at the 5% level of 
significance (without Bonferroni correction) would be 424,260 and 556,654, respectively; the 
corresponding sample sizes at the genome-wide significance level (5 × 10)Â) would be 
2,140,573 and 2,808,560, respectively. We therefore found that 10 of the 12 hypothesized 
autosomal candidate genes harbor no candidate SNPs that replicate, while two (SLC1802 and 
COMT) each contain a SNP that is suggestively associated with general risk tolerance (with a P 
value less than 0.05 after Bonferroni correction for 92 tests) but whose effect is very small.  
In the previous literature, three of the 15 autosomal candidate genes (DRD4, DRD5 and SLC6A4 
(the latter is also commonly referred to as SERT or 5-HTT)) have mainly been tested for 
association with behavioral traits using alleles of structural variants located within these genes. 
For example, risk tolerance has previously been tested for association with a variable number 
tandem repeat in the DRD4 gene referred to as the 7R polymorphism11. Our GWAS summary 
statistics include nine SNPs within the DRD4 gene. Although we do not know the exact LD 
between these nine SNPs and the 7R polymorphism, it is very likely that at least some of them 
tag the 7R polymorphism very well because the DRD4 gene spans only 3,401 base pairs on 
chromosome 11, and variants in such close physical proximity tend to be in high LD. The lowest 
Bonferroni-corrected P value of a SNP in the DRD4 gene is 0.47 (rs201554946). The gene 
DRD5 has mainly been tested for association with a microsatellite that can take many different 
alleles164, and no SNPs within DRD5 were found in our literature review to have been tested 
directly for association with risk tolerance. DRD5 spans 2,375 base pairs on chromosome 4, in 
which we have seven SNPs in our GWAS summary statistics, and none of the SNPs have a 
Bonferroni-corrected P value less than 1. The gene SLC6A4 has mainly been tested for 
association with risk tolerance via a degenerate repeat polymorphism in a region of the gene 
called 5-HTTPLR165, and alleles of this repeat polymorphism are tagged by the SNPs rs2129785, 
rs11867581, and rs25531166. The SNPs rs2129785 and rs11867581 are available in our GWAS 
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results and their Bonferroni-corrected P values are both 1. Based on these results we cannot 
reject the null hypothesis that none of these three genes is associated with risk tolerance.  
Extended Data Fig. 3.4b and Fig. 1c display local Manhattan plots of the loci around the 15 
most commonly tested candidate genes in the prior literature on the genetics of risk tolerance. 
Each locus comprises all SNPs within 500 kb of the gene’s borders that are in LD	(𝑟" > 0.1) 
with a SNP in the gene. As can be seen in Extended Data Fig. 3.4b, only one of the 15 loci 
(around the gene DRD2) contains lead SNPs for any of our seven GWAS, and these SNPs are 
only genome-wide significant in our GWAS of drinks per week. One SNP in the SLC6A4 (SERT) 
locus is genome-wide significant in our GWAS of adventurousness. However, this SNP 
(rs112739039) is not a lead SNP in our GWAS of adventurousness because it is located in the 
locus of another SNP (rs6505239; see Supplementary Table 3.2). The nearest gene to 
rs112739039, RAB11FIP4, is located ~1Mb upstream of SLC6A4. In our meta-analysis of 
general risk tolerance, this SLC6A4 SNP is not genome-wide significant and is included in the 
locus defined by rs11080149 and nearest gene OMG, which is also located ~1Mb upstream of 
SLC6A4 (see Supplementary Table 3.1).  
The local Manhattan plots of the loci around the 15 candidate genes (Extended Data Fig. 3.4b 
and Fig. 1c) can be compared to those of the five main long-range LD regions and candidate 
inversions described in Supplementary Information section 3.2 (Extended Data Fig. 3.4, a 
and c, and Fig. 1, a and b). These five regions contain numerous lead SNPs for most or all of our 
seven main GWAS. 
In summary, no candidate genes that have been tested with SNPs in the previous literature, nor 
the candidate genes tested with alleles of structural variation, contain genome-wide significant 
SNPs in our discovery GWAS, while two candidate genes each contain a SNP with a suggestive 
association (i.e., with a Bonferroni-corrected P value smaller than 0.05, after Bonferroni 
correction for 93 tests). However, a sample size of more than 2 million individuals would be 
required to have 80% power to replicate these two SNPs at the genome-wide significance level, 
and a sample size of more than 400,000 would be required to replicate these SNPs at the 5% 
level of significance. We therefore conclude that these two SNPs are relatively unimportant in 
terms of their effects on general risk tolerance, and that previous candidate gene studies testing 
these SNPs for association with behavioral phenotypes were severely underpowered to detect 
their very small effects. 
11.2.4 Competitive gene-set analysis with MAGMA: Testing genes under selection 
among Europeans 
A number of theorists have posited that attitudes toward risk have been under evolutionary 
pressure157–159. In particular, if decisions involving risk have to be made frequently and if 
decision mistakes have a severe impact on fitness, theoretical models suggest that selective 
pressure will favor risk attitudes that maximize fitness in a given environment158. Consequently, 
changes in the environment can induce selective pressure for different levels of risk tolerance. It 
is obvious that the environment in which people live and make choices has changed dramatically 
over the past few millennia, with many fitness-related risk factors declining in importance, and 
new ones arising (e.g. due to urbanization, technological progress, and increasing populations). 
Hence, it is conceivable that general risk tolerance has been under selective pressure in our 
recent evolutionary past. 
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To test if risk tolerance was subject to recent selective pressure among people of European 
descent, we constructed a gene-set based on 17 genes that were highlighted as having been under 
recent selective pressure among Europeans by the 1000 Genomes phase 3 analyses167 (see 
Supplementary Table 11.5). We performed a competitive gene-set analysis with MAGMA and 
with the summary statistics from the meta-analysis of our discovery and replication GWAS of 
general risk tolerance, to test whether the genes in this gene-set are more strongly associated with 
general risk tolerance than other genes.  
The gene-set based on the genes that have been highlighted as having been under recent selective 
pressure among Europeans showed no association with general risk tolerance (P value = 0.90, 
Supplementary Table 11.5). Thus, this test provides no evidence suggesting that risk tolerance 
has been subject to recent selective pressure. However, this absence of evidence is not evidence 
of absence: our test may have failed to detect evolutionary pressure for several reasons, including 
limited statistical power. Further, we only tested if a set of genes that have been highlighted as 
having been under evolutionary pressure is associated with general risk tolerance; future research 
could also test whether genes that are associated with risk tolerance have been under 
evolutionary pressure. 
11.3 Discussion 
In summary, we find no evidence of enrichment for the main pathways and genes that had 
previously been hypothesized to relate to risk tolerance. We also note that none of the 
bioinformatics analyses we report in Supplementary Information section 12 point to these 
pathways or genes either (we note, however, that some brain regions identified in analyses we 
report below are areas where dopamine and serotonin play important roles.) By contrast, some 
those bioinformatics analysis point to a role for the glutamate and GABA neurotransmitters.  
Our null replication results are consistent with the poor replication record that candidate gene 
studies in social-science genomics have typically had15,16,18,20,152–155. Given that the sample size 
of our GWAS is several orders of magnitudes larger than any previous candidate gene study on 
risk tolerance, our results put a credible, tight upper bound on the effect sizes of the genes that 
were tested, and allow us to rule out the possibility that these genes have particularly large effect 
sizes compared to typical genetic variants.  
However, our results do not imply that the main biological pathways we identified in our 
literature review are irrelevant for risk tolerance, as variations further downstream in these 
pathways (e.g. damaged glands, pharmacological interventions) may have much stronger effects 
on risk tolerance than the genes that were tested.  
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12 Biological annotation 
This section reports biological annotation of our GWAS results. Throughout, we focus on our 
primary phenotype, self-reported general risk tolerance, because it has by far the largest GWAS 
sample size and because the other main phenotypes analyzed in this paper are genetically 
correlated with it. The goal of these analyses is to gain biological insight (1) into the genome-
wide biological correlates of the general-risk-tolerance phenotype (with a suite of bioinformatic 
analyses that use GWAS summary statistics for large sets of SNPs across the genome), and (2) 
about the lead loci from our discovery GWAS of general risk tolerance (by looking up the 
functional status of the SNPs in these loci). For all analyses in this section, we use the summary 
statistics from the meta-analysis of the discovery and replication GWAS of general risk 
tolerance. 
In Supplementary Information section 12.1, we use partitioned LD Score regression74 to test 
for polygenic enrichment in specific genomic regions, such as gene transcription start sites, 
evolutionarily conserved regions, and sections of the genome epigenetically modified in certain 
tissues.  
In Supplementary Information section 12.2, we use MAGMA156 to conduct hypothesis-free 
analyses to identify specific genes that are associated with general risk tolerance. We also use a 
co-expression database to gain insight into the functions of the significant MAGMA genes. 
In Supplementary Information section 12.3, we perform transcriptome-wide analysis with 
Summary-based Mendelian Randomization (SMR), which leverages genome-wide data to 
discover genes whose expression significantly associates with general risk tolerance. In addition, 
the “HEIDI” test feature of SMR is able to discard expression quantitative trait loci (eQTL) 
associations that are caused merely by linkage, thereby discarding genes that are spuriously 
associated with general risk tolerance. 
In Supplementary Information section 12.4, we use DEPICT168 to prioritize tissues, gene sets, 
and genes that are implicated by our GWAS results. Like MAGMA, DEPICT is a gene-based 
tool. However, in contrast to MAGMA, DEPICT uses reconstituted gene sets that are based on 
co-expression patterns to prioritize genes, gene sets, and pathways.   
In Supplementary Information section 12.5, to follow up on the results from other biological 
annotation analyses, we conduct an ex post MAGMA gene set analysis156 to test for enrichment 
of GABA and glutamate pathways in general risk tolerance. 
In Supplementary Information section 12.6, we report a number of analyses that annotate our 
general-risk-tolerance lead loci, to gain insights into the biological systems they may affect. 
First, we check whether our lead loci contain protein-altering variants (i.e., genetic variants 
which result in a structural difference in the protein structure encoded by a gene, collectively 
known as ‘nonsynonymous’ variants). Second, we look up the lead loci in an expression 
quantitative trait loci (eQTL) database that contains associations between genetic variants and 
gene expression levels.  
Finally, in Supplementary Information section 12.7, we highlight the most important results of 
these analyses and summarize the conclusions we derive from them.   
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12.1 Functional partitioning of heritability with stratified LD Score 
regression 
12.1.1 Background and methods 
In this section, we discuss the results of our stratified LD Score regression analyses74. (In 
addition to ref.74, the Supplementary Information of Okbay et al.18 also contains a detailed 
description of the methodology.) With these analyses, we break down (“partition”) the SNP-
based heritability of general risk tolerance across SNPs with various functional genomic 
annotations. We used the GWAS summary statistics from the meta-analysis of the discovery and 
replication GWAS of general risk tolerance (after applying genomic control using the intercept 
of the LD Score regression, as usual) for these analyses. 
Stratified LD Score regression is based on the relationship 
(12) 𝐸¼𝜒K"½ = 𝑁­𝜏vℓ(𝑗, 𝑐) + 𝑁𝑎 + 1,^v®*  
where 𝜒K" = 𝑁𝛽ZK" is the GWAS chi-square statistic for SNP j, N is the GWAS sample size, c 
indexes the functional categories (which do not have to be disjoint), ℓ(𝑗, 𝑐) is the stratified LD 
Score of SNP j with respect to functional category 𝑐, 𝜏v is the average contribution to heritability 
of a SNP due to its membership in category 𝑐, and a is a term that measures the contribution of 
confounding biases such as cryptic relatedness and population stratification. 
Finucane et al.74 present derivations of this equation and show how estimates of 𝜏v that result 
from estimating the implied regression can be used to obtain estimates of the heritability 
ascribable to the various functional categories. Enrichment is then defined as the fraction of the 
total heritability captured by the functional annotation category divided by the fraction of SNPs 
in that category.  
To partition the SNP-based heritability of risk tolerance using the results of our GWAS meta-
analysis, we followed the procedure described by Finucane et al.74 and applied in two recent 
papers by Okbay et al.16,18. That is, we used the stratified LD scores calculated from the 
European-ancestry samples in the 1000 Genomes Project (1000G) (accessed on March 14, 2016), 
but in the regressions themselves included only the chi-square statistics of the ~1 million 
HapMap3 SNPs with minor allele frequency (MAF) > 0.05. This decision was motivated by the 
facts that HapMap3 SNPs are a comprehensive set of common genetic markers that can be 
imputed with high accuracy across different groups and genotyping platforms143,169; that the LD 
scores of SNPs with low MAFs can introduce too much statistical noise when used in the 
analysis; and that the per-SNP heritability may substantially differ for common and rare SNPs. 
We performed two distinct analyses. We first estimated the stratified LD Score regression for the 
functional genomic regions of the “baseline” model. The functional categories in the baseline 
model consist of one category containing all SNPs, 24 categories corresponding to 24 main 
functional annotations of interest (which include, for example, evolutionarily conserved regions 
in mammals and regions epigenetically regulated to be accessible to gene transcription), 
categories corresponding to 500 bp windows around regions belonging to each of these 24 
annotations (to correct for spurious associations driven by variants located near the physical 
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borders of the functional genomic regions), and categories corresponding to 100-bp windows 
around ChIP-seq peaks (regions that are DNase hypersensitive, also known as “open chromatin,” 
or associated with the histone marks H3K4me1, H3K4me3, H3K9ac, or H3K27ac). The full 
baseline model contains 53 predictors (including the predictor for the category containing all 
SNPs).   
Second, to gain tissue-level resolution, we used the tissue-level annotations provided by 
Finucane et al. These consist of 220 cell-type-specific annotations for four histone marks that are 
subsequently grouped into 10 broad tissue type annotations (Adrenal/Pancreas, Central Nervous 
System, Cardiovascular, Connective/Bone, Gastrointestinal, Immune/Hematopoietic, Kidney, 
Liver, Skeletal Muscle, and Other). Histone marks are posttranslational modifications of histones 
that alter their interaction with the DNA wound around them. For example, the acetylation of 
lysine (an amino acid present in the histone protein) may facilitate gene expression by reducing 
the electrical attraction between DNA and the histone, making the DNA strand more receptive 
for transcription (and thus, gene expression). While certain histone marks are associated with 
increased DNA transcription, other histone marks’ effects on DNA transcription depend on the 
combination of the chemical form and the location of the modification. For instance, mono-
methylation of histone H3K9 (denoted H3K9me1) is associated with activation of gene 
expression, while tri-methylation of H3K9 (denoted H3K9me3) is associated with repression of 
gene expression170. The association between SNPs and histone modifications differs per tissue 
and developmental stage, and has been mapped extensively by the RoadMap Epigenomics 
project171. For instance, SNPs important for eye function are likely to be “tightly bound” to 
histone proteins in the liver, where they do not need to be expressed, but “loosely” bound to 
histones in the eye, where their expression is crucial. Here, we used LDSC partitioning of 
heritability to test if risk tolerance SNPs are enriched in (or near) tissue-specific histone marks, 
which would suggest that those tissues might be of biological importance for general risk 
tolerance. 
The functional annotation categories we used here are associated with the histone marks 
H3K4me1, H3K4me3, H3K9ac and H3K27ac, which are all known to increase transcription 
rate172. However, we note that the probability of any gene being transcribed and thus expressed 
further depends on the presence of other epigenetic modifications, such as epigenetic 
modifications of the DNA sequence itself (for example, methylation of CpG-islands). This 
means that the four histone modifications we study here do not deterministically increase gene 
expression rates, but rather do so in a probabilistic manner.  
We added each of the 10 tissue annotations to the baseline model (resulting in 10 separate 
regressions, each with 54 predictors), and assessed the magnitude and statistical significance of 
the observed enrichment. To benchmark these tissue-level results, we compared them to the 
corresponding estimates we obtained using the summary statistics of the most recent GWAS of 
height83 (http://www.broadinstitute.org/collaboration/giant/index.php).  
To correct for multiple hypothesis testing, we applied a Bonferroni correction for 52 two-sided 
tests in the baseline model (i.e., for 52 annotationsccc), and for 10 two-sided tests in the tissue 
type models (i.e., for 10 tissue types).  
                                                        
ccc The baseline model has 53 predictors, but we do not adjust for the predictor for the category containing all SNPs. 
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12.1.2 Results: The “baseline” model  
The results for the baseline model are shown in Supplementary Table 12.1. The baseline 
annotations “Conserved” and “H3K9ac peaks” are the most enriched, with enrichment estimates 
that remain significant after Bonferroni correction for 52 tests. The “Conserved” category shows 
the strongest enrichment (~15.8-fold) and accounts for 41% (SE = 5.0%) of the heritability of 
general risk tolerance; the “H3K9ac peaks” category shows a 5.5-fold enrichment and accounts 
for 21% (SE = 3.7%) of the heritability of general risk tolerance. 
12.1.3 Results: Tissue types 
The results of the tissue-level analyses are reported in Extended Data Fig. 12.3a, and 
Supplementary Table 12.2. For general risk tolerance, the enrichment of Central Nervous 
System is strongest (~2.94-fold, P = 5.90 × 10–20), followed by Adrenal/Pancreas (~2.47-fold, P 
= 1.41 × 10–7). The enrichment estimates for Immune/Hematopoietic, Cardiovascular, Liver, and 
Skeletal Muscle are also significant, and also survive Bonferroni correction. Our estimates imply 
that SNPs bearing the Central Nervous System and Adrenal/Pancreas annotations account for 
43.8% (SE = 2.8%) and 23.1% (SE = 2.5%) of the heritability of general risk tolerance, 
respectively; the corresponding figure for Immune/Hematopoietic is 37.6% (SE = 3.6%). These 
estimates are all highly significant and survive Bonferroni correction for ten tests.  
However, the enrichment statistics are potentially misleading because of possible confounding. 
For example, many SNPs bear multiple annotations. It is thus of interest to examine the 𝜏v 
estimates of each tissue (i.e., the coefficients from the stratified LD Score regression). The 𝜏v for 
a given tissue type and phenotype corresponds to the effect of a one-unit increase in a SNP’s 
stratified tissue-specific LD score on the expected square of the SNP’s GWAS estimate from the 
phenotype’s GWAS (where the SNP genotype has been standardized), after controlling for the 
annotations from the baseline model. It is also an estimate of the expected increase in the 
phenotypic variance accounted for by a SNP due to the SNP’s being in the given tissue category, 
controlling for the annotations from the baseline model. SNPs that bear a tissue annotation with a 
large and positive 𝜏v will tend to account for a larger share of a phenotype’s heritability.  
Extended Data Fig. 12.3a shows, for general risk tolerance and height, the ratio of the 𝜏v 
estimates over the LD Score estimates of phenotypic heritabilityddd,eee. For each phenotype, we 
normalized the 𝜏v’s and their standard errors by the LD Score heritabilityfff to increase 
comparability across phenotypes. Here, only Central Nervous System (z = 8.81, P = 6.04 × 10–19) 
and Immune/Hematopoietic (z = 3.19, P = 1.42 × 10–3) have positive coefficients surviving 
Bonferroni correction (note that these analyses excluded SNPs in the MHC region on 
chromosome 6). We also verified that the coefficient for Immune/Hematopoietic remained 
positive and highly significant (z = 4.71, P = 2.47 × 10–6) even after controlling for Central 
Nervous System (in addition to the baseline annotations) in the LD Score partitioned regression. 
                                                        
ddd Based on the LD score framework, ℎ·¸¨^,`" = ∑ 𝑀vv 𝜏v,`, where y denotes the phenotype and Mc is the number of 
SNPs with annotation c among the SNPs used to calculate the LD scores. Thus, normalizing the 𝜏v’s by ℎ·¸¨^,`"  is 
equivalent to normalizing the 𝜏v’s by a weighted sum of the 𝜏v’s, where the weights are given by the number of 
SNPs with the different annotations. 
eee The confidence intervals were obtained with the delta method, assuming zero covariance between the 𝜏v’s and the 
phenotypes’ LD score heritabilities. 
fff Each phenotype’s LD score heritability was obtained from the phenotype’s LD score regression 42.  
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Thus, the positive coefficient for Immune/Hematopoietic is not due to possible overlap between 
the Immune/Hematopoietic and Central Nervous System annotations.  
In these respects, general risk tolerance differs notably from a physical trait such as height, for 
which Connective/Bone has the largest positive z-score (z = 6.08, P = 1.20 × 10–9) and Central 
Nervous System is the only tissue-level annotation with a negative coefficient74,ggg. Finally, we 
note that the coefficients for Cardiovascular, Gastrointestinal, Liver, and Skeletal Muscle (which 
were significantly enriched) have negative 𝜏v coefficients for general risk tolerance. This means 
that the GWAS signal is actually negatively enriched for histone marks in these tissues, after 
taking the baseline annotations into account. 
12.1.4 Discussion  
The results of our baseline annotation model are similar to those reported by Finucane et al.74 for 
a set of nine phenotypes and to those reported by Okbay et al.16,18 for educational attainment, 
subjective well-being, depressive symptoms, and neuroticism. That is, evolutionary conserved 
regions (i.e. conserved in mammals173) bear the most significant enrichment, followed by 
annotations relating to modification of gene expression. This is in line with a large body of 
literature that suggests that complex traits are likely to mainly be affected by genetic variants 
involved in the modification of gene expression, rather than by direct coding variants174. In 
particular, the significant enrichment of “H3K9ac histone marks” points to the involvement of 
active gene promoters in general risk tolerance175. 
The evolutionarily conserved category denotes regions of the genome that have been conserved 
in mammals throughout evolution. The evolutionary conservation of a genomic region can be 
studied through assessment of the “mutation rate” of such a region. That is, some regions of the 
genome accumulate base-pair substitutions more slowly than predicted by a model of selective 
neutrality173, which implies that mutations in such regions tend to have deleterious effects that 
decrease evolutionary fitness, and are therefore subject to natural selection. 
As for the tissue enrichments, we obtained significant 𝜏v estimates for Central Nervous System 
and Immune/Hematopoietic cell types. As explained above, this implies that risk-tolerance 
associated SNPs that are in or near histone marks in these tissues contribute relatively more to 
the per-SNP heritability of risk tolerance than most other SNPs. Because risk tolerance is a 
psychological trait, central nervous system enrichment is not surprising. More interesting is the 
current lack of significance of the 𝜏v estimates for Adrenal/Pancreas. This suggests the highly 
significant enrichment estimate for Adrenal/Pancreas is due to overlap with SNPs bearing other 
annotations rather than to the partial effect of bearing the Adrenal/Pancreas annotation, and may 
possibly question the role for the stress-response system in risk tolerance176–178. We note, 
however, that the lack of significance of the 𝜏v estimates for Adrenal/Pancreas could also be due 
to lack of statistical power or to imprecisions or imperfections in the SNP annotations. The 
stress-response system is driven by the hormones cortisol and (nor)epinephrine (also known by 
the name (nor)adrenaline), which are all produced in the adrenals.  
                                                        
ggg We caution that a detailed quantitative comparison of the results for the height and the general-risk-tolerance 
GWAS might be misleading, because the sample size of the height GWAS is smaller than that of the risk-tolerance 
GWAS, and because the heritability of height is substantially higher than the heritability of general risk tolerance. 
Nonetheless, our results suggest that different tissue types tend to be relatively more enriched for the two 
phenotypes. 
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To the best of our knowledge, we are the first to find significant LDSC tissue enrichment of the 
immune system in a psychological or neuropsychiatric trait (although enrichment of specific 
immune pathways and/or immune tissue enhancer regions has been implicated in 
schizophrenia69,179, bipolar disorder180 and major depression181). We note that involvement of the 
immune system is not corroborated by our other analyses (aside from the large number of genes 
significant in the MHC region across out MAGMA, SMR and lookup analyses), and it is unclear 
how to interpret this finding.  
12.2 Identifying genes associated with general risk tolerance with MAGMA 
To identify genes that are significantly associated with general risk tolerance, we conducted a 
gene analysis with MAGMA156 (defined in Supplementary Information section 11.2) for each 
of ~18,000 genes, in a hypothesis-free manner. We then used the Gene Network182 co-expression 
database to gain insight into the functions of the significant MAGMA genes. 
12.2.1 Gene analysis with MAGMA: Testing ~18,000 protein-coding genes  
The gene-based analysis was performed with MAGMA156 using the summary statistics from our 
meta-analysis of the discovery and replication GWAS of general risk tolerance (after applying 
genomic control using the intercept of the LD Score regression). 
All the SNPs from these summary statistics were annotated to genes based on NCBI 37.3.13 
gene definitions. Only SNPs located between the transcription start and stop sites of a gene were 
annotated to that gene. A per-gene test statistic is calculated as the mean of the GWAS –log10(P) 
values for all the SNPs between the transcription start and stop sites of a gene; MAGMA then 
calculates a P value for the resulting gene test statistic, using a procedure that takes into account 
the non-independence of the SNPs within the gene due to LD183. We used our main reference 
panel (described in Supplementary Information section 2.4) as reference data to estimate LD. 
Bonferroni correction was applied to account for multiple testing, counting each gene as an 
independent test. 
The SNP-to-gene annotation yielded 18,224 protein-coding genes containing at least one SNP 
present in the current GWAS. After Bonferroni correction for 18,224 tests, 285 genes showed a 
significant association with general risk tolerance (Supplementary Table 12.3). We will 
henceforth refer to these as the “MAGMA genes.” The top ten MAGMA genes are: CADM2 
(chr. 3: 85 Mb, P = 1.08 × 10–50; all the P values reported in this paragraph are Bonferroni-
corrected P values), MSRA (chr. 8: 9 Mb, P = 1.61 × 10–28), XKR6 (chr. 8: 10 Mb, P = 3.54 × 10–
23), FOXP2 (chr.7: 113 Mb, P = 9.94 × 10–19), MFHAS1 (chr. 8: 8 Mb, P = 2.76 × 10–18), RP1L1 
(chr. 8: 10 Mb, P = 2.04 × 10–15), FOXP1 (chr. 3: 71 Mb, P = 2.23 × 10–13), RBFOX1 (chr. 16: 5 
Mb, P = 1.99 × 10–12), ARNTL (chr. 11: 13 Mb, P = 2.27 × 10–11), and ERI1 (chr. 8: 9 Mb, P = 
7.49 × 10–11).  
The results show that several long-range LD or inversion regions of the genome contain a 
disproportionate number of MAGMA genes (which is not surprising, since MAGMA does not 
correct for LD between genes in its gene-based test). For instance, the Human Leukocyte 
Antigen (HLA) region (and its surrounding area) carries a relatively large number of significant 
genes: there are 29 significant genes in the chr.6: 25-32 Mb region, of which 11 are zinc finger 
genes, six are histone protein genes, and three are olfactory function genes (none of the HLA-
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genes themselves are significant, however). The large candidate inversion region on 
chromosome 8 (chr.8: 8 to 12 Mb, previously associated with neuroticism and depressive 
symptoms18) and its surrounding area carry 21 significant genes, 13 of which are among the top 
30 most significant MAGMA genes, and of which MSRA is the most significant by far 
(Bonferroni-corrected P = 1.61 × 10–28). A long-range LD region on chromosome five (chr.5: 
135-138 Mb) contains 10 significant genes, of which ETF1 is the most significant by far 
(Bonferroni-corrected P = 7.46 × 10–7). Finally, we note that several of these genes (MSRA, 
ERI1, XKR6, and ETF1) were also significant in the SMR analyses, although only in the analysis 
of blood cis-eQTLs, and not in the analysis with GTEx data on cis-eQTLs from brain regions 
(lack of replication with the brain eQTL data may be because these data are based on relatively 
small samples and statistical power was consequently limited). 
12.2.2 Using co-expression to predict gene function  
We used a co-expression database called Gene Network182 (accessed 6 September 2017) to gain 
further insight into the functions of the MAGMA genes. The advantage of Gene Network lies in 
its ability to assign functions to a gene, even if that gene has not been annotated with a function 
in an actual empirical experiment (as described below). This is an important advantage because 
many human genes have not yet been studied in depth and hence have poorly understood 
functions. Therefore, looking up only the genes with empirically established functions in 
databases is in most cases not fully informative. 
The gene functions used by Gene Network are derived from expert-curated sets of genes known 
as “gene sets” or “pathways.” The experts involved in the curation of such gene sets 
continuously review the empirical literature of a gene, and assign a gene its functions based on 
empirical results from laboratory experiments. Gene Network then assigns genes “membership” 
to these expert-curated gene sets by establishing “guilt-by-association” based on their co-
expression with genes that are known members of such gene sets. A total of 14,461 functionally 
defined gene sets served as input, taken from standard databases such as Gene Ontology184 (GO), 
Reactome185,186, and Kyoto Encyclopedia of Genes and Genomes187 (KEGG). These co-
expression patterns also serve as input for DEPICT168 (Supplementary Information section 
12.4). All members of the functionally defined gene sets or pathways share a particular 
biological function, which can range from very specific and bottom-up functions (e.g., “clathrin 
binding”) to more coarsely defined and top-down functions (e.g., “hormone activity”). The 
biological function can also refer to the cellular site where the gene performs its function (e.g., 
“neuromuscular junction”).  
We briefly describe the Gene Network method here, noting that in-depth documentation of the 
method can be found in Fehrmann et al.182 and Pers et al.168. The Supplementary Information of 
Okbay et al.18 also contains a detailed description. Gene Network uses information from a total 
of 77,840 publicly available human, mouse, and rat Affymetrix microarrays from the Gene 
Expression Omnibus. These microarrays measure expression levels of at least 19,997 human 
genes (or, in the case of mouse and rat experiments, their mouse- or rat-orthologs). Gene co-
expression levels were measured in Pearson correlation coefficients. The resulting correlation 
matrix was broken down into principal components (PCs), which gave rise to a total of 2,206 
reliable “transcriptional components” (TCs). 
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Each PC (i.e. transcriptional component) captures a shared pattern of gene expression across 
experiments, implying shared biology of the genes that load highly on the PC. The PCs can 
capture subtle patterns of co-expression that potentially reflect shared biological pathways 
among genes, which would typically be overshadowed by strong global transcriptomic effects, 
and thus missed in a straightforward correlation analysis.  
Subsequently, the authors of this method tested whether the pattern of co-expression captured by 
the PC significantly differentiated members of the gene set from all other genes, by testing the 
difference between the mean PC loading of the gene set versus the mean loading of all genes not 
in the gene set, using a Welch t-test for unequal variances. Each row of the resultant 14,461	×	2,206 matrix of t-statistics (each element corresponding to a gene set and PC) was then 
correlated with the PC loadings of the individual genes, to test whether the expression patterns of 
each gene and gene set were correlated. Finally, the thresholds for declaring a correlation 
between a gene’s PC loadings and a gene set’s t-statistics as statistically significant were chosen 
to satisfy False Discovery Rate (FDR) < 0.05. Thus, each gene’s membership to each gene set 
was tested, allowing significant associations to be queried from the Gene Network database. 
From this database, we first recorded for each MAGMA gene all statistically significant results 
(i.e., all gene sets that are significantly correlated with the genes’ PC loadings), derived from 
gene sets and pathways from the Gene Ontology184 (http://amigo.geneontology.org/amigo) 
domains Biological Process, Cellular Compartment, and Molecular Function. We also recorded 
the results listed under the Reactome185 (http://www.reactome.org/) pathways and under the 
Kyoto Encyclopedia of Genes and Genomes187 (KEGG, http://www.genome.jp/kegg/) pathways. 
In each case, we report (in Supplementary Table 12.4) the five most frequently occurring gene 
sets across the MAGMA genes. 
Gene Network also reports organs, tissues, and cell types in which the gene under investigation 
is significantly and specifically expressed (compared to other tissues). For each MAGMA gene, 
we recorded all these organs, tissues and cell types where the area under the receiver operating 
characteristic curve (AUC), with respect to the discriminating power of measured gene 
expression, exceeded 0.80 according to Gene Network. Gene Network derived this AUC from 
the difference between the samples of the focal tissue and all other tissues in the distribution of 
the queried gene’s expression level. These differences were determined by text-mining the 
descriptions provided by experimenters who uploaded the expression data to the Gene 
Expression Omnibus (GEO). Note that the tissue/cell type labels taken from the Medical Subject 
Headings (MeSH) database can refer to different levels of a hierarchy and are therefore not 
necessarily mutually exclusive. 
We note that the method has three potential inherent drawbacks. First, only genes with reliable 
gene expression data (i.e., which have survived quality control) are included in the database. 
Therefore, the co-expression matrix might exclude genes that may be important but that have not 
yielded reliable expression data. For instance, FTO (a gene implicated in obesity) is a notable 
gene not included in the database.  
Second, the method does not assign functions to genes that have unique patterns of gene 
expression but that may well play a role in known biological processes.  
The third potential drawback of our querying method is that some of the significant MAGMA 
genes may only capture signal from other, nearby MAGMA genes, and not have any independent 
causal effects of their own.  In this analysis, we conduct the search for each of the MAGMA 
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genes and sum their predicted gene functions as if they were independent. This potential 
dependence among genes must, however, be taken into account when interpreting the predicted 
gene function counts. 
For each of the three Gene Ontology (GO) domains, the Reactome pathways, the KEGG 
pathways, and the significant organs, tissues, and cell types, Supplementary Table 12.4 lists the 
five most frequently occurring predicted gene functions, cellular components, and cell-
type/tissues for the 266 MAGMA genes that were present in the Gene Network database. The 
most frequently occurring terms overwhelmingly point to neural function and anatomy. To a 
lesser degree, functions related to gene expression are also highlighted.  
The top five tissues are all brain tissues: prefrontal cortex, which is predicted for 88 genes, 
frontal lobe (81 genes), visual cortex (81 genes), parietal lobe (80 genes), and putamen (which is 
part of the basal ganglia; 80 genes). The most interesting of these tissues is likely the prefrontal 
cortex, which is crucial for inhibition of emotion and planning of behavior188, and is one of the 
last brain regions to mature during pubertal development189. 
The top terms for GO biological process and GO molecular function are “glutamate signaling 
pathway” (12 genes) and “glutamate receptor activity” (15 genes), respectively, while the top 
occurring terms for GO cellular component refer to dendritic (22 genes) and synaptic (22 genes) 
cell components. GO biological process also infers several functions related to modification of 
gene expression, namely “chromatin modification and organization” (11 genes) and “histone 
modification” (9 genes). The top terms for Reactome are “neuronal system” (20 genes), with the 
remainder of top terms referring to synaptic and neurotransmitter functions. Four out of five 
terms for KEGG are neural, with “calcium signaling pathway” (20 genes) as the top term. The 
only non-neural annotation for KEGG is “spliceosome” (18 genes). 
12.3 Identifying genes associated with general risk tolerance with SMR 
12.3.1 Background 
The rationale for the Summary-based Mendelian Randomization (SMR) test, which is one of 
several methods that test for an association between gene expression and trait variation (e.g., 
refs.190–192), is that GWAS associations for complex traits and common diseases are enriched in 
non-coding regulatory regions of the genome (e.g., ref.69), suggesting that many causal variants 
influence trait variation through regulation of gene expression. There is also evidence that causal 
variants often do not target the gene closest to the association signal (e.g., ref.193).  
SMR differs from our eQTL lookups of top GWAS SNPs (Supplementary Information section 
12.6.3) in several important ways. First, it differs in its starting point: instead of testing all top 
GWAS SNPs for association with a probe, it tests all gene expression probes with a significant 
SNP association (i.e., all significant cis-eQTLs in a certain tissue dataset) for association with the 
phenotype. To this end, it uses SNPs as instrumental variables for gene expression levels to 
estimate the association between gene expression levels and the phenotype (as described in 
further detail below).  
In this sense, SMR is more powerful than the eQTL lookups, where the number of tests is 
informed by the stringent GWAS P value threshold (as only genome-wide significant SNPs are 
put forward for eQTL testing). In SMR, the number of tests is informed by the number of 
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significant eQTLs, which runs in the thousands. In this way, SMR can in principle uncover many 
more gene-phenotype associations than the eQTL lookups. 
In addition, the “HEIDI” test feature of SMR is able to discard eQTL associations that are caused 
by mere linkage, thereby discarding genes that are “spuriously” associated with the phenotype 
(as described in further detail below). This feature distinguishes SMR from other transcriptome-
wide analysis methods, and from the eQTL lookups, which may uncover genes that are merely 
associated with the phenotype due to linkage. We still perform the eQTL lookups, however, as 
they can give us some insight into the functional annotation of our GWAS top hits.  
12.3.2 Methods 
Summary statistic-based Mendelian Randomization (SMR)192 is a method for estimating the 
effect of an exposure (x), such as gene expression, on a phenotype of interest (y), using 
summary-level data on estimated SNP effects (z, the instrumental variable) from large-scale 
GWAS and eQTL studies. In a Mendelian Randomization (MR) framework, the effect of x on y 
(bxy) is:  𝑏¬ï` = 𝑏¬ð`/𝛽Zðï, 
where 𝑏¬ð` is the estimated SNP effect from a GWAS for trait y and 𝛽Zðï is the estimated SNP 
effect on the expression level of gene x from an independent eQTL study.  
The sampling variance of 𝑏¬ï` is given by: 𝑣𝑎𝑟(𝑏¬ï`) ≈ 𝑏ð"`𝛽ðï" ñ𝑣𝑎𝑟(𝛽Zðï)𝛽ðï" + 𝑣𝑎𝑟(𝑏¬ð`)𝑏ð"` − 2𝑐𝑜𝑣(𝛽Zðï, 𝑏¬ð`)𝛽ðï𝑏ð` ò, 
where 𝑐𝑜𝑣(𝛽Zðï, 𝑏¬ð`) is assumed to be zero if 𝛽ðï and 𝑏ð` are estimated in independent cohorts. If 𝛽Zðï and 𝑏¬ð` are used in place of 𝛽ðï and 𝑏ð` (which are unknown), then the SMR test statistic, 
which is approximately 𝜒", takes the form:  𝑇 Ñô = 𝑏¬ï`" /𝑣𝑎𝑟(𝑏¬ï`) ≈ 𝑧ð"` 𝑧ðï"𝑧ð"` + 𝑧ðï" , 
where 𝑧ð` and 𝑧ðï are the estimated z statistics from the GWAS and eQTL studies, respectively.  
A significant SMR test result could be due to causality (i.e., if the effect of z on y is via x), 
pleiotropy (i.e., if z has pleiotropic effects on x and y) or linkage (i.e., if z1 affects x and z2 affects 
y, and z1 and z2 are in linkage disequilibrium). Like all MR methods, SMR is unable to 
distinguish between causality and pleiotropy on the basis of a single genetic instrumental 
variable (i.e., the top cis-eQTL as opposed to multiple cis and trans-eQTLs), and so we do not 
distinguish between pleiotropy and causality in our analyses. 
On the other hand, it is possible, under some assumptions, to distinguish pleiotropy (or causality) 
from linkage using the HEIDI (Heterogeneity In Dependent Instruments) test developed by Zhu 
et al.192. The rationale for the HEIDI test is that if the same causal variant has a pleiotropic effect 
on gene expression and the trait, then the estimate of bxy should be identical for any SNP in LD 
with the causal variant. Therefore, a test for linkage is equivalent to testing for heterogeneity in 
the estimates of bxy for the top cis-eQTL and any other significant SNPs in the cis-eQTL region. 
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If there are m such variants (excluding the top cis-eQTL), and if we define 𝑑5 = 𝑏ï`(5) − 𝑏ï`(s¹w) 
and 𝐝Z = ö𝑑Z*, 𝑑Z", . . . 𝑑Z÷ø, then the HEIDI test against the null hypothesis d = 0 takes the form: 𝑇º»q¸q =­ 𝑧ù(5)"÷5 , 
where 𝑧ù(5) equals 𝑑Z5/Q𝑣𝑎𝑟(𝑑Z5). SNPs with r2 > 0.9 with the top cis-eQTL are excluded from 
the set of m SNPs in the HEIDI test, because statistical power to distinguish between linkage and 
pleiotropy is limited if the causal variants have close to perfect LD. The test also excludes SNPs 
with eQTL P values > 1.6 x 10-3, due to the need to remove weak instrumental variables.  
For a complete description of the SMR and HEIDI tests, see Zhu et al.192. 
12.3.3 Data 
SMR requires summary statistics from large-scale GWAS and eQTL studies and genotype data 
from an ancestry-matched reference sample for estimating linkage disequilibrium. We used 
estimates of SNP effects (bzy) from the meta-analysis of our discovery and replication GWAS of 
general risk tolerance, and we used summary data on cis-eQTLs (bzx) from the eQTLgen 
Consortium's meta-analysis of 14,115 whole blood and peripheral blood samples (in prep.). We 
excluded probes in the MHC (26.1 to 33.8Mb on chromosome 6 based on hg19) due to the 
complexity of linkage disequilibrium in this genomic region, and we excluded SNPs with MAF 
< 0.01 and INFO score < 0.3. Analyses were restricted to probes with at least one cis-eQTL 
(defined as +/-1Mb from the middle of the probe) with P < 5 × 10–8, because Mendelian 
randomization assumes that the instrumental variable has a strong effect on the exposure. After 
filtering we had access to summary data on 12,751 probes and 10,209,777 (1000 Genomes 
imputed) SNPs. We used Bonferroni correction to account for multiple testing, resulting in a 
genome-wide significance threshold for the SMR test of P < 3.9 × 10–6 (= 0.05/12,751).  
We based our primary analyses on eQTLs identified in blood (in the eQTLgen data) because the 
available sample size is at least an order of magnitude larger than for any other human tissue, and 
so this strategy maximizes statistical power for genes with shared genetic control of regulation 
across tissues. However, genetic control of regulation of some genes is tissue-specific, and so for 
each of the 21 probes passing both the SMR and HEIDI tests in the eQTLgen analysis, we also 
performed SMR analyses using estimates of SNP effects on gene expression in the human brain. 
We used summary eQTL data from the Genotype Tissue Expression Consortium (GTEx) for 11 
brain regions (anterior cingulate cortex, caudate basal ganglia, cerebellar hemisphere, 
cerebellum, cortex, frontal cortex, hippocampus, hypothalamus, nucleus accumbens basal 
ganglia, pituitary, putamen basal ganglia) with sample size exceeding 70 (GTEx release v6p). 
We mapped Illumina expression probes in eQTLgen to GTEx transcripts using Ensembl gene 
IDs. We applied a relaxed eQTL P value threshold for inclusion of transcripts in the analysis of 
brain eQTLs (P < 2.5 × 10–3), due to the small number of transcripts tested per tissue, and we 
used a correspondingly lower significance threshold for the SMR test (P < 2.16 × 10–4, based on 
correction for testing of 21 probes in each of 11 brain regions). 
We used our main reference panel (Supplementary Information section 2.4) for LD estimation. 
All analyses used hg19 coordinates.  
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12.3.4 Results and discussion 
We used SMR to test for association between gene expression in blood and general risk tolerance 
using summary data from our GWAS meta-analysis and blood cis-eQTLs from the eQTLgen 
consortium. We identified 42 genes (tagged by 46 probes) at experiment-wide significance (P < 
3.9 × 10-6), of which 19 (tagged by 21 probes) passed the HEIDI test, indicating we could not 
reject the null hypothesis of a single causal variant with pleiotropic effects on both risk tolerance 
and gene expression in blood (Supplementary Table 12.5). Thirteen of the 19 significant genes 
(68%) were in reported genome-wide significant loci for general risk tolerance, whereas the 
remaining six (CTNNA1, SIL1, ZCCHC7, HNRNPK, HINFP, LYZ) were “novel” discoveries, 
insomuch as no reported general-risk-tolerance GWAS locus was located within 0.5Mb. These 
latter discoveries point to genetic loci that are likely to be identified with genome-wide 
significance in larger GWAS of general risk tolerance. Several genes passing the SMR and 
HEIDI tests, including the top ranked gene MSRA (PSMR = 1.8 × 10–13, PHEIDI = 8.8 × 10–2), ERI1 
(PSMR = 1.1 × 10-7, PHEIDI = 8.5 × 10–2) and XKR6 (PSMR = 4.3 × 10–10, PHEIDI = 0.59), were also 
significantly associated with general risk tolerance in the MAGMA analysis (Supplementary 
Information section 12.2).  
For each of the 21 probes passing both the SMR and HEIDI tests in the eQTLgen blood analysis, 
we repeated the SMR analysis for general risk tolerance using summary data on cis-eQTLs from 
the 11 GTEx v6p brain regions (Supplementary Table 12.5). Three genes passed both the SMR 
and HEIDI tests in one or more brain regions: CTNNA1 (chromosome 5, 138.11Mb) was 
significant in caudate basal ganglia, cerebellum and cerebellar hemisphere; CENPV 
(chromosome 17, 16.25Mb) was significant in putamen basal ganglia, nucleus accumbens basal 
ganglia, caudate basal ganglia, anterior cingulate cortex (BA24), hippocampus and 
hypothalamus; and ZSWIM7 (chromosome 17, 15.89Mb) was significant in cerebellum, 
cerebellar hemisphere, cortex, anterior cingulate cortex (BA24) and frontal cortex (BA9). These 
brain regions overlap with those identified by the DEPICT tissue prioritization analysis (see 
Supplementary Information section 12.4). For CTNNA1 and CENPV (Extended Data Fig. 
12.2), the risk-tolerance increasing allele was associated with decreased gene expression in blood 
and each of the respective brain regions. For ZSWIM7, the risk-tolerance increasing allele was 
associated with increased gene expression in blood, cerebellum and cerebellar hemisphere, but 
the results were inconsistent for cortex, anterior cingulate cortex and frontal cortex (i.e., the risk-
tolerance increasing allele was associated with decreased expression). These findings suggest 
that CTNNA1 and CENPV are putatively functional genes for risk-taking behavior but that more 
investigation is required to confirm the association with ZSWIM7. 
According to the GTEx portal website, CENPV is highly expressed in many tissues, but 
especially in the brain’s cerebellum, while CTNNA1 is not particularly strongly expressed in 
brain tissue (compared to the other tissues). The function of CENPV has not been studied 
frequently, but two studies have discovered functions in cell division194 and migration195. 
CTNNA1, on the other hand, has been studied widely for its role in tumor suppression (e.g. 
ref.196), and mutations in this gene are known to lead to retinal pigment dystrophy, causing 
macular disease197. Both CTNNA1 and CENPV were significantly associated in the MAGMA 
gene based test, but neither were prioritized by DEPICT at FDR > 0.20. Therefore, the putative 
roles CENPV and CTNNA1 may play in general risk tolerance remain unclear. 
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12.4 Prioritization of tissues, gene sets, and genes using DEPICT  
12.4.1 Background and methods 
DEPICT (Data-driven Expression Prioritized Integration for Complex Traits) is a computational 
tool that uses a set of GWAS summary statistics as input and allows enrichment analysis of 
tissues and gene sets and prioritization of genes in the associated loci (see ref.168  for details).  
For this work, we used DEPICT release 194hhh. DEPICT was run using the summary statistics of 
the meta-analysis of the discovery and replication GWAS of general risk tolerance (after 
applying genomic control using the intercept of the LD Score regression). Only SNPs with 
GWAS P values less than 10-5 were used as input, and DEPICT-defined loci were defined by 
clumping these SNPs (PLINK clumping parameters: --clump-p1 1e-5 --clump-r2 0.1 --clump-kb 
500, using 1000 Genomes Project pilot phase data as reference). Locus boundaries were then 
defined using a LD r2 threshold of 0.5, and overlapping loci were merged, yielding 464 
autosomal loci comprising 1,060 genes. DEPICT was run using default settings: 500 
permutations for bias adjustment; 50 replications for false discovery rate estimation; normalized 
expression data from 77,840 Affymetrix microarrays for gene set reconstitution; 10,968 
reconstituted gene sets for gene set enrichment analysis; and testing 209 tissue/cell types 
assembled from Medical Subject Headings (MeSH) annotations from 37,427 Affymetrix U133 
Plus 2.0 Array samples for enrichment in tissue/cell type expression168,182. Furthermore, gene 
expression data from 37 RNA-sequenced tissues from the Genotype-Tissue Expression (GTEx) 
Consortium58 were used for tissue enrichment analysis.  
12.4.2 Results: Prioritized tissues, gene sets, and genes 
We begin by reporting the results of the DEPICT tissue enrichment analysis, which we 
conducted using GTEx RNA-sequencing gene expression data as well as using microarray data 
from 209 tissues168,182. The DEPICT tissue enrichment analysis identifies tissues in which genes 
near general-risk-tolerance-associated SNPs are significantly overexpressed relative to genes in 
random sets of loci matched by gene density.  
Using GTEx RNA-sequencing gene expression data, we identified eight significantly enriched 
tissues (FDR < 0.01), which all represent different areas of the brain (Fig. 3b and 
Supplementary Table 12.6). The top three prioritized tissues were cortical brain regions, 
namely “Frontal Cortex (BA9),” “Anterior Cingulate Cortex (BA24)” and “Cortex.” The cortical 
regions BA24 and BA9 are respectively located in the ventral anterior cingulate area and in the 
dorsolateral and medial prefrontal cortex198,199. These two regions had initially been respectively 
associated with memory and emotion processing, though more recent work stresses their role in 
executive functions such as “executive control of behavior,” “inferential reasoning,” and 
“learning and decision making”200–204. The DEPICT tissue prioritization analysis with the GTEx 
data also points to subcortical regions, including notably the nucleus accumbens, caudate, and 
putamen, which form the basal ganglia205, as well as the amygdala. The basal ganglia and 
amygdala are known for their respective role in motor control (and its impairment in Parkinson’s 
disease), and in the processing of negative emotions, such as fear. However, recent evidence also 
                                                        
hhh DEPICT release 194 handles GWAS data imputed with 1000 Genomes Project reference data and was 
downloaded in February 2016 from: 
https://data.broadinstitute.org/mpg/depict/depict_download/bundles/DEPICT_v1_rel194.tar.gz.  
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supports a role for the basal ganglia and the amygdala in reward processing and decision-
making206–209. 
Using microarray data from 209 tissues, we replicated the brain enrichment and identified overall 
19 significantly enriched tissues (FDR < 0.01) which are all part of the central nervous system 
(CNS) (Extended Data Fig. 12.3b and Supplementary Table 12.7).  Note that we also 
observed an enrichment for the retina, which is part of the CNS but in DEPICT is categorized as 
“Sense Organs.” This analysis additionally showed expression in deeper brain structures, such as 
the rhombencephalon and metencephalon. The metencephalon, also known as the midbrain, is 
the major location of dopamine neurons210 ; we note, however, that this exact location, known as 
substantia nigra, was not prioritized by DEPICT in the analysis of GTEx tissues (FDR > 0.20). 
Moreover, the results seem to have little specificity toward the reward and decision-making 
system, as they also show expression in other CNS regions with diverse functions (e.g., the 
visual cortex). 
Next, we report the results of the DEPICT gene set enrichment and gene prioritization analyses. 
DEPICT “reconstituted gene sets” are predefined gene sets taken from several bioinformatic 
databases (including Gene Ontology, Reactome, and Kyoto Encyclopedia of Genes and 
Genomes) that have been reconstituted using co-expression data to represent the weight of 
evidence of a given gene belonging to the gene set—as opposed to the all-or-nothing 
representation for the predefined gene sets (see Pers et al., 2015168, for details). Each gene’s 
membership score with respect to a given reconstituted gene set is simply the z-statistic of the 
correlation between the gene’s vector of transcriptional components (TC) loadings and the binary 
gene set’s t-statistics with respect to the TCs—the same z-statistics used for testing the statistical 
significance of the Gene Network predictions. We identified 93 reconstituted gene sets that are 
significantly enriched (FDR < 0.01) for genes found among the general-risk-tolerance-associated 
loci (Supplementary Table 12.8). We used the Affinity Propagation tool211 to cluster related 
reconstituted gene sets into a network diagram (Fig. 3a)iii. The most strongly enriched gene sets 
highlight pathways related to the CNS. These include gene sets for regulation of neuronal 
projections (most notably synaptic and dendritic development) and synaptic transmission. 
Several of the most significant pathways relate to synaptic transmission activity, in particular 
GABA and glutamate neurotransmitter signaling. We were able to prioritize at least one gene at 
106 of 464 loci defined by DEPICT (23% of the loci) at FDR < 0.01. In total DEPICT prioritized 
122 genes (Supplementary Table 12.9) across those 106 loci. 
The most significantly enriched reconstituted gene set is “dendrite development.” The presence 
of dendrites distinguishes neurons from all other cell types; these unique structures bestow the 
ability to receive signals of high spatiotemporal resolution. We mention just one aspect of 
dendrite development implicated by our results: the coordination or mutual influence required to 
juxtapose the axonic and dendritic sides of the developing synapse. In certain hippocampal 
pyramidal neurons, recognition molecules of the NGL/NTNG family produce a 
compartmentalization of the dendritic tree by ensuring the innervation of distinct portions of the 
tree by axons from correspondingly distinct sources. NTGN1 and NTNG2 encode ligands for 
receptors encoded by LRRC4C (also called NGL1) and LRRC4 (also called NGL2) respectively 
(NTGN1 is not prioritized by DEPICT, but NTNG2 and LRRC4 are prioritized at FDR < 0.01 and 
LRRC4C is prioritized at FDR < 0.05). LRRC4C and LRRC4 are members of the leucine-rich 
                                                        
iii The script to produce the network diagram can be downloaded from https://github.com/perslab/DEPICT. 
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repeat family, whose overarching function may be the exploitation of both family size and 
alternative splicing to create unique molecular fingerprints enabling precision wiring between 
neurons212,213. Incoming axons bearing NTGN1 and NTNG2 respectively somehow find their 
corresponding receptors (LRRC4C, LRRC4) and thereby innervate non-overlapping 
compartments on distal and proximal dendrites214. These leucine-rich repeats are synaptic cell 
adhesion molecules (CAMs, such as CADM2) that transmit signals to the dendritic interior upon 
trans-synaptic binding, and thus their compartmental distribution may bestow varying 
information-processing properties along the length of a dendritic tree. 
Our results implicate a number of different neurotransmitter receptors embedded in the 
membrane of the mature dendrite. Glutamate is the most abundantly employed excitatory 
neurotransmitter in the brain. When glutamate released from the axon of a transmitting 
presynaptic neuron binds to a fast-acting AMPA-type glutamate receptor embedded in the 
dendrite of the receiving postsynaptic neuron, the channel coupled to the receptor momentarily 
opens by a lock-and-key mechanism and permits a massive influx of Na+ ions. This is the 
primary mechanism leading to rapid depolarization of the receiving neuron, which can lead in 
turn to the neuron firing its own signal along its axon. Our DEPICT-prioritized genes include 
GRIA1, which encodes the most common subunit appearing in the AMPA-type glutamate 
receptor. 
Two genes encoding subunits of NMDA-type glutamate receptors are among our DEPICT-
prioritized genes (GRIN2A, GRIN2B). NMDA-type glutamate receptors act like coincidence 
detectors: they only open when glutamate has landed on the receptor and the postsynaptic 
membrane potential has been sufficiently depolarized by the opening of other excitatory channels 
to remove the Mg2+ block. The emerging picture is of a receptor whose task is not to respond 
immediately to any given input impinging on the dendrite but rather to admit an agent of change 
into the dendrite in response to a temporal coincidence of synapse-specific input and membrane 
depolarization.  
So far we have been discussing excitatory neurotransmission—that is, a signal from one neuron 
to the next that pushes the receiving neuron closer to its own firing threshold. Now we turn to 
inhibitory neurotransmission, which has the effect of pushing the receiving neuron further away 
from its firing threshold. The most important source of inhibition in the cortex is mediated by 
receptors for the neurotransmitter GABA. They produce inhibition in many cases by generating 
hyperpolarizing changes in membrane potential that counteract the depolarizing changes caused 
by Na+ influx through opened glutamate receptors. GABAA receptors mediate the effects of 
alcohol intoxication and drugs such as benzodiazepines and barbiturates, which have anxiolytic 
effects 
A GABAergic neuron typically establishes outgoing connections only with neurons in its local 
vicinity. A glutamatergic pyramidal neuron, in contrast, often sends its axon to neurons that are 
far away (e.g., the opposite hemisphere). When this local connectivity of GABAergic neurons is 
emphasized, they are called interneurons. Because it is not possible to construct an information-
processing device from only inhibitory neurons, we can reasonably say that they play some 
supporting or modulatory role. 
GABAA receptor subunits are grouped into subfamilies known respectively as α, β, γ, δ, ε, θ, φ, 
and ρ215, the first three of which are represented in our DEPICT-prioritized genes (GABRA2, 
GABRA4, GABRB1, GABRG3). A complete receptor is composed of five subunits; the 
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combinatorial number of possible pentamers is quite impressive, even if we put aside alternative 
splicing. Some subunits of GABAA receptors contain regulatory sites for phosphorylation and 
domains that interact with proteins such as the product of GPHN involved in receptor trafficking 
and localization at synapses216. 
The importance of both excitatory and inhibitory neurotransmission is affirmed by the significant 
enrichment of gene sets such as “glutamate receptor activity,” “abnormal miniature excitatory 
postsynaptic currents,” and “GABAA receptor activity.” Note that the cluster named after the 
latter gene set contains the second-most significant gene set in the entire analysis (Fig. 3a).  
Four out of the top five prioritized genes encode proteins with transcriptional regulatory activity, 
some known to play a role in brain development. The strongest prioritized gene, FOXG1, 
encodes a transcription factor known to cause the congenital variant of Rett-syndrome217, a 
severe neurodevelopmental disease. The second strongest prioritized gene, ASH1L, encodes a 
histone lysine N-methyltransferase involved in chromatin modification and has been implicated 
in autism and neurodevelopmental disorders218. The third strongest prioritized gene, FAM190A 
(alias CCSER1), is a relatively unknown gene with no previous reported associations to brain-
related phenotypes. The fourth and fifth strongest prioritized genes, FOXO6 and NEUROD, both 
encode transcription factors and have been implicated in Alzheimer’s Disease and regulation of 
memory consolidation, respectively219,220. 
12.5 Competitive gene-set analysis with MAGMA: Testing gene sets related 
to GABA and glutamate neurotransmitters 
12.5.1 Background 
Since both the DEPICT pathway analysis and the Gene Network analysis of MAGMA genes 
both pointed to glutamate and GABA neurotransmitters, we decided to also perform an ex post 
MAGMA competitive gene-set analysis of relevant glutamate and GABA gene sets. This 
allowed us to directly compare the enrichment of these gene sets to that of the gene sets 
associated with dopamine, serotonin, testosterone, estrogen, and cortisol, which we also tested in 
a MAGMA gene set analysis described, as described in Supplementary Information section 
11.2.  
Similar to what we did in Supplementary Information section 11.2, we looked up all relevant 
glutamate and GABA gene sets in MSigDB v6.1jjj and merged the resulting sets into one 
glutamate and one GABA superset. In addition, we tested the GABA and glutamate gene sets 
which were significant (FDR < 0.05) in DEPICT (see Supplementary Information section 
12.4), although we updated the genes in those sets according to the gene sets in MSigDB v6.1. 
Thus, in total, we conducted a MAGMA gene set analysis to test four glutamate and GABA gene 
sets (Panel B in Supplementary Table 11.2): 
1) All GABA sets significant in DEPICT (FDR < 0.05, six gene sets) or with more than 10 
counts in the Gene Network analysis of MAGMA genes (one gene set), containing 68 
unique genes 
                                                        
jjj See http://software.broadinstitute.org/cancer/software/gsea/wiki/index.php/MSigDB_v6.1_Release_Notes for 
details on this release 
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2) All glutamate sets significant in DEPICT (FDR < 0.05, 12 gene sets) or with more than 
10 counts in the Gene Network analysis of MAGMA genes (zero gene sets), containing 
159 unique genes 
3) All relevant GABA sets in MSigDB v6.1 (13 gene sets), containing 134 unique genes 
4) All relevant glutamate sets in MSigDB v6.1 (27 gene sets), containing 276 unique genes 
We tested all four sets together, and MAGMA computed the family-wise error correction 
accordingly. 
12.5.2 Results and discussion 
None of the four gene sets were significant (lower Bonferroni-corrected P = 0.299, Panel B in 
Supplementary Table 11.3). We are unsure why this might be the case but, as we further 
discuss this in Supplementary Information section 12.7.4, our MAGMA competitive gene-set 
analysis of the four glutamate and GABA gene sets has some likely limitations. First, the 
statistical power of a MAGMA gene set analysis fails to increase substantially with increasing 
sample sizes163. Second, important effects of single SNPs in a gene set may be overshadowed by 
the high average P values of other SNPs in the gene or gene set. Third, it might be that only 
specific glutamate and/or GABA genes or pathways might be relevant for general risk tolerance, 
and that our merging of those pathways into major glutamate and GABA sets decreased our 
statistical power for discovery of relevant effects. (In the MAGMA gene-based analysis, only 12 
of the 354 unique GABA/glutamate genes included in the four gene sets tested here were 
significant at Bonferroni-corrected P < 0.05.)  
12.6 Lookup of protein-altering variants and cis-eQTLs 
In this section, we conducted several analyses that annotate the 132 lead SNPs from the meta-
analysis of the discovery and replication GWAS of general risk tolerance, to gain insights about 
the biological systems they may affect. (For consistency with the rest of the bioannotation 
analyses, we performed these analyses with the 132 lead SNPs of the meta-analysis combining 
the discovery and replication GWAS of general risk tolerance, and not with the 124 lead SNPs 
from the discovery GWAS.kkk)  
                                                        
kkk Because the lead SNPs of the discovery GWAS are not a perfect subset of the lead SNPs of the meta-analysis of 
the discovery and replication GWAS, we investigated the overlap of the identified loci. The discovery GWAS 
identified 124 lead SNPs, and the meta-analysis of the discovery and replication GWAS identified 132 lead SNPs; 
97 of these are lead SNPs in both. We investigated if the non-overlapping lead SNPs of each GWAS are in LD with 
a lead SNP of the other (defined here as r2 > 0.1). The discovery GWAS identified seven lead SNPs that are not 
located in the locus of a lead SNP of the meta-analysis of the discovery and replication GWAS, and the meta-
analysis of the discovery and replication GWAS identified 15 lead SNPs that are not located in the locus of a lead 
SNP of the discovery GWAS. (The list of these seven and 15 SNPs is available upon request.) These seven and 15 
lead SNPs are all highly significant (P < 5E–7) in the other GWAS. In conclusion, approximately 117 loci overlap 
across the two GWAS, and the 15 additionally identified loci in the meta-analysis of the discovery and replication 
GWAS are all highly significant in the discovery GWAS. The slightly larger number of lead SNPs in the meta-
analysis of the discovery and replication GWAS was to be expected because of the increased statistical power due to 
the inclusion of the replication GWAS.  
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Specifically, we examined the overlap between these lead SNPs and various SNPs and genes that 
have been identified or annotated in previous GWAS and functional genomic databases. First, 
we checked whether our lead loci contain protein-altering variants. Second, we looked up the 
lead loci in an expression quantitative trait loci (eQTL) database.  
12.6.1 SNPs in LD with lead SNPs 
Since the genome is characterized by widespread linkage disequilibrium (LD), it is important to 
examine the overlap with SNPs that are in LD with our lead SNPs (as opposed to only 
considering our lead SNPs). Moreover, some data sources do not contain some of our lead SNPs 
but contain SNPs in strong LD with them, and a lead SNP does not actually have to be the causal 
SNP in the locus: it may just be the most often genotyped or most accurately imputed SNP (i.e., 
the SNP measured with the least measurement error and therefore yielding a lower P value); it 
may tag an unmeasured causal SNP in the LD block; or it may simply be the most significant 
SNP in the block due to sampling variation. For these reasons, it is crucial to also consider the 
LD partners of the lead SNP. We obtained a list of SNPs in strong LD with our lead SNPs using 
the PLINK –r2 command in our main reference panel (described in Supplementary 
Information section 2.4). Here we used an LD cutoff of r2 > 0.6 and a distance cutoff of 250kb 
from the lead SNP. We refer to these SNPs as the “LD partners” of our lead SNPs. In total, the 
clumping procedure designated 132 “lead SNPs,” which tagged a total of 8,199 LD partners.  
12.6.2 LD with protein-altering variants 
Using the Haploreg v4.1 database221  (download date 18 May 2016, 
http://www.broadinstitute.org/mammals/haploreg/haploreg.php), we ascertained the protein-
altering status of our lead SNPs and their LD partners. More precisely, we ascertained whether 
our lead SNPs and their LD partners are annotated as “missense,” “nonsense,” “splice site 
donor/acceptor,” or “frameshift” in the 1000 Genomes Phase 3 European population. The 
Haploreg database uses annotations from dbSNP55 to determine functional status. We examined 
these annotations because protein-altering variants have a higher a priori probability of being 
causally relevant: they can result in stronger phenotypic differences between individuals 
compared to non-protein-altering variants. Most of the genome is non-coding, which underlines 
the importance of the detection of protein-altering variants. 
The results can be found in Supplementary Table 12.10. We found that there were eight 
protein-altering SNPs among the lead SNPs’ LD partners, including two of the lead SNPs 
themselves. All protein-altering variants were relatively common (with 0.11 < MAF < 0.50) 
missense variants (meaning that they result in an amino acid change). The two missense lead 
SNPs are in genes WSCD2 (on chromosome 12) and NF1 (on chromosome 17). Little is known 
about WSCD2, but it is highly expressed in the brain and has predicted functions in long term 
memory and calcium signaling, according to Gene Network182. NF1 is involved in the genetic 
disorder “neurofibromatosis,” which is characterized by widespread fibromatous tumor 
formation and cognitive disability222. Other missense variants in LD with our lead SNPs were 
found in FREM1 and BHLHE22. FREM1 encodes a protein that may play a role in craniofacial 
and renal development, while BHLHE22 is thought to be involved in the differentiation of 
sensory neurons. The remaining four missense variants in LD with our lead SNPs were in the 
HLA-region, of which three were in the olfactory receptor gene OR2J2, and one in histone gene 
HIST1H1T.  
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12.6.3 eQTL lookup  
The publicly available results from the Genotype-tissue expression project (GTEx, 
www.gtexportal.org, version v6p)58 allow us to look up significant associations between our lead 
SNP and their LD partners and cis-gene expression in distinct human tissues. The GTEx team 
obtained postmortem samples from human donors and used RNA sequencing to measure RNA 
levels in distinct tissues from those samples. The GTEx team also genotyped the donors with 
SNP microarrays. The lookup of the risk-tolerance lead SNPs and their LD partners was 
performed on the publicly accessible summary statistics (downloaded 13 December 2016, 
version v6p) of the significant gene-cis-SNP pairs from GTEx. We only considered the set of 
significant cis-eQTLs (i.e., gene-cis-SNP pairs), where the cis-window is defined as a 1MB 
window around the gene’s transcription start site. In addition, when a gene transcript was a 
significant eQTL for more than one of our query SNPs, we only report the eQTL statistics (i.e., 
effect size, P value) for the SNP in highest LD with the lead SNP (which might be the lead SNP 
itself). That way, we only report each significant eQTL gene once in each tissue (even though the 
gene may have appeared several times for the tissue, for several lead SNPs and LD partners). In 
cases where more than one lead SNP was an eQTL for the same gene, we report the eQTL for 
only one of them. 
To identify statistically significant cis-eQTLs, the GTEx consortium computes a gene-specific 
nominal P value threshold for each gene, with a permutation method as described in more detail 
in ref.223. The eQTLs we report here are all statistically significant, in the sense that the nominal 
P value of the slope of the regression of the gene’s expression value on the SNP was smaller than 
the gene-specific nominal P value threshold. This regression also included several technical 
covariates, such as the top principal components of the genetic relatedness matrix.lll 
We only recorded findings for the following pre-selected tissues, which we suspected could be of 
biological relevance for risk tolerance: (1) all 11 brain tissuesmmm available in the GTEx data; (2) 
tibial nerve tissue; (3) thyroid tissue; (4) gonadal (i.e. testis and ovary) tissue; and (5) adrenal 
gland tissue. In addition, we queried (6) the “whole blood” tissue for eQTLs, as this tissue had 
the highest sample size. Since expression profiles in whole blood and the brain are moderately 
correlated, we might uncover potentially interesting eQTLs by using information from whole 
blood224,225. 
The donor samples sizes for the brain tissues range from n = 72 to 103, and sample sizes for the 
other five tissues range from n = 126 to 338. We included tibial nerve tissue (a peripheral nerve 
located in the lower leg) because the eQTL results for this tissue are based on a relatively large 
sample size (compared to the brain tissues) of n = 256. Since central and peripheral nervous 
tissues are anatomically similar, their expression profiles are likely to be comparable. Thyroid 
tissue is included because thyroid hormone is essential for healthy brain development, and might 
be associated with mood and cognition226,227. Testis and ovary tissue are included, as these 
organs produce sex hormones (e.g., testosterone, estrogen) that might be involved in risk 
tolerance, as detailed in our literature review (Supplementary Information section 11.1). 
Adrenal tissue is included because the adrenals produce hormones associated with the general 
stress response (i.e., (nor)epinephrine and cortisol), which might be related to risk tolerance, as 
                                                        
lll For additional details, see http://www.gtexportal.org/home/documentationPage#staticTextAnalysisMethods and 
ref.223. 
mmm These include pituitary tissue (which GTEx Portal does not list among brain tissues). 
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detailed in our literature review (Supplementary Information section 11.1). Note that the 
presence of eQTLs in these tissues does not imply statistical enrichment of the GWAS signal in 
these tissues; it merely shows that our lead SNPs are associated with gene expression in these 
tissues (which might simply be a result of pleiotropy, and which thus might not be of causal 
relevance to general risk tolerance). 
Supplementary Table 12.11 reports the results. We find eQTL overlaps in every tissue 
(including all individual brain tissues) we queried. In total, we find 188 unique gene transcripts 
for 59 different lead SNPs. 82 of these gene transcripts only had Ensembl gene IDs and no gene 
symbols (i.e. letter symbol gene names such as “HLA” which is an abbreviation of Human 
Leukocyte Antigen, according to the HUGO gene nomenclature committee), most likely because 
they do not have named gene products (i.e., proteins). Out of the 188 unique gene transcripts, 47 
lie in or near the human MHC (i.e., Major Histocompatibility Complex, also known as Human 
Leukocyte Antigen (HLA)) region (~chr. 6: 26-32 Mb), of which five are HLA-genes.  
Finally, we note that there was one eQTL for a GABA gene (GABRG1, or GABAA receptor 
gamma1 subunit), in which the general-risk-tolerance-increasing allele decreased expression of 
GABRG1 in tibial nerve tissue. We found no eQTLs for glutamate genes in any of the queried 
tissues. 
12.7 Summary of main findings from the biological annotation analyses 
The overall goal of the analyses described in this section was to gain insight into the biology of 
general risk tolerance. We employed two general approaches. First, we leveraged data at the 
genome-wide level to prioritize potentially relevant tissues and genomic annotations (using 
LDSC partitioning of heritability) and genes (using MAGMA gene-based analysis, SMR 
transcriptome-wide analysis, and DEPICT gene prioritization analyses). Second, we focused on 
the loci around the general-risk-tolerance lead SNPs (in the lookups of protein-altering variants 
and GTEx eQTLs) to gain insight into the biological functions of our lead SNPs. Here, we 
summarize the results of those analyses.  
12.7.1 Enrichment of SNPs annotated to the central nervous system 
First, we tested enrichment of the GWAS signal in 10 different tissues/cell-types using LDSC 
partitioning of heritability. After controlling for tissue overlap and correcting for multiple testing, 
we found significant positive involvement for the central nervous system and the immune 
system. Involvement of the central nervous system was expected (since general risk tolerance is 
a behavioral trait), but enrichment of immune cell types might be surprising. To the best of our 
knowledge, immune enrichment in LDSC partitioning analyses has not previously been reported 
for a behavioral or psychiatric trait, although we note again that enrichment of specific immune 
pathways and/or immune tissue enhancer regions has been implicated in schizophrenia69,179, 
bipolar disorder180 and major depression181).  
We note that enrichment of immune tissues or function did not come forward in any of the other 
analyses. Further research is therefore needed to corroborate a role for immune processes in 
general risk tolerance. Finally, we note that several additional tissues, such as liver and 
adrenal/pancreatic tissues, showed statistically significant enrichment, but that our estimates of 
their partial effects on enrichment (i.e., their 𝜏v coefficients) were not significant, thereby 
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suggesting that their enrichment may have been primarily driven by other overlapping 
annotations. We therefore cannot claim a role for the adrenal system in general risk tolerance. 
However, this non-finding might be a result of the combination of adrenal with pancreas tissue, 
and the possible non-specificity of histone marks to these particular tissues. More fine-grained 
analyses are therefore needed to corroborate or refute a role for the adrenal system in modulating 
risk tolerance. 
12.7.2 Enrichment of SNPs near genes that are highly expressed in the frontal and 
prefrontal cortex 
While the LDSC partitioning results pointed to the central nervous system (which technically 
includes the brain, brainstem and spinal cord), results from the other analyses allowed us to gain 
deeper insight into which particular brain regions might be of relevance to general risk tolerance. 
Although the overlap between the genes prioritized by DEPICT and the significant MAGMA 
genes was not very high (only 71 out of 285 genes of the MAGMA genes were among the 215 
genes prioritized at FDR < 0.05 by the DEPICT gene prioritization analysis), both the Gene 
Network functional analysis of the MAGMA genes and the DEPICT tissue enrichment analysis 
with the GTEx tissue-specific gene-expression data separately point to enrichment of the frontal 
cortex, and in particular the prefrontal cortex. The frontal cortex is a large and functionally and 
anatomically complex brain area; it is the largest neocortical region in humans and primates, and 
receives and integrates neuronal input from both cortical and subcortical regions188. The 
posterior dorsal area of the frontal cortex contains the motor cortex, which is responsible for 
planning and directing bodily movement; damage to this area can result in perturbed motor 
function or paralysis. The prefrontal cortex (the most anterior part of the brain), on the other 
hand, is involved in planning, directing, and inhibiting emotion, behavior and cognition (broadly 
known as “executive function”). Damage to the prefrontal cortex has been well-documented due 
to the widespread practice of prefrontal lobotomy (a relatively simple surgical procedure) in 20th 
century America and with textbook patient cases of accidental lesion such as Phineas Gage. 
Damage to the prefrontal cortex can result in severe impairment marked by behavioral 
disinhibition and emotional deregulation, cognitive disability, impaired decision making, a 
tendency to display context-inappropriate behavior, and inability to plan future action188. The 
frontal cortex is also one of the last brain areas to mature during development (with full 
maturation reached around age 25)189, which has been postulated to underlie the social and 
behavioral disinhibition and increased display of risk-taking behaviors that characterizes puberty 
and adolescence228–230.  
At a finer resolution, the DEPICT tissue enrichment analyses with the GTEx tissue-specific 
gene-expression data show that genes near general-risk-tolerance-associated SNPs are highly 
expressed in the prefrontal cortex (BA24 and B9) and the basal ganglia (nucleus accumbens, 
caudate, putamen), compared to other organs and tissues. The DEPICT tissue enrichment 
analysis using the microarray data confirmed these CNS regions’ enrichment, and additionally 
showed expression in deeper brain structures like the midbrain, among other tissues. The Gene 
Network tissue enrichment analyses also point to enrichment of the prefrontal cortex, and of the 
putamen, which is part of the basal ganglia. Finally, two of the three genes that passed both the 
SMR and HEIDI tests, CTNNA1 and CENPV, were significant in parts of the basal ganglia 
(CTNNA1 was significant in the caudate and CENPV was significant in the putamen, nucleus 
accumbens, and caudate).  
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12.7.3 A possible convergence with results from the neuroscientific literature 
Interestingly, the prefrontal cortex, the basal ganglia and the midbrain are the major components 
of the cortical-basal ganglia circuit, which includes and connects the reward system, the motor 
system, and the cognitive and behavioral control systems. This whole network of brain regions 
has been shown to be critically involved in learning, motivation, behavioral control, and 
decision-making, notably under risk and uncertainty, in both humans and non-human 
primates210,231. Decision making under risk requires several cognitive processes (e.g. such as 
reward processing, fear, or higher executive control) underpinned by different neural systems 
which are coherently connected and integrated in current models of the cortical-basal ganglia 
circuit. In this complex circuit, the processing of reward and decision-making is presumed to be 
largely underpinned by dopamine207,232. Dopaminergic neurons are mostly located in the 
midbrain (substantia nigra and ventral tegmental area) where they project to the basal ganglia 
and the prefrontal cortex, and appear to encode signals about past and future rewards, used to 
guide behavior207,232.  
There is therefore a remarkable concordance between the enriched CNS regions highlighted by 
the DEPICT analyses and the circuit in charge of reward processing, behavioral control, and 
decision-making defined by decades of behavioral and physiological studies in human and non-
human primates210. It is however difficult to claim that this circuit is specifically tagged by the 
DEPICT tissue enrichment analysis with the GTEx data, given that the GTEx data only cover a 
fraction of all brain regions, mostly restricted to brain regions overlapping with the cortical-basal 
ganglia circuit. Although these results, in line with a large body of neuroscientific studies, 
suggest a role of the cortical-basal ganglia circuit in the risk-tolerance phenotype, their 
inferential value should therefore be considered with caution.  
12.7.4 A likely role for glutamate and GABA neurotransmitters in the modulation of 
risk tolerance 
In addition to neuroanatomy, much speculation has revolved around the role of specific 
hormones and neurotransmitter systems in modulating general risk tolerance. Our review of the 
literature attempting to link risk tolerance to biological pathways (Supplementary Information 
section 11) identified five main biological pathways that have been tested by this literature: the 
steroid hormone cortisol, the monoamines dopamine and serotonin, and the steroid sex hormones 
estrogen and testosterone. Consistent with the lack of enrichment reported in Supplementary 
Information section 11 for genes associated with these five pathways, neither the Gene Network 
analysis of the MAGMA genes nor the DEPICT gene set prioritization analysis point to these 
pathways. (As mentioned above, however, we note that our results are consistent with a role of 
the cortical-basal ganglia circuit in modulating risk tolerance, and that dopamine is presumed to 
play an important role in that circuit.) 
On the other hand, both the Gene Network functional analysis of the MAGMA genes and the 
DEPICT gene set prioritization analysis point to a role for glutamate and GABA 
neurotransmitters, which are the main excitatory and inhibitory neurotransmitters in the brain, 
respectively233. They are colloquially referred to as the “workhorses” of the brain, as they are the 
brain’s principal neurotransmitters. At the time of writing, no other published large-scale GWAS 
of cognition, personality, or neuropsychiatric phenotypes has pointed to clear roles for both 
glutamate and GABA, although we note that glutamate neurotransmission has been implicated in 
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recent GWAS of schizophrenia – by recent analyses of common SNPs69  and rare and de novo 
mutations234,235 – and of major depression181. That our results, unlike those of other well-
powered GWAS, point to both these neurotransmitters suggests that the relative balance between 
excitatory and inhibitory neurotransmission may be a relatively strong contributor to variation in 
risk tolerance across individuals. 
However, we do note that none of the four glutamate and GABA gene sets we tested in an ex 
post MAGMA competitive gene-set analysis were significant (Supplementary Information 
section 12.5). We are unsure why this might be the case, but we note that this analysis had some 
likely limitations. First, its statistical power barely increases with increasing sample sizes163. 
Second, a MAGMA competitive gene-set analysis might not be the optimal approach for 
discovery of subtle but phenotypically important genetic effects driven by regulatory regions, as 
this analysis effectively calculates a weighted average of GWAS -log10(P) values across each 
gene in the gene set (where the average is weighted to correct for LD between SNPs). Hence, 
important regulatory effects of single SNPs may be overshadowed by the high average P values 
of other SNPs in the gene sets. A third possible explanation is that only specific glutamate and/or 
GABA genes or pathways might be relevant in general risk tolerance, and that our merging of 
those pathways into major glutamate and GABA supersets decreased our statistical power for 
discovery of relevant effects. (In the MAGMA gene-based analysis, only 12 of the 354 unique 
GABA/glutamate genes included in the four gene sets tested here were significant at Bonferroni-
corrected P < 0.05.) Hence, the lack of significance of the four glutamate and GABA gene sets 
we tested in the ex post MAGMA competitive gene-set analysis does not nullify the evidence 
from our Gene Network and the DEPICT analyses that glutamatergic and GABAergic 
neurotransmission contributes to variation in risk tolerance across individuals. 
12.7.5 A possible link between the immune system and risk tolerance 
We now briefly discuss the LDSC immune tissue enrichment. We noted that, to the best of our 
knowledge, general risk tolerance is the first behavioral trait to show immune tissue enrichment 
in LDSC partitioned analysis according to tissue type, and that this enrichment was independent 
of SNPs in the MHC region. We also noted that none of our other analyses show immune 
enrichment—the Andersson236 “FANTOM5” enhancers (which are indicative of immune 
activity74) were not a significant genomic annotation in the LDSC partitioned analyses according 
to genomic annotation, and the DEPICT and Gene Network analyses of MAGMA genes also did 
not show immune pathways (although it is noteworthy that these bioannotation analyses 
excluded the MHC region). However, we do find GWAS hits in the MHC region, and several 
genes in this region came up in the MAGMA and GTEx lookup analyses. That is, 29 of the 285 
genes significant in MAGMA and 47 of the 188 GTEx eQTL lookups were in (or around the 
borders of) the MHC region (while SMR excluded SNPs in the MHC region). While a role for 
the immune system in neuropsychiatric traits and related behavior is feasible given previous 
enrichment of immune pathways for psychiatric traits69,180,181,235, we are unsure how to interpret a 
role for the immune system in general risk tolerance, given that our results do not unequivocally 
point in this direction. Researchers have previously theorized a role for a “behavioral immune 
system”237,238 in human behavior. This is seen to be complementary to the “real” immune 
system—that is, humans are said to employ risk averse behaviors to minimize their risk of 
infectious disease. An extension of this theory could be that individuals who are genetically 
prone to “weaker” immune systems might be more risk averse than others, but this is extremely 
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speculative. Before accepting such conclusions, we encourage future bioannotation work to 
uncover which specific immune pathways might be involved in general risk tolerance. 
12.7.6 The CADM2 gene and risk tolerance 
Finally, we briefly discuss the top locus from our discovery GWAS of general risk tolerance. 
The top lead SNP that marks this locus is located in the intronic region of CADM2, and is our 
most significant general-risk-tolerance lead SNP by far, with a P value that is fifteen orders of 
magnitude smaller than the second lead SNP’s P value (P = 2.1 × 10–40 vs. P = 7.6  × 10–25). The 
CADM2 locus was previously identified by a study using the relatively small sample size of the 
first release of UK Biobank data50, and all of our six supplementary GWAS phenotypes 
identified lead SNPs within or near CADM2 (Supplementary Information section 3). CADM2 
was by far the most significant MAGMA gene, and was also prioritized by DEPICT at FDR < 
0.01. However, we do note that only CADM2’s antisense RNA partner CADM2-AS1 was a 
significant cis-eQTL gene in our GTEx lookup tissues, while CADM2 failed the HEIDI-test for 
heterogeneity in the SMR analysis. This suggests that CADM2 may not be the causal gene in the 
locus, or that its effect on general risk tolerance is not mediated by CADM2 expression. 
However, we do stress that the brain eQTL and SMR analyses are strongly underpowered due to 
the relatively small samples sizes for brain tissues, and we can thus not properly study CADM2 
expression in relevant brain tissues. 
According to GTEx, CADM2 is overexpressed in the brain, and in particular in the frontal cortex. 
CADM2 is a large gene (spanning more than 1 Mb) located in a long-range LD region, and has 
been associated with a myriad of behavioral phenotypes in previous GWAS (Supplementary 
Information section 3). CADM2 encodes a member of the synaptic cell adhesion molecule 
family. Molecules in this family have been found to be crucial for synapse formation56 and 
plasticity57, and have been associated with autism239 and impaired social behavior240. However, 
CADM2 itself has mainly been studied for its potential role in tumor progression241; its specific 
role in the brain is unclear. We therefore propose CADM2 as an interesting candidate gene for 
future follow up work.  
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